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I Introduction
I.1 Definition of apoptosis
Programmed cell death (PCD) or apoptosis is essential for a wide variety of
physiological processes in multicellular organisms such as embryonic development,
differentiation and adult tissue homeostasis.
In 1890, William Councilman demonstrated for the first time cell death in humans by
visualizing vacuolated acidophilic bodies in the liver from yellow fever patients. The term
apoptosis was finally established by Kerr and colleagues. The authors distinguished
between the morphological changes found in both animal development and tissue
homeostasis and the pathological cell death that occurs in response to external toxic factors
such as inflammation. The latter process is coined necrosis and is characterized by
dispersed chromatin, cell swelling and early disruption of the plasma membrane with
subsequent inflammation responses.
In contrast, apoptosis functions as a genetically regulated program to eliminate cells in
an orderly manner. Several morphological changes have been associated with apoptosis
including plasma membrane blebbing, cell shrinkage and chromatin condensation (Fig. I-1)
(Wyllie, 1997). Molecular changes include internucleosomal DNA cleavage (Wyllie, 1980)
and exposure of phosphatidylserine (PS) on the extracellular side of the plasma membrane
(Fadok et al., 1992). Following enzymes have been implicated in mediating nuclear
changes triggered by PCD: caspases, granzyme B, cathepsin B, Ca2+-regulated serine
protease and histone-associated protease (Robertson et al., 2000). The most prominent
protease substrate is the caspase-activated DNase or CAD that exists in non-apoptotic cells
as an inactive complex associated to an inhibitory subunit ICAD. During apoptosis,
caspase-3 cleaves the inhibitor, allowing the nuclease to cut at the linker region between
nucleosomes thus producing DNA fragments corresponding to multiple integers of 180 –
200 base pairs (Enari et al., 1998; Liu et al., 1997). Indeed, most of the morphological
changes observed during PCD are caused by a group of cysteine proteases that are
activated in apoptotic cells. Normally, cells undergoing apoptosis dissociate finally into
small vesicles, the so-called apoptotic bodies that are phagocytosed either by neighbouring
cells or by macrophages (Savill and Fadok, 2000). In contrast to necrosis, removal of
apoptotic cells by phagocytes occurs without leakage of cellular constituents, thereby
preventing inflammation of the surrounding tissue. A broad range of receptor-ligand
Introduction
2
interactions, either directly or via serum-derived bridging molecules, mediate the
recognition and death body clearance. However, many of the involved proteins are poorly
characterized and the mechanisms are not yet fully understood with the exception of
phosphatidylserine. This “eat me” signal, normally present in the internal leaflet of the
plasma membrane, is exposed through activation of a flippase on the cell surface of dying
cells (Fadok et al., 1992). The quickness of the apoptotic process and of the engulfment of
dying cells by phagocytes explicates the phenomenon, why PCD was not recognized for a
long time as an essential feature of animal development and homeostasis (Jacobson et al.,
1997).
Techniques for detection of apoptotic changes such as terminal deoxynucleotidyl-
transferase-mediated incorporation of labelled nucleotides at DNA breaks (Gavrieli et al.,
1992), detection of cell surface-exposed PS with annexin V (Koopman et al., 1994) and
visualization of apparent subdiploid DNA content with propidium iodide (Nicoletti et al.,
1991) belong nowadays to the standard procedures for quantification of apoptotic cells.
Figure I-1. Schematic representation of the morphological changes occurring during apoptosis. Upon a death stimulus,
the dying cell shows typical morphological characteristics such as cell shrinkage, condensation of the heterochromatin
and maintenance of organelles. Finally, the apoptotic cell dissociates into apoptotic bodies that are phagocytosed and
degraded by macrophages.
I.2 Impact of apoptosis
The apoptotic process plays a pivotal role in the development of multicellular
organisms including slime moulds, nematodes and vertebrates. An illustrating example
represents the involvement of apoptosis in sculpting parts of the body by eliminating the
interdigital regions in the formation of digits of higher vertebrates. Similarly, PCD
functions to carve out solid structure, in order to create lumina. Hereby, ectodermal cells in
the core of the developing mouse embryo are destined to die thus forming the preamniotic
cavity (Coucouvanis and Martin, 1995). Apoptosis has also an important role in
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eliminating cells or structures that are no longer needed including some neurons that are
only functional at a certain stage during development of mammalian cerebral cortex.
Furthermore, apoptosis serves to build up sex specific structures. In female mammals, the
Muellerian duct is responsible for the formation of the uterus and oviducts, whereas it is
lost in males by PCD. On the other hand, the Wolffian duct gives rise to the male
reproductive organs and is removed in females. Apoptosis might also be implicated in
differentiation processes, for example skin keratinocytes and red blood cells lose their
nucleus and other organelles in the terminal differentiation phase (Nataraj et al., 1994).
Red blood cells have a limited life span of about 3 months, while the death of skin
keratinocytes serves to create a layer on the skin surface (Jacobson et al., 1997).
During the whole life span, regulation of tissue homeostasis by programmed cell death
exerts an crucial role in multicellular organisms. The immune system can offer some
examples of tight control. In response to antigens, peripheral T lymphocytes proliferate and
expand to produce a population that is able to react against a certain antigen. After
developing the immune response, antigen-specific T lymphocytes, except a few ones that
will survive to become memory cells, must be killed by activating the apoptotic program
(Brunner et al., 1995; Dhein et al., 1995; Ju et al., 1995). Another example is the
constitutive cell surface expression of the death ligand FasL, thus contributing to
immunological privilege of some organs by killing infiltrating lymphocytes and
inflammatory cells that express the death receptor Fas (Green and Ware, 1997). In
addition, apoptosis is a significant physiological mechanism for establishing B cell
tolerance and shaping the B-cell repertoire. B cells are subject to cell death throughout
many stages of their maturation and 60 – 70% cell loss has been estimated during the pre-B
to B cell transition in bone marrow (Krammer, 2000).
As described, apoptosis is critical for the development and cellular homeostasis in
metazoans as well as for the defence against damaged or infected cells. Deregulation of the
apoptotic machinery can lead to a broad range of human diseases. Irreversible loss of cells
in brain and heart can have dramatic consequences for the organism, while potently
dangerous cells that show resistance to apoptotic responses are thought to be the origin of
many types of cancer (Fig. I-2) (Reed, 2001). In malignant neoplasia, the balance of
apoptosis and proliferation is shifted towards proliferation, either by reduced apoptosis
and/or accelerated S-phase entry. Aberrant regulation in the cell suicide program has been
experimentally demonstrated in AIDS, Alzheimer, Parkinson, autoimmunity, cancer, heart
failure, inflammation, osteoporosis and stroke (Mattson, 2000; Thompson, 1995; Zornig et
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al., 2001). Molecular alterations in apoptotic genes such as mutations, up- or
downregulation of transcription/translation or conformational changes can lead to
perturbations of the apoptotic pathways. Consequently, efforts to identify apoptosis-
suitable targets for drug discovery would promise new opportunities for developing
innovative therapeutical strategies that can lead to a better treatment of many illnesses by
reducing undesirable side effects (Reed, 1999).
Figure I-2. Implication of apoptosis-related proteins in human diseases. Cell homeostasis is regulated by a dynamic
balance between proliferation and apoptosis. A failure of normal cell turnover leads to cell accumulation such as cancer.
Conversely, irreversible loss of cells causes neurodegenerative disorders (1Roy et al., 1995; 2Suzuki et al., 2000; 3Haass
and De Strooper, 1999; 4Polymeropoulos, 1998; 5Brandt et al., 1996; 6Rampino et al., 1997; 7Dierlamm et al., 1999;
8Teitz et al., 2000; 9Soengas et al., 2001; 10McDermott et al., 1999; 11Vaishnaw et al., 1999; ALPS: autoimmune
lymphoproliferative syndrome; SMA: spinal muscular atrophy).
I.3 Evolution of the apoptotic machinery
The nematode Caenorhabditis elegans has served as an excellent genetic model, in
which stages of programmed cell death can be observed during its invariant, lineage-
restricted development where 131 of the 1090 somatic cells die by apoptosis, thereby
creating an adult worm consisting of 959 cells.  Important core components of the
apoptotic machinery have been discovered through the generation of many C. elegans
mutants. Several studies demonstrated that three genes egl-1, ced-3  and ced-4 are
Neurodegenerative disorders Cancer/Autoimmunity
NAIP deletion (SMA)
1
NAP-1 downregulation (Alzheimer)
2
Presenilin mutations (Alzheimer)
3
a-synclein mutations (Parkinson)
4
Huntingtin mutations (Huntington)
5
Bax mutations (colon cancer)6
cIAP2 rearrangement (MALT lymphoma)7
Caspase-8 deletion (neuroblastoma)8
Apaf-1 silencing by methylation (melanoma)9
TNFR1 mutations (autoinflamm. syndrome)10
CD95 mutations (ALPS)11
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necessary in the course of cell death. Loss-of-function mutations of each gene cause
survival of all 131 doomed cells. Conversely, functional loss of ced-9 leads to massive
ectopic cell death suggesting a pro-survival role for Ced-9 (Ellis and Horvitz, 1986; Ellis et
al., 1991; Hengartner et al., 1992).
Interestingly, the basic cell suicide components are highly conserved throughout
evolution, which resulted in rapid identification of the homologues in vertebrates. The gene
products for egl-1, ced-3, ced-4 and ced-9 correspond to mammalian BH3-only proteins,
caspase family, APAF-1 and anti-apoptotic Bcl-2 members, respectively (Conradt and
Horvitz, 1998; Hengartner and Horvitz, 1994; Yuan et al., 1993; Zou et al., 1997).
Nevertheless, comparing the apoptotic systems of invertebrates and vertebrates has led to
the conclusion that the apoptosis machineries of vertebrates are characterized by an
increased complexity. This is reflected by an expansion and diversification of proteins
containing evolutionarily conserved domains. Moreover, some proteins with undetectable
counterparts have been recently identified such as the pro-apoptotic protein Smac/Diablo
that is specific to vertebrates (Aravind et al., 2001).
I.4 Apoptosis signalling pathways
Programmed cell death can be triggered by a variety of apoptotic stimuli such as
physiological activators, damage-related inducers and therapy-associated agents. They
often exert their effects in a cell-type and species-dependent manner (Strasser et al., 2000).
Numerous chemotherapeutic agents, UV- and g- irradiation, heat shock, osmotic imbalance
and increased intracellular calcium are general inducers in most types of cells (Thompson,
1995). Examples of a more selective induction are massive apoptosis of thymocytes
exposed to glucocorticoids (Cory, 1995) or apoptosis of growth factor-deprived T cells
(Rebollo et al., 1995).
Most growth factors function through anti-apoptotic signalling on their target cells.
Cytokines such as interleukins regulate survival through their receptors that trigger a
cascade of intracellular signalling. The interleukin-2 receptor subfamily is defined by the
presence of the common IL-2R g-chain that is found in receptors for IL-4, IL-7, IL-9 and
IL-15. Binding of IL-2 to its high-affinity receptor induces the dimerization of IL-2Rb and
g-chain and activates at least two signalling transduction mechanisms: Jak/Stat- and
Ras/PI3 kinase pathway (Cacalano and Johnston, 1999). The latter one plays a critical role
in apoptosis regulation. PI3 kinase induces the generation of phosphorylated lipids that can
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act as second messenger to activate serine/threonine Akt kinase. Subsequently, Akt
phosphorylates Bad preventing its pro-apoptotic function and thereby transmitting survival
signals (Blume-Jensen et al., 1998; Datta et al., 1997; del Peso et al., 1997). IL-4 is a
cytokine that among other biologic effects stimulates the proliferation of T and B cells
(Nelms et al., 1999). Although the receptors for IL-2 and IL-4 have several features in
common, IL-4 evokes in part different responses. In fact, the mechanisms that control
apoptosis via IL-2R and IL-4R seem to be different as previously demonstrated (Cerezo et
al., 1999; Gomez et al., 1998; Quelle et al., 1995; Rebollo et al., 2000).
PCD can be triggered by extracellular signals or by apoptotic stimuli generated inside
the cell, for example after DNA damage or through production of reactive oxygen species.
Based on these observations, two major apoptosis signalling pathways have been
distinguished (Fig. I-3), the death receptor (extrinsic) pathway and the mitochondrial
(intrinsic) pathway (Hengartner, 2000).
Figure I-3. Two major apoptosis signalling pathways in mammalian cells: the mitochondrial and death receptor mediated
pathway (see text for details).
The tumor necrosis factor receptor (TNFR) family composed of TNFR1, Fas (CD95),
DR3, TRAIL-R1 and TRAIL-R2 is involved in transmitting the apoptotic signal from the
cell surface inside the cell. Upon receptor aggregation by ligand binding (TNF, FasL,
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ligand for DR3 or TRAIL), intracellular adapter proteins including FADD/MORT1,
TRADD and RAIDD are recruited to the cytoplasmic regions of the death receptors
through death-domain (DD) associations thus forming the death-inducing signalling
complex (DISC). In turn, FADD binds procaspase-8 via DED (death effector domain)
interactions present in both proteins that results in caspase-8 autoproteolytic activation and
initiating a caspase cascade leading to cell death (Fig. I-3) (Ashkenazi and Dixit, 1998).
The important roles for FADD and Caspase-8 in death receptor signalling were defined
from fadd-/- and casp-8-/- mice (Varfolomeev et al., 1998; Yeh et al., 1998). In response to
Fas, TNF-R1 or DR3 stimulation, both fadd- and casp-8-deficient mouse embryonic
fibroblasts (MEFs) are resistant to apoptosis. However, these cells remained sensitive to
agents including chemotherapeutics that signal via the mitochondrial death pathway.
A vast array of apoptotic stimuli such as DNA damage and growth factor deprivation
can induce the mitochondrial cell death pathway by permeabilization of the outer
mitochondrial membrane and leakage of mitochondrial pro-apoptotic molecules into the
cytosol (Adrain and Martin, 2001; Kroemer and Reed, 2000). The most prominent
releasing factor is cytochrome c that functions as an electron transfer molecule between
complex III and IV of the mitochondrial respiratory chain in healthy cells. In apoptotic
circumstances, cytochrome c is released into the cytosol, where it induces the assembly of
a ternary complex, called the “apoptosome”. Goldstein and colleagues (2000)
demonstrated that once initiated, cytochrome c is rapidly released from all mitochondria
within five minutes. Cytochrome c binds to the mammalian Ced-4 homolog Apaf-1 (Liu et
al., 1996; Zou et al., 1997). This event facilitates ATP-binding to Apaf-1 and its
oligomerization that is accompanied by recruitment of procaspase-9. In turn, caspase-9 is
activated autoproteolytically and triggers activation of caspase-3 (Fig. 3). Results from
gene knockout (KO) mice emphasize the importance of each component of the apoptosome
complex in regulating apoptosis. Deleting apaf-1, casp-3 or casp-9 causes inhibition of
nearly all neuronal cell death during normal development (Honarpour et al., 2001; Kuida et
al., 1996; Kuida et al., 1998; Yoshida et al., 1998). Upon UV- or g-irradiation, MEFs and
embryonic stem cells from these mice failed to stimulate caspases. In the same way,
cytochrome c KO cells were resistant to various death stimuli (Li et al., 2000).
Besides cytochrome c, several other apoptogenic factors are released from the
mitochondrial intermembrane space into the cytosol: Smac/Diablo, HtrA2/Omi, AIF and
Endo G. Smac (Second Mitochondrial Activator of Caspases) or Diablo (Direct IAP
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Binding protein with Low pI) contains a N-terminal mitochondrial targeting sequence that
is removed on import into the intermembrane space of mitochondria. Upon various
apoptotic stimuli, leakage of mature Smac into the cytosol leads to its binding to IAPs
(inhibitor of apoptosis) and subsequently to IAP inhibition (Du et al., 2000; Verhagen et
al., 2000). Structural and biochemical studies have demonstrated that the first four amino
acids of mature Smac (AVPI) were responsible for the interaction with the BIR2 and BIR3
domains of XIAP (Chai et al., 2000; Chai et al., 2001; Liu et al., 2000; Srinivasula et al.,
2001; Wu et al., 2000). By binding to IAPs, Smac displaces active caspases and thus
promote cell death, for example Smac relieved the inhibition of processed caspase-9 by
associating to XIAP in response to UV irradiation (Ekert et al., 2001). Recently, it has
been shown that a splice variant of Smac lacking its IAP-binding domain was also able to
cause apoptosis to the same extent as Smac (Roberts et al., 2001). Therefore, caspase
activation facilitated by Smac may involve additional mechanisms that are independent
from its interaction with IAPs. Smac-deficient mice are viable, grow normally and no
histological aberrations have been observed suggesting the existence of a redundant pro-
apoptotic protein that can substitute the function of Smac (Okada et al., 2002). Recently,
HtrA2/Omi (high temperature requirement) has been identified by four different groups as
a novel IAP binding protein that is released from the mitochondria into the cytosol upon
treatment with staurosporine or UV-irradiation (Hegde et al., 2002; Martins et al., 2002;
Suzuki et al., 2001b; Verhagen et al., 2002). Besides its pro-apoptotic effect through
caspase liberation from IAP binding, HtrA2 is able to function as a serine protease that
promotes apoptosis in a caspase-independent manner (Hegde et al., 2002; Suzuki et al.,
2001b). Crystal structure analysis of HtrA2/Omi revealed that its active conformational
state is a homotrimer since monomeric mutants are unable to induce cell death and are
deficient in serine protease activity (Li et al., 2002). Two further proteins, AIF (apoptosis
inducing factor) and Endo G (endonuclease G), have been reported to translocate from
mitochondria to nuclei during apoptotic conditions catalyzing high molecular weight DNA
cleavage and nucleosomal DNA fragmentation, respectively (Li et al., 2001; Susin et al.,
1996; Susin et al., 1999). Given that AIF as well as Endo G exerts their pro-apoptotic
effects independent of caspase activation indicates the existence of two parallel
mitochondrial pathways, a caspase-dependent and caspase-independent way.
The death receptor pathway was thought to act independently from the mitochondrial
cell death pathway converging on the level of downstream caspases. However, a crosstalk
between these two signalling pathways has been discovered (Gross et al., 1999b; Li et al.,
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1998; Luo et al., 1998). Upon activation of surface receptors Bid, a Bcl-2 family member,
is cleaved by caspase-8 generating truncated Bid (tBid) that translocates from the cytosol
to mitochondria and induces cytochrome c release in cooperation with other death agonists
of the Bcl-2 family (Fig. I-3). Hepatocytes from bid KO mice are resistant to Fas and TNF-
induced apoptosis, but remain susceptible to apoptotic stimuli that signals via mitochondria
and do not use the death receptor pathway (Yin et al., 1999).
I.5 Core components of the cell death process
Caspases, the aspartate-specific cysteine proteases, have been involved in the process
of apoptosis with the discovery of ced-3 that is required for cell death in the nematode
Caenorhabditis elegans (Yuan et al., 1993). Although fourteen different caspases have
been identified throughout the last decade, comparison of caspases between species could
provide clear evidence for the existence of only twelve conserved caspases. These
proteases can be classified into two functional groups (Fig. I-4): those that are implicated
in the processing of pro-inflammatory cytokines (caspases-1, -4, -5 and -11) and those that
are involved in the apoptotic scenery (caspases-2, -3, -6, -7, -8, -9, -10 and -12). The
apoptotic group can be divided into two subgroups. Initiator caspases (-2, -8, -9, -10 and -
12) play a pivotal role in initiating caspase activation cascade during apoptosis and contain
long N-terminal protein domains such as caspase-recruitment domain (CARD) and death
effector domain (DED) that promote their interaction with activator molecules (Hofmann,
1999). These caspases generally act upstream of the small prodomain-containing apoptotic
executioners (caspase-3, -6, -7), which are thought to be responsible for the demolition
phase of programmed cell death by cleaving specific death substrates (Thornberry and
Lazebnik, 1998).
All caspases are synthesized as inactive proenzymes that comprise three domains: a N-
terminal prodomain, a large subunit containing the active cysteine within a conserved Q-A-
C-X-G motif and a C-terminal small subunit. Caspases recognize a tetrapeptide motif (X-
E-X-D) in their substrates with an absolute requirement for aspartic acid in the P1 position
and a preferred P3 position for glutamic acid (Thornberry et al., 1997). To be activated,
they are first cleaved between the large and small subunit followed by a second proteolytic
event that removes the N-terminal prodomain. Structural characterization of different
caspases revealed that the active caspase is built up as a tetramer of two large and two
small subunits, with two active sites (Blanchard et al., 1999; Chai et al., 2001; Renatus et
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al., 2001; Rotonda et al., 1996; Walker et al., 1994; Wilson et al., 1994). Remarkably, all
these cleavage sites occur at specific aspartic acid residue suggesting that caspases are
capable to auto-activate themselves or to transactivate other caspases as part of an
amplification cascade (Thornberry et al., 1997).
Figure I-4. Structural organisation of mammalian caspases. (A) Based on their phylogenetic relationship, caspases can be
divided into three groups: inflammatory caspases (black; only caspase-1 is shown) that mediate cytokine maturation,
while the apoptotic caspases are either downstream effectors (orange) or upstream effectors (purple) of cell death. The
position of the first activation cleavage between the large (p20) and small (p10) subunits is illustrated with a large arrow.
Removal of the prodomain of a caspase is not required for its catalytic activity (medium arrows). Additional cleavage
sites are represented by small arrows. The four surface loops (L1-L4) that shape the catalytic groove are shown. (B)
Caspases are synthesized as precursors and their activation involves proteolytic processing between domains resulting in
association of the large and the small subunits to form a heterotetramer (modified according to Shi, 2002).
Besides the initiation of the apoptotic process by caspase-2, -8 and -10 via death
receptor pathway or by caspase-9 via mitochondrial pathway, it has recently been reported
the identification of a third initiation mechanism via the endoplasmic reticulum (Nakagawa
et al., 2000). Caspase-12 mediates an ER-specific cell death pathway that is required for
amyloid-b protein specific neurotoxicity found in Alzheimer’s disease.
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Among the downstream effectors, caspase-3 is thought to be the primary executioner
caspase, while caspase-6 and -7 seem to play a minor, more specialized role in the
degradation phase of apoptosis (Slee et al., 2001). Most probably, these three effector
caspases are responsible for the apoptotic phenotype by cleavage of important substrates.
These caspase substrates can be divided into different categories depending on their
putative function within the cell. Targets for caspases are pro- and anti-apoptotic proteins
as well as molecules implicated in signalling, cell structure, cellular repair and
macromolecular synthesis (Wolf et al., 1999). Caspase-3 is able to cut the anti-apoptotic
proteins Bcl-2 and Bcl-xL converting their C-terminal fragments into pro-apoptotic
molecules (Cheng et al., 1997; Clem et al., 1998). Another caspase-3 target is the
mentioned ICAD, whose cleavage leads to translocation of nuclease CAD into the nucleus
causing internucleosomal DNA-fragmentation (Enari et al., 1998; Liu et al., 1997;
Sakahira et al., 1998). Cleavage of lamins results in nuclear shrinkage and budding
(Buendia et al., 1999; Rao et al., 1996). Loss of cell structure may be caused by cleavage
of cytoskeletal proteins including gelsolin and fodrin (Kothakota et al., 1997). Poly (-ADP-
ribose) polymerase (PARP) cleavage probably facilitates DNA-degradation during
apoptosis by preventing its function as a double-strand break repair enzyme (Casciola-
Rosen et al., 1996). In some cases, removal of the inhibitory subunit results in increased
protein activity, for example cleavage of p21-activated kinase 2 (Pak2) and Rho-associated
kinase 1 (Rock-1) leads to truncated proteins with enhanced kinase activity that contribute
to blebbing of the plasma membrane (Coleman et al., 2001; Rudel and Bokoch, 1997;
Sebbagh et al., 2001). Up to date, more than 150 caspase substrates have been published
although their biological relevance is often unclear; probably many of them only represent
by-products of the cell death program. KO studies shed light on the physiological
importance of different caspases providing evidence that each caspase plays a distinct role
in various developmental processes within specific organs and tissues. Casp-8-deficient
mice fail to develop proper heart muscle, whereas deficiency of casp-3 or casp-9 results in
aberrant brain development (Kuida et al., 1998; Varfolomeev et al., 1998; Woo et al.,
1998). Lastly, several observations confirmed that additional proteases also function in the
apoptotic scenery in a cell-type specific manner such as granzyme B and perforin that are
released by cytotoxic T lymphocytes to promote killing of tumorigenic and virus-infected
cells (Heusel et al., 1994). Moreover, the calcium-dependent protease calpain, the aspartic
protease cathepsin D and the apoptosis protease 24 have been implicated in cell death
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induced upon certain stimuli such as Fas, TNFa , interferon g  or B cell receptor
crosslinking (Deiss et al., 1996; Ruiz-Vela et al., 1999; Wright et al., 1997).
As unrestricted caspase activation would have dramatic consequences for cell fate,
caspases must be kept in check by natural inhibitors. These inhibitors of apoptosis (IAPs)
were initially discovered in baculovirus, where they suppress cell death in infected host
cells. So far, eight distinct IAPs have been identified in the human genome. IAPs contain
one or more zinc-binding BIR (baculovirus IAP repeat) domains that are essential for their
anti-apoptotic properties (Salvesen and Duckett, 2002). XIAP, c-IAP1 and c-IAP2 have
been shown to directly inhibit caspase-3, -7 and -9, but not caspase-1, -6, -8 nor -10.
(Deveraux et al., 1997; Deveraux et al., 1999; Roy et al., 1997), among which XIAP seems
to have the broadest and strongest anti-apoptotic activity. The corresponding BIR domains
in XIAP, c-IAP1 and c-IAP2 are highly conserved in sequence and function. Structural
analysis demonstrated that the BIR3 domain of XIAP binds directly to the small subunit of
caspase-9 whereas the linker region between BIR1 and BIR2 specifically targets caspase-3
and -7 (Chai et al., 2001; Huang et al., 2001; Riedl et al., 2001; Srinivasula et al., 2001). In
this way, XIAP prevents binding of normal caspase substrates through masking the active
cysteine residues in the caspase dimer. Several IAPs possess a C-terminal RING domain
that catalyzes the degradation of both themselves and the bound caspase by ubiquitination
(Yang et al., 2000). In response to stress stimuli, the IAP-mediated caspase inhibition can
be removed by, at least, two pro-apoptotic proteins, Smac and HtrA2 (Chai et al., 2000;
Srinivasula et al., 2000; Suzuki et al., 2001b) that are able to interact with IAPs through
their IAP-binding tetrapeptide motif. Recently, additional functions for IAPs have been
observed including cell cycle regulation and signal transduction (Levkau et al., 2001;
Yamaguchi et al., 1999).
Besides IAPs, several other proteins appear to block the apoptotic pathway by caspase
inhibition. Hsp70 was found to be associated to Apaf-1 within the apoptosome preventing
recruitment of procaspase-9 (Beere et al., 2000; Saleh et al., 1999). Alpha B-crystallin can
interact with partially processed caspase-3 that results in inhibition of autoproteolytic
processing of caspase-3 (Kamradt et al., 2001). The small heat shock protein Hsp27 blocks
etoposide-induced cell death by preventing cytochrome c-dependent activation of
procaspase-9 (Garrido et al., 1999).
In approximately 80% of patients with human follicular B-cell lymphoma, the proto-
oncogene bcl-2 is translocated next to the immunoglobulin heavy chain enhancer on
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chromosome 14 leading to its massive overexpression in B cells (Tsujimoto et al., 1985).
Further studies demonstrated that Bcl-2 suppresses lymphocyte apoptosis rather than
promoting cell proliferation (Vaux et al., 1988). Hence, the involvement of Bcl-2 in the
t(14;18) chromosomal translocation and its novel function as anti-apoptotic molecule
prompted investigators to search for other related proteins. Proteins of the Bcl-2 family
play a pivotal role in the cell death scenery by regulating the apoptotic threshold at the
mitochondrial level (Cory and Adams, 2002). This family comprises both anti- and pro-
apoptotic members (Fig. I-5). The pro-survival proteins of the Bcl-2 family share three to
four regions of similarity (BH1-BH4: Bcl-2 Homology) and include five proteins: Bcl-2,
Bcl-xL, Bcl-w, A1 and Mcl-1. The pro-apoptotic Bcl-2-like proteins can be divided into
two subclasses. The Bax-like subgroup including Bax itself, Bak and Bok/Mtd contains
BH1 – BH3 domains, but lacks the N-terminal BH4 domain. The second subgroup, the
BH3-only proteins (Bad, Bid, Bik/Nbk, Bim/Bod, Blk, Bmf, Nip3, Nix and Noxa and
Puma), shares only homology in a stretch of 9-16 amino acids, called BH3 motif (Fig. I-5)
suggesting that this domain has emerged from convergent evolution (Gross et al., 1999a;
Strasser et al., 2000).
Figure I-5. Schematic diagram of the Bcl-2 family of proteins. Bcl-2 family members possess up to four Bcl-2 homology
domains (BH1-4) and a C-terminal hydrophobic transmembrane segment (TM) allowing their insertion into membranes.
This family includes both anti-apoptotic and pro-apoptotic members. The latter can be further subdivided into two groups
based on structure-function analyses: the multidomain Bax-subfamily and a divergent subset of BH3-only members.
Conserved a-helices are indicated (modified according to Cory and Adams, 2002).
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Many Bcl-2 members also possess a conserved C-terminal transmembrane region that
mediates their localization to different organelles including nuclear envelope, endoplasmic
reticulum and in particular to the outer mitochondrial membrane (Krajewski et al., 1993;
Mathai et al., 2002; Riparbelli et al., 1995; Zha et al., 1996b). The BH3 motif constitutes
structurally an amphipathic helix capable of binding to the hydrophobic cleft formed by
BH1, BH2 and BH3 domains of pro-survival members (Sattler et al., 1997). Mutational
analysis of the BH3 region indicates that substitution along the hydrophobic face with
charged residue influence the potential to dimerize and to exert its killing function (Wang
et al., 1998b). Interaction between the distinct Bcl-2 family members have been described
in a series of studies using techniques such as yeast two hybrid, co-immunoprecipitation,
crosslinking experiments and in vitro binding assays (Hirotani et al., 1999; Minn et al.,
1999; Oltvai et al., 1993; Zha et al., 1997). Although Bax and Bid belong to different pro-
apoptotic subgroups and are therefore supposed to function at different levels in the
apoptotic pathway, NMR studies revealed a strikingly similar structure (Chou et al., 1999;
McDonnell et al., 1999; Suzuki et al., 2000). Furthermore, these protein structures even
resemble those structures of the anti-apoptotic molecules Bcl-xL and Bcl-2 (Muchmore et
al., 1996; Petros et al., 2001). The proteins comprise two central hydrophobic helices (a5
and a6) bordered by amphipathic helices as well as flexible loops that link the a-helices
(Fig. I-5).
Bcl-2 can exert its anti-apoptotic effect in response to a broad range of death stimuli
such as g-irradiation, glucocorticoids, DNA-damage and chemotherapeutics agents
(Miyashita and Reed, 1993; Nunez et al., 1990; Ryan et al., 1994; Zhan et al., 1999). Bcl-2
is an integral membrane protein in healthy cells located in mitochondria, ER and nuclear
envelope, whereas Bcl-w and Bcl-xL get only in tight contact with organelle membranes
upon an apoptotic stimulus (Janiak et al., 1994). The C-terminal transmembrane anchor
appears to be necessary for its pro-survival function, since mutants lacking this domain
show a reduced ability to inhibit cell death (Nguyen et al., 1994; Tanaka et al., 1993). As
the Bcl-2 protein sequence did not exhibit any similarity with known enzymes, research
has been extensively focused on its biochemical and molecular functions in recent years.
The markedly similarity of Bcl-xL to pore-forming domains of bacterial proteins including
diphtheria toxin and colicins (Muchmore et al., 1996) lead to the proposal that Bcl-2
family members are able to form ion channels in synthetic lipid membranes, which has
been confirmed in case of Bcl-2, Bcl-xL and Bax (Antonsson et al., 1997; Minn et al.,
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1997; Schendel et al., 1997; Schlesinger et al., 1997). Bcl-2 and Bcl-xL only form channels
under non-physiological acidic conditions and show preference for K+, while Bax ion
channels seem to occur at pH neutral conditions with a slight Cl- preference. Probably, this
kind of pore forming into intracellular membranes is implicated in the regulation of cell
death at the mitochondria level. Expression of Bcl-2 and Bcl-xL prevents the leakage of
cytochrome c from the mitochondria into the cytosol in response to many death-inducing
factors, whereas Bax promote it thereby activating caspases (Jurgensmeier et al., 1998;
Kluck et al., 1997; Vander Heiden et al., 1997; Yang et al., 1997a). Further experiments
demonstrated that Bcl-2 can regulate a series of metabolic events at mitochondria
suggesting that it act as a general guardian of mitochondrial physiology. Bcl-2 was shown
to block the generation of reactive oxygen species and intracellular acidification, to
stabilize the mitochondrial membrane potential and to regulate the mitochondrial proton
flux. These Bcl-2 functions have been correlated with its ability to prevent apoptosis
(Gottlieb et al., 1996; Hockenbery et al., 1993; Kane et al., 1993; Shimizu et al., 1998;
Zamzami et al., 1995).
The anti-apoptotic function of Bcl-2 can be modulated by post-translational changes
such as phosphorylation and proteolysis. Phosphorylation occurs at different serine and
threonine residues induced by drugs like paclitaxel and vincristine that affect microtubule
integrity. Probably, phosphorylated Bcl-2 cannot bind to Bax and loses the ability to fulfil
its pro-survival function (Haldar et al., 1995; Haldar et al., 1996; Srivastava et al., 1998).
On the contrary, Ito et al. (1997) have described Bcl-2 phosphorylation at serine 70 in
response to IL-3 that is required for its anti-apoptotic activity. Another report demonstrated
the dephosphorylation of Bcl-2 by PP2A in ceramide-induced cell death (Ruvolo et al.,
1999). Taken together, the function of Bcl-2 phosphorylation regulating its anti-apoptotic
role still remains obscure. The proteolytic cleavage of Bcl-2 and Bcl-xL results in reduced
anti-apoptotic activity and convert the cleaved product in pro-apoptotic molecules (Cheng
et al., 1997; Clem et al., 1998).
Besides its interactions with pro-apoptotic members (Bad, Bak, Bax and Bik), Bcl-2 is
able to bind to various non-Bcl-2 proteins including Ras (Fernandez-Sarabia and Bischoff,
1993), Raf (Wang et al., 1994), Bag-1 (Takayama et al., 1995), p53BP2 (Naumovski and
Cleary, 1996), Calcineurin (Shibasaki et al., 1997), SMN (Iwahashi et al., 1997) and
Presenilin (Alberici et al., 1999). The Ras isoform, R-Ras p23, was the first described Bcl-
2 interacting protein. Subsequently, other Ras family member have been shown to
associate with Bcl-2 such as K-, H- and N-Ras that show distinct behaviour in
Introduction
16
mitochondrial localization dependent on presence or absence of IL-2 (Rebollo et al., 1999).
The Ras-binding protein Raf-1 binds to Bcl-2 thus directing Raf-1 to mitochondria, where
it can enhance the anti-apoptotic activity of Bcl-2 (Wang et al., 1996). The interaction
between Bcl-2 and the serine/threonine phosphatase calcineurin results in the translocation
of calcineurin to cytoplasmic membranes and suppression of the activity of transcription
factor NFAT (Shibasaki et al., 1997). Bcl-2-deficient mice develop almost normal, but they
show some abnormalities with increasing age such as hair hypopigmentation, distortion of
their small intestines and polycystic kidney disease (Veis et al., 1993).
Bcl-x shows significant similarity to Bcl-2. Alternative splicing arise two Bcl-x
isoforms, the death-suppressing Bcl-xL and the death-promoting Bcl-xs. The latter lacks the
BH1 and BH2 domain and can act as a dominant interfering regulator of either Bcl-xL or
Bcl-2 (Boise et al., 1993; Minn et al., 1996). Probably, Bcl-xs exerts its pro-apoptotic
function in a caspase-independent manner (Fridman et al., 1999; Fridman et al., 2001). In
mice and rat, a third isoform has been described although its role in PCD is not clear
(Gonzalez-Garcia et al., 1994; Shiraiwa et al., 1996). In response to microtubule- or DNA-
damage, phosphorylation of Bcl-xL by JNK may occur at distinct threonine residues
diminishing its pro-survival effects (Fan et al., 2000; Kharbanda et al., 2000). Although a
direct interaction between Bcl-xL and Apaf-1 has been demonstrated by in vitro
experiments, the physiological relevance remains doubtful (Hausmann et al., 2000; Hu et
al., 1998; Pan et al., 1998). The anti-apoptotic protein Aven might be a more promising
candidate that binds to Bcl-xL and Apaf-1 linking Bcl-2 family members to the apoptosome
(Chau et al., 2000). Transgenic expression of Bcl-xL causes resistance of lymphocytes to
cytotoxic insults provoked by dexamethasone, g-irradiation or ionomycin. These results
agree with observations described in Bcl-2 transgenic mice (Chao et al., 1995; Grillot et
al., 1995). Despite the similar functions of Bcl-2 and Bcl-xL in antagonizing the apoptotic
process, their physiological roles appear to be different. KO studies confirmed that bcl-xL-
deficient mice, in contrast to the viable bcl-2 KO mice, die at embryonic age E13 with
profound apoptosis of differentiating neurons in the developing brain, spinal cord and
dorsal ganglia and of haematopoietic cells in liver (Motoyama et al., 1995). The anti-
apoptotic Bcl-2 family includes additional member such as Bcl-w, A1/Bfl-1 and Mcl-1.
Overexpression of Bcl-w protects cells from PCD triggered by IL-3 withdrawal or
irradiation (Gibson et al., 1996). In Bcl-w molecules, the C-terminal tail can occupy the
hydrophobic cleft formed by BH1, BH2 and BH3 domains as it was demonstrated for Bax.
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Gene targeting of bcl-w, a1 and mcl-1 revealed different roles in development. In the
absence of bcl-w, mice are viable, but show deep defects in spermatogenesis. A1-defecient
mice exhibit accelerated neutrophil apoptosis and mcl-1 deficiency results in peri-
implantation embryonic lethality at E3.5–4 (Hamasaki et al., 1998; Print et al., 1998;
Rinkenberger et al., 2000; Ross et al., 1998).
Until recently, it was not clear if pro-apoptotic multidomain Bax/Bak-like proteins
function in the same way as BH3-only proteins. Experiments with double KO mice for
Bax/Bak have elucidated that Bax and Bak have indeed a distinct role in apoptosis
regulation compared to BH3-only proteins. Mice deficient either in bax or bak do not
exhibit severe impairments but those lacking both genes showed profound developmental
defects and about 90% die perinatally (Lindsten et al., 2000). Remarkably, BH3-only
proteins including Bad, Bid, Bim or Noxa are incapable to induce apoptosis in embryonic
fibroblast of bax-/-bak-/- mice, whereas mice lacking only one copy of each gene are prone
to undergo programmed cell death (Cheng et al., 2001; Zong et al., 2001). These results
demonstrate that BH3-only proteins are merely able to kill cells in the presence of
Bax/Bak-like proteins. On the other hand, Bax/Bak-like proteins require a death-inducing
signal from BH3-only proteins that act as stress sensors of the cell. Thus, BH3-only
proteins and Bax/Bak-like proteins appear to function at different levels and to be
indispensable for initiation of the apoptotic process.
Bax and Bak are ubiquitously expressed, while the less well-studied Bok protein can
predominantly be found in reproductive tissues. All of them have three BH domains, BH1-
BH3, and contain a C-terminal hydrophobic domain. Numerous Bax splice variants have
been detected (Apte et al., 1995; Thomas et al., 1999; Zhou et al., 1998), one splice
isoform of Bok and a neuron-specific splice transcript of Bak (N-Bak) have also been
described (Hsu and Hsueh, 1998; Sun et al., 2001). Interestingly, N-Bak lacks BH1 and
BH2 domains and its overexpression results in apoptotic cell death in non-neuronal cells,
but not in neurons (Sun et al., 2001). Upon apoptotic stimuli, Bax expression was found to
be upregulated mediated by the tumor suppressor protein p53 and several SP1-like factors
(Krajewski et al., 1995; Miyashita and Reed, 1995; Thornborrow and Manfredi, 2001).
However, mice lacking only one copy of either bax or bak show a normal phenotype
(Lindsten et al., 2000) suggesting that the gene dosage is less important and that
transcriptional upregulation of Bax and Bak does not appear to play a critical role in
apoptosis regulation.
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In healthy cells or tissues, Bax is mainly localized in the cytosol as a monomer
(Desagher et al., 1999; Hsu and Youle, 1998; Nechushtan et al., 1999; Wolter et al., 1997).
On the contrary, Bak seems to be associated to mitochondria of normal cells (Griffiths et
al., 1999; Krajewski et al., 1996). In response to apoptotic stimuli, Bax changes its
conformation and translocates to mitochondria where it is found as large oligomers
(Antonsson et al., 2001; Hsu et al., 1997). Both, the N-terminal and the C-terminal domain
are implicated in the conformational change. The C-terminal a-helix was shown to occupy
the hydrophobic groove formed by BH1, BH2 and BH3 domains, whereas this domain is
removed from the cleft in apoptotic cells leading to complex formation (Desagher et al.,
1999; Suzuki et al., 2000). Although little is known about Bak, it appears to behave in the
same manner like Bax. It has been reported that Bak interacts with Bcl-xL at the
mitochondria suggesting neutralization of Bak’s pro-apoptotic role. After apoptotic
stimulation, Bak is released due to its conformational change and is able to exert its pro-
apoptotic activity via oligomerization (Griffiths et al., 1999; Nechushtan et al., 2001). Bax
and Bak can be activated by interaction with the BH3-only protein tBid resulting in their
oligomerization and insertion into the outer mitochondrial membrane (Eskes et al., 2000;
W e i  et al., 2000). The observations that enforced dimerization and constitutive
mitochondrial localization of Bax enhance its pro-apoptotic effect underline the importance
of Bax oligomers at mitochondria in PCD (Gross et al., 1998; Suzuki et al., 2000). Indeed,
Bax oligomers show channel activity whereas Bax monomers are not able to form pores.
These Bax channels have multiconductance levels, are pH sensitive, slightly cation
selective, Ca2+ insensitive (Antonsson et al., 1997; Schlesinger et al., 1997) and are capable
to release cytochrome c from liposomes (Saito et al., 2000). The anti-apoptotic protein Bcl-
2 has been reported to block Bax activation by preventing its oligomerization. The
molecular mechanism still remains unclear. Bcl-2/Bax interaction has been observed by
fluorescence resonance energy transfer (Mahajan et al., 1998), but immunoprecipitation
and crosslinking experiments gave no hints for such association (Mikhailov et al., 2001).
So far, ten distinct BH3-only proteins have been described in mammals (Fig. I-5)
(Fleischer et al., in press; Huang and Strasser, 2000). The question for this redundancy is
certainly justified. It has been suggested that BH3-only members are thought to function as
death sensors, by which various death stimuli seem to activate different BH3-only proteins.
Most probably, they could exert their pro-apoptotic activity in a cell-type specific manner
transducing the apoptotic signal to mitochondria (Bouillet and Strasser, 2002) suggesting
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that they function upstream in the apoptosis pathway. Despite the heterogeneity and poor
definition of the BH3 motif, two conserved residues can be identified on closer inspection,
namely the leucine and aspartic acid residues that represent the most responsible amino
acids for mediating the pro-apoptotic activity of the BH3 domain (Lutz, 2000; Wang et al.,
1998b; Zha et al., 1997). Very recent experiments gave more detailed information about
the function of the BH3 domain (Letai et al., 2002). Here, the authors distinguished
between two classes of BH3-only proteins. Upon a cell death-inducing stimulus, Bid-like
BH3 domains are able to bind to Bax and Bak. This direct interaction leads to Bax/Bak
activation and oligomerization in mitochondrial membranes accompanied with subsequent
cytochrome c release into the cytosol. The anti-apoptotic members Bcl-2 and Bcl-xL that
act as a kind of decoy receptors are able to block the pro-apoptotic effect by sequestration
of Bid-like BH3 ligands. Conversely, instead of activating the multi-BH domain family
member, the Bad-like BH3 proteins trigger apoptosis by binding and neutralizing Bcl-2
and Bcl-xL. In this way, Bid-like BH3 ligands get to be free from their sequestration by
Bcl-2 and Bcl-xL and can function as activators of multi-BH domain family members.
Regarding these new findings, the selectivity of each BH3-only protein has yet to be re-
examined with caution. Recent studies have shed light on the mechanisms, by which BH3-
containing proteins are controlled. Depending on death signals or survival factors they will
be activated or deactivated, respectively. BH3-only proteins are regulated by a variety of
transcriptional and post-translational mechanisms that are subsequently discussed more in
detail.
I.6 Transcriptional and post-translational regulation of BH3-only
proteins
The fact that expression of the C. elegans BH3-protein Egl-1 lies under control of
different transcription factors or repressors (Conradt and Horvitz, 1998; Conradt and
Horvitz, 1999) has prompted scientists to search for transcriptionally regulated BH3-only
proteins in mammals (Wang, 2001). In addition, requirement of de novo synthesis of
specific messenger RNA and their translated products was shown to play an important role
in the induction of the apoptotic process. Indeed, PCD can sometimes be suppressed by
inhibiting transcription or translation suggesting that apoptosis is mediated by new
synthesized cellular components (Fortin et al., 2001; Holcik et al., 2000). Several studies
have been performed to identify genes that are activated by p53 and activate the apoptotic
pathway (Reed, 1999). Recently, Puma/Bbc3 as well as Noxa have been described as p53-
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inducible genes that appear to transduce apoptotic signals in response to DNA-damage
(Han et al., 2001; Nakano and Vousden, 2001; Oda et al., 2000; Yu et al., 2001). Puma is
localized to mitochondria, where it interacts with Bcl-2 resulting in cytochrome c release
as well as caspase-9 and -3 activation. On the contrary, another group has demonstrated
that Puma can also be upregulated by p53-independent death stimuli including
dexamethasone treatment of thymocytes and serum deprivation in cancer cells suggesting
that Puma acts as a common target in diverse apoptotic signalling pathways (Han et al.,
2001). Noxa has been discovered as a second p53-target gene by mRNA differential
display. Upon x-ray irradiation, increased expression of Noxa mRNA and protein has been
shown in wild-type, but not in p53-deficient thymocytes. Noxa translocates to
mitochondria and associates with anti-apoptotic Bcl-2 and Bcl-xL leading to a decrease in
mitochondrial membrane potential and cytochrome c leakage into the cytosol.
Another mammalian BH3-only protein DP5 is transcriptionally regulated in rat
sympathetic neurons after NGF deprivation or following exposure to amyloid b peptides
(Imaizumi et al., 1997; Imaizumi et al., 1999). Optic nerve transection can also cause
increased DP5 expression in the adult rat that was stably expressed at high levels for one
week (Wakabayashi et al., 2002). Moreover, the human homologue of DP5, Harakiri
(Hrk), functions as a rapid upregulated protein in haematopoietic progenitors after growth
factor deprivation or treatment with chemotherapeutic drugs, probably through regulation
of intracellular calcium stores (Sanz  et al., 2000). The same group described a
transcriptional repression mechanism triggered by IL-3 that blocks the expression of Hrk
(Sanz et al., 2001). The 3’ untranslated region of the hrk gene contains a downstream
regulatory element (DRE), to which the calcium-controlled protein Dream is able to bind
and to inhibit the transcription of Hrk in the presence of IL-3. The activity of Dream is
regulated by calcium mobilization and direct phosphorylation through a PI3-kinase
dependent pathway.
Recent studies have suggested that Hrk and Bim are induced in neuronal cells
undergoing apoptosis following trophic or growth factor withdrawal. This induction seems
to be dependent on the JNK signalling pathway since addition of the inhibitor of JNK
CEP-1347 blocks the upregulation of BH3-only proteins in hyperpolarized granule neurons
(Harris and Johnson, 2001; Whitfield et al., 2001). Bim deletion in NGF- or K+-deprived
neurons leads to protection against cytochrome c release and neuronal apoptosis (Putcha et
al., 2001). Elevated Bim levels through activation of the Forkhead transcription factor
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FKHR-L1 have been reported in lymphocytes upon IL-3 withdrawal. PI3K/PKB-mediated
inhibition of FKHR-L1 can therefore contribute to survival of haematopoietic cells
(Dijkers et al., 2000; Dijkers et al., 2002). Another Forkhead transcription factor FoxO3
has been implicated in the upregulation of Bim (Stahl et al., 2002). They proposed a
model, in which FoxO transcription factors are inactivated by IL-2 resulting in T cell
proliferation and survival. Recently, several groups have identified some novel isoforms of
Bim, indicating that alternative splicing might play an important role in Bim regulation but
the functions of the distinct isoforms have yet to be determined (Liu et al., 2002; Marani et
al., 2002; U et al., 2001). Bimg inhibits clonal growth and promote apoptosis in prostate
cancer cells. BimAD and BimS are able to interact with the pro-apoptotic multidomain
member Bax leading to its conformational change required for its killing activity on
mitochondria.
The BH3-only protein Bid, known to be controlled by posttranslational modifications
as described below, has been identified by DNA microarray analysis as a target for the
transcription factor Ets-1 that is involved in PCD of serum-deprived HUVECs (Teruyama
et al., 2001). A different stress stimulus, high glucose levels, causes increased Bid and Bik
levels in human pancreatic islets of Langerhans (Federici et al., 2001). A further DNA
microarray study suggested that Bik is transcriptionally upregulated in E1A-induced
apoptosis that is mediated via p53 (Mathai et al., 2002). Elevated Bik expression was also
shown after sIGM ligation in human B lymphoma cells. Sustained Bik expression
correlates with B cell apoptosis since calcineurin or PI3K inhibitors are able to diminish
Bik transcription and consequently block the apoptotic process (Jiang and Clark, 2001).
The BH3-only protein Nip3 has been proposed to play a crucial role in cell death
triggered by hypoxia that occurs after ischemic injury. The transcription factors PlagL2
and HIFa appear to mediate Nip3 transactivation via a functional hypoxia-responsive
element located in the nip3 promoter (Bruick, 2000; Mizutani et al., 2002). Nix, a close
relative to Nip3, has been described as a mitochondrial death protein that is upregulated in
cardiac hypertrophy leading to cytochrome c release, activation of caspase-3 and apoptotic
cell death. Nix probably represents a key protein implicated in the development of heart
failure (Yussman et al., 2002).
Post-translational modifications play a critical role in the regulation of BH3-only
proteins. The pro-apoptotic function of Bad is regulated by its phosphorylation status.
Phosphorylation of Bad at serine 112 and 136 has been observed upon exposure of cells
Introduction
22
with different growth factors like PDGF, NGF, IL-2, IL-3 and IL-4 (Ayllon et al., 2000;
Ayllon et al., 2002a; Blume-Jensen et al., 1998; Datta et al., 1997; del Peso et al., 1997).
Akt is the major kinase responsible for serine 136 phosphorylation (Datta et al., 1997; del
Peso et al., 1997), although other protein kinases such as Pak1, PKCq and p70S6K were
also shown to phosphorylate this serine residue depending on the stimulus (Datta et al.,
1997; del Peso et al., 1997; Harada et al., 2001; Schurmann et al., 2000; Villalba et al.,
2001). The kinases PKA and RSK phosphorylate Bad at serine 112 upon IL-3 withdrawal
or TPA stimulation (Harada et al., 1999; Tan et al., 1999). These phosphorylation events
mediate the interaction between Bad and the cytoplasmic protein 14-3-3, thus avoiding its
association with Bcl-2 and Bcl-xL and promoting cell survival (Zha et al., 1996b).
However, it has been published that the 14-3-3/Bad interaction cannot be recovered in vivo
by means of co-immunoprecipitation experiments (Ayllon et al., 2001; Ayllon et al.,
2002a). One explanation could be the great diversity of pathways that growth factor use for
survival signalling. Later, several groups described an additional Bad phosphorylation site
at serine 155 by PKA or RSK (Datta et al., 2000; Lizcano et al., 2000; Virdee et al., 2000;
Zhou et al., 2000). This phosphorylation site also serves to inhibit binding between Bad
and Bcl-xL blocking the pro-apoptotic function of Bad. Recently, two further
phosphorylation sites have been identified at serine 128 and 170. The phosphorylation at
serine 170 inactivate the pro-apoptotic effect of Bad (Dramsi et al., 2002), whereas serine
128 phosphorylation inhibit the association of Bad with 14-3-3 stimulating the cell death
activity of Bad in cerebellar granule neurons (Konishi et al., 2002). Except serine 128
phosphorylation, growth factors appear to inhibit Bad pro-apoptotic function by inducing
phosphorylation at one or more serine residues. Growth factor deprivation results in Bad
dephosphorylation, allowing its migration to mitochondria, where it promotes apoptosis.
So far, three serine/threonine Bad phosphatases have been described: PP1a, PP2A and
PP2B (Calcineurin) (Ayllon et al., 2000; Chiang et al., 2001; Wang et al., 1999). PP1 is a
holoenzyme that requires a regulatory subunit to access its substrates (Cohen, 2002) (Fig.
I-6). Upon IL-2 and IL-4 deprivation, Bcl-2 as well as Bcl-w or Bcl-xL are able to function
as regulatory subunits that direct PP1a to Bad for its dephosphorylation (Ayllon et al.,
2001; Ayllon et al., 2002a). Alternatively, subcellular localization and caspase cleavage
influence the cell death-inducing activity of Bad as described below. Two further BH3-
only proteins have been shown to be controlled by phosphorylation. Bik is phosphorylated
at threonine 33 and serine 35 by a kinase related to casein kinase II. These phosphorylation
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events are required for efficient Bik-mediated cell death, but they do not affect the
interaction between Bik and Bcl-2 (Verma et al., 2001). Finally, several serine residues of
Bid are phosphorylation targets for CKI and CKII and its phosporylation prevents cleavage
by caspase-8 (Desagher et al., 2001).
Figure I-6. The serine/threonine phosphatase PP1 is a holoenzyme and consists of a catalytic (PP1c) as well as a
regulatory subunit. Depending on the regulatory subunit, PP1 is targeted to distinct substrates thus regulating diverse
cellular processes including transcription, muscle contraction, neuronal signalling and apoptosis.
Several BH3-only proteins are activated or deactivated via proteolysis. In healthy
cells, Bid remains in the cytosol and different apoptotic signals induce its cleavage and
translocation of the truncated molecule (tBid) to mitochondria, where it promotes exit of
cytochrome c. After death receptor stimulation, activated caspase-8 cleaves Bid generating
two fragments (Li et al., 1998; Luo et al., 1998). The carboxy-terminal fragment has a
newly exposed glycine residue that is myristoylated and targets tBid to mitochondria (Zha
et al., 2000). Bid can also be proteolysed by granzyme B during granule-mediated
cytotoxic T-lymphocyte killing (Barry et al., 2000; Heibein et al., 2000) and its truncated
product translocates to mitochondria. The cleavage site of caspase-8 differs from that of
granzyme B. The described phosphorylation site of Bid only affects caspase-8, but not
granzyme B cleavage (Desagher et al., 2001). Calpain is another protease that is involved
in Bid cleavage triggered by cisplatin or myocardial ischemia resulting in cytochrome c
release from the mitochondria (Chen et al., 2001; Mandic et al., 2002). Recently, it has
been shown that Bad serves as a caspase-3 substrate in response to IL-3 deprivation
enhancing the pro-apoptotic activity of Bad. This truncated fragment is hardly
• Subunit M110 (muscle contraction)
• Subunit GM (glycogen metabolism)
• Spinophilin (neuronal signalling)
• NIPP1 (RNA processing)
• AKAP149 (Lamin polymerization)
• Bcl-2 (programmed cell death)
Introduction
24
phosphorylated at serine 112 and 136 and it weekly interacts with 14-3-3 but its binding to
Bcl-xL remains unaffected (Condorelli et al., 2001).
One strategy to modulate protein function is to control its subcellular localization to
distinct organelles or cellular structures. The BH3-only protein Bim is regulated by
transcriptional upregulation and by alternative splicing. However, two isoforms BimL and
BimEL are also controlled by their interaction with the microtubule-associated dynein motor
complex. In healthy cells, BimL and BimEL are associated to LC8 (component of the dynein
motor complex) thereby sequestered to these cytoskeletal structures. Upon an apoptotic
stimulus, both proteins are released and translocate to cytoplasmic membranes, where they
bind to Bcl-2 (Puthalakath et al., 1999). This process occurs independent of caspase
activity assuming an upstream signalling event in apoptosis. Another BH3-only protein
Bmf is controlled in a similar way being sequestered in the myosin V actin motor by its
binding to LC2 in healthy cells. Certain damage signals including anoikis (loss of cell
attachment) induce the release of Bmf together with LC2 allowing them to interact with
Bcl-2 at mitochondria; this process is also caspase-independent (Puthalakath et al., 2001).
The authors have proposed a model, in which Bim as well as Bmf function as “sentinels”
localized on the main cytoskeletal structures that are able to sense intracellular cell
damage.
Besides phosphorylation and cleavage, the function of Bad is also regulated by
subcellular localization. In IL-4 stimulated T-cells, Bad does not interact with 14-3-3, but a
major fraction of Bad was found in rafts (plasma membrane microdomains enriched in
sphingolipids and cholesterol) (Ayllon et al., 2002b). This pool of Bad is dephosphorylated
but it is unable to exert its pro-apoptotic function because it is sequestered in these plasma
membrane structures. Withdrawal of IL-4 induces disorganization of lipid rafts resulting in
segregation of dephosphorylated Bad from plasma membrane and translocation to
mitochondria correlating with T-lymphocyte death.
I.7 Control of mitochondrial protein release by the Bcl-2 family
Mitochondria are the main target for the action of the Bcl-2 protein family. However,
the precise molecular mechanism, by which pro-survival members prevent and pro-
apoptotic members induce permeabilization of the outer mitochondrial membrane is still a
matter of debate. Two principle models have been proposed (Fig. I-7): the PTP model and
the Bax/Bak model (Martinou and Green, 2001; Zamzami and Kroemer, 2001).
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The first model implies the opening of the permeability transition pore (PTP) upon an
apoptotic stimulus. PTP is a multiprotein complex that contains as core components
VDAC (voltage-dependent anion channel) in the outer and ANT (adenine nucleotide
translocator) in the inner mitochondrial membrane (Crompton et al., 1999). The inner
membrane is nearly impermeable, a feature that is essential for oxidative phosphorylation.
The outer membrane allows the diffusion of particles up to 5 kDa such as ADP/ATP,
NADH and FADH (Zamzami and Kroemer, 2001). Opening of the PTP was reported to
result in loss of mitochondrial membrane potential, swelling of the mitochondrial matrix
and rupture of the outer membrane, allowing the leakage of apoptogenic proteins from the
intermembrane space into the cytosol (Fig. I-7A). Alternatively, the PTP could serve as a
channel for the release of these pro-apoptotic molecules. Members of the Bcl-2 family
including Bax, Bcl-2 and Bcl-xL have been shown to interact with ANT and VDAC (Marzo
et al., 1998a; Marzo et al., 1998b; Narita et al., 1998; Shimizu et al., 1999). Bax and Bak
are supposed to induce opening of the PTP, whereas Bcl-2 and Bcl-xL inhibit this
mechanism.
Figure I-7. Two distinct models for the release of mitochondrial apoptogenic proteins. (A) PTP model. Pro-apoptotic
Bcl-2-like proteins such as Bax interact with the PTP complex and trigger its opening leading to swelling of the
mitochondrial matrix and rupture of the outer mitochondrial membrane. Alternatively, the PTP could directly serve as a
channel for the release of intermembrane space proteins. Anti-apoptotic Bcl-2/Bcl-xL molecules prevent PTP opening.
(B) Bax/Bak model. BH3-only proteins transduce the death signal via two different mechanisms. Either Bid-like BH3
ligands bind directly to and activate Bax/Bak molecules or Bad-like BH3-only proteins associate with pro-survival
proteins including Bcl-2 and Bcl-xL to prevent sequestration of Bid-like BH3 ligands by Bcl-2/Bcl-xL. In both cases,
activated Bax/Bak proteins change their conformation and form oligomers in the outer mitochondrial membrane resulting
in leakage of apoptogenic proteins into the cytosol (modified according to van Loo et al., 2002)
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The second model presents a more active role for Bcl-2 like proteins (Fig. I-7B). In
response to death stimuli, BH3-only proteins mediate the apoptotic signal through two
different mechanisms. Either Bid-like BH3 ligands interact directly with Bax/Bak
molecules thereby activating multi-BH domain proteins or Bad-like BH3-only proteins
bind to pro-survival proteins Bcl-2 as well as Bcl-xL and prevent the sequestration of Bid-
like BH3 ligands by Bcl-2/Bcl-xL (Letai et al., 2002). In both cases, activated Bax and Bak
change their conformation and form oligomers in the outer mitochondrial membrane.
Probably, they are able to generate heterotetrameric channels, through which
intermembrane space proteins such as cytochrome c, AIF, endonuclease G, Smac and
HtrA2 are released (Antonsson et al., 2000; Saito et al., 2000; Suzuki et al., 2000). Once in
the cytosol, the apoptogenic factors can exert their pro-apoptotic effect resulting in death of
the cell.
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I.8 Aims of the study
The goal of the present study was to elucidate the signalling pathways implicated in
the regulation of the apoptotic process. Growth factor deprivation was used as a
physiological stimulus for induction of programmed cell death.
The specific aims were as follows:
1. Identification of new proteins involved in the induction of apoptosis
It is known that de novo synthesis of new messenger RNA is required for the apoptotic
process. On the basis of this observation, RDA (representational difference analysis) was
chosen as approach to screen for new genes that are transcriptionally upregulated in
response to IL-2 deprivation.
2. Identification of novel protein-protein interaction in programmed cell death
The yeast-two hybrid system and co-immunoprecipitation experiments were used to search
for novel apoptosis-related proteins that are able to interact with Bcl-xL and Bcl-w in IL-4-
dependent T-lymphocytes.
3. Contribution of subcellular localization of proteins to apoptosis
It has been described that some proteins change its cellular localization depending on death
or survival signals. To address this question, the different subcellular localization of the
pro-apoptotic molecule Bad was analyzed defining its role in IL-4-induced apoptosis.
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II Materials and Methods
II.1 Materials
II.1.1 Chemicals
Unless otherwise stated, all laboratory chemicals were of quality pro analysi and were
mainly purchased from Merck (Darmstadt, Germany), New England Biolabs (Beverly,
USA), Roche (Basel, Switzerland) and Sigma-Aldrich (St. Louis, MO). All standard
solutions, media and buffers were prepared according to Sambrook et al. (1989) and
Ausubel et al. (1994) using deionized, double-destilled water. Compositions of non-
standard buffers are listed in the respective method section. All solutions were sterilized by
autoclaving (25 min/121°C/2 bar) whereas thermolabile components were sterile filtered
(0.2 mm) and added to the media/buffer after autoclaving and cooling to 50°C.
II.1.2 Bacterial strains
The bacterial strains E. coli XL1-Blue or E. coli DH5a were used for conventional
cloning procedures. These strains are thought to be very suitable for yielding plasmid DNA
of high quality.
II.1.3 Plasmids
pcDNA3-Bcl-xL pcDNA3.1 expression construct containing the cDNA for
mouse Bcl-xL was kindly provided by Dr. L. del Peso
(Madrid, Spain).
pcDNA3-Aiolos pcDNA3 expression vector containing the cDNA for mouse
Aiolos.
pGAD-Bcl-xL pGAD expression construct containing the cDNA for Bcl-xL.
pCIneo-ITM2BS pCIneo expression vector containing the cDNA for the short
splice variant of murine ITM2B.
pCIneo-ITM2BS-HA pCIneo expression vector containing the cDNA for the short
splice variant of murine ITM2B fused with the hemagglutinin
tag (HA) at the C-terminal.
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pCIneo-HA-ITM2BS pCIneo expression vector containing the cDNA for the short
splice variant of murine ITM2B fused with the hemagglutinin
tag (HA) at the N-terminal.
pCIneo-ITM2BL pCIneo vector containing the cDNA for the long splice
variant of murine ITM2B.
pCIneo-ITM2BL-HA pCIneo expression vector containing the cDNA for the long
splice variant of murine ITM2B fused with the hemagglutinin
tag (HA) at the C-terminal.
pCIneo-HA-ITM2BL pCIneo expression vector containing the cDNA for the long
splice variant of murine ITM2B fused with the hemagglutinin
tag (HA) at the N-terminal.
pKCR-IL4.neo pKCR expression vector containing  the cDNA for murine
interleukin 4.
pSFFV-hBcl-2 pSFFV expression vector containing the cDNA for human
Bcl-2.
II.1.4 Enzymes and kits
Unless otherwise stated, enzymes for DNA manipulation were purchased from New
England Biolabs (Beverly, USA), Promega (Madison, WI) or Roche (Basel, Switzerland).
Kits for plasmid DNA purification were from Qiagen (Hilden, Germany).
II.1.5 Antibodies
Primary Antibodies
Anti-14-3-3 Upstate Biotechnology (Lake Placid, NY), rabbit, polyclonal.
Anti-Aiolos Generated in our laboratory, rabbit, polyclonal, against peptide
of Aiolos spanning amino acid sequence 368-384 (Romero et
al., 1999).
Anti-Bad Transduction Laboratories (Lexington, KY), mouse,
monoclonal.
Anti-Bad serine112 New England Biolabs (Beverly, MA), rabbit, polyclonal.
Anti-Bad serine155 Cell Signaling Technology (Beverly, MA), rabbit, polyclonal.
Anti-Bad serine136 New England Biolabs (Beverly, MA), rabbit, polyclonal.
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Anti-Bcl-2 Transduction Laboratories (Lexington, KY), mouse, mono-
clonal.
Anti-Bcl-xL Transduction Laboratories (Lexington, KY), mouse, mono-
clonal.
Anti-Bcl-w Calbiochem (La Jolla, CA), rabbit, polyclonal.
Anti-Calnexin Transduction Laboratories (Lexington, KY), mouse, mono-
clonal.
Anti-Caspase-3 Transduction Laboratories (Lexington, KY), mouse, mono-
clonal.
Anti-Caspase-3 BD Biosciences (San Jose, CA), rabbit, polyclonal.
Anti-Caspase-9 MBL (Naka-ku Nagoya, Japan), mouse, monoclonal.
Anti-Cytochrome c BD Biosciences (San Jose, CA), mouse, monoclonal.
Anti-GM1 Sigma-Aldrich (St. Louis, MO), anti-Cholera toxin-biotin
Anti-HA Babco (Richmond, CA), mouse, monoclonal.
Anti-Histones Chemicon International (Temecula, CA), mouse, monoclonal
Anti-ITM2B Generated in our laboratory, rabbit, polyclonal, against peptide
of ITM2BS spanning amino acid sequence 39-55 (Fleischer et
al., 2002a).
Anti-Lck Upstate Biotechnology (Lake Placid, NY), rabbit, polyclonal.
Mito 2813 Gift from Dr. A. Serrano (Madrid, Spain), obtained from the
serum of a patient with primary biliary cirrhosis, shown to
recognize the E2 polypeptide of the mammalian mitochondrial
pyruvate dehydrogenase complex (Claveria et al., 1998).
Anti-p53 Transduction Laboratories (Lexington, KY), mouse, mono-
clonal.
Anti-p55 IL-2R Gift from Dr. C. Pitton, mouse, monoclonal.
Anti-Phosphoserine Calbiochem (La Jolla, CA), mouse, monoclonal.
Anti-Phosphotyrosine Transduction Laboratories (Lexington, KY).
Anti-PP1a Calbiochem (La Jolla, CA), rabbit, polyclonal.
Anti-PP1a Transduction Laboratories (Lexington, KY), mouse, mono-
clonal.
Anti-PP1a Upstate Biotechnology (Lake Placid, NY), rabbit, polyclonal.
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Anti-Raf Transduction Laboratories (Lexington, KY), mouse,
monoclonal.
Anti-Ras (pan) Oncogene (San Diego, CA), mouse, monoclonal.
Secondary Antibodies
PO-anti-mouse Ig Dako (Glostrup, Denmark), peroxidase-conjugated immuno-
globulins
PO-anti-rabbit Ig Dako (Glostrup, Denmark), peroxidase-conjugated immuno-
globulins
Anti-rabbit IgG Alexa488 Molecular Probes (Eugene Probes, OR)
Anti-rabbit IgG biotin Jackson Immuno Research (West Grove, PA)
Anti-human IgG Cy2 Jackson Immuno Research (West Grove, PA)
Anti-rabbit IgG Cy3 Jackson Immuno Research (West Grove, PA)
Streptavidin Cy5 Jackson Immuno Research (West Grove, PA)
II.1.6 Synthetic oligonucleotides and peptides
The following oligonucleotides were purchased from Isogen Bioscience (Maarssen,
Netherlands).
5’ hBcl-2 5’ TCTGGAATTCATGGCGCACGCTGGGAGAACAGGGTA 3’
3’ hBcl-2 5’ CAGTCTCGAGTCACTTGTGGCCCAGATAGGCACCCA 3’
5’ ITM2BS 5’ TTTTGTCGACGCCGCCATGTGTTTCGGACTGGCCTT
             CATG 3’
3’ ITM2BS 5’ TTTTGCGGCCGCTCAAGAACAAATTAAAGTCTCCAC
             AGC 3’
5’ HA-ITM2BS 5’ TGTGCTCGAGGCCGCCATGTACCCATACGATGTTCC
             AGATTACGCTATGTGTTTCGGACTGGCCTTCATG 3’
3’ HA-ITM2BS 5’ TGTGTCTAGATCAAGAACAAATTAAAGTCTCCACAG 3’
5’ ITM2BS-HA 5’ TGTGCTCGAGGCCGCCATGTGTTTCGGACTGGCCTT
             CATG 3’
3’ ITM2BS-HA 5’ TGTGTCTAGATCAAGCGTAATCTGGAACATCGTATG
             GGTACATAGAACAAATTAAAGTCTCCACAGC 3’
5’ ITM2BL 5’ TTTTGTCGACGCCGCCATGGTGAAGGTGACGTTCAA
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             CTCG 3’
3’ ITM2BL 5’ TTTTGCGGCCGCTCAAGAACAAATTAAAGTCTCCAC
             AGC 3’
5’ HA-ITM2BL 5’ TGTGCTCGAGGCCGCCATGTACCCATACGATGTTCC
             AGATTACGCTATGGTGAAGGTGACGTTCAACTCG 3’
3’ HA-ITM2BL 5’ TGTGTCTAGATCAAGAACAAATTAAAGTCTCCACAG 3’
5’ ITM2BL-HA 5’ TGTGCTCGAGGCCGCCATGGTGAAGGTGACGTTCAA
             CTCG 3’
3’ ITM2BL-HA 5’ TGTGTCTAGATCAAGCGTAATCTGGAACATCGTATG
             GGTACATAGAACAAATTAAAGTCTCCACAGC 3’
5’ ITM2BS*  5’ GTGTACTACTGTGGAGAAAAGTACATCAAAGCTGAC
             GTCATCCTG 3
3’ ITM2BS*  5’ CAGGATGACGTCAGCTTTGATGTACTTTTCTCCACA
             GTAGTACAC 3
Sense-Aiolos 5’ ATGGAAGATATACAA 3’
Antisense Aiolos 5’ TTGTATATCTTCCAT 3’
Sense-Bcl-xL 5’ ATGTCTCAGAGCAAC 3’
Antisense Bcl-xL 5’ GTTGCTCTGAGACAT 3’
Sense-Bcl-w 5’ ATGGCGACCCCAGCC 3’
Antisense Bcl-w 5’ GGCTGGGGTCGCCAT 3’
Peptides were synthesized on an automated multiple peptide synthesizer using the
solid-phase procedure and standard Fmoc chemistry. The purity and composition of the
peptides were confirmed through reverse-phase high performance liquid chromatography
and amino acid analysis.
ITM2BS (39-55) KDDVILNEPSADAPAAR
R-peptide NWGRIVAFFSF
R*-peptide NWGRIAAAFSF
F-peptide GDEFELRYRRAF
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II.2 DNA- and RNA-methods
II.2.1 Isolation of plasmid DNA from E. coli
Overnight E. coli cultures were harvested and plasmid DNA was isolated according to
the manufacturer’s instructions (Qiagen, Miniprep and Maxiprep-Kit). Minipreparations
were performed for cloning procedures and maxipreparations were used for preparative
purposes. Isolated DNA was dissolved in deionized, double-distilled water.
II.2.2 DNA agarose gel electrophoresis and extraction
Analytical and preparative gel electrophoresis of double-stranded DNA fragments was
performed in 0.8-1.5% agarose gels supplemented with ethidium bromide (0.1 mg/ml) as
described (Sambrook et al., 1989). DNA fragment sizes were determined by using DNA
marker. Bands were visualized using a UV transilluminator at 302 nm. In preparative
electrophoresis the desired DNA fragment was excised with a sterile scalpel and extracted
with Ultrafree-DA filter (Millipore, Marlborough, MA) by centrifuging 10 min at 5,000 g.
II.2.3 Precipitation and quantitative analysis of nucleic acids
RNA and DNA precipitations were performed using Pellet Paint Co-Precipitant
(Novagen, Madison, WI) according to the manufacturer’s instructions. Briefly, the nucleic
acid sample was mixed with 2 ml Pellet Paint, 0.1 volume 3 M sodium acetate, 2 volumes
of ethanol and incubated at R.T. for 2 min. After a 5 min spin at 14,000 g, the pellet was
washed with several volumes of 70% ethanol and resuspended in deionized double
destilled water. The concentration of nucleic acids was determined with a UV spectrometer
measuring the extinction at 260 nm. One unit of extinction corresponds to 50 mg double-
stranded DNA/ml or 40 mg RNA/ml. The quotient of E260/E280 indicates the purity of
nucleic acids that should be in the range of 1.8-2.0.
II.2.4 Molecular cloning by polymerase chain reaction (PCR)
Plasmids were cloned using polymerase chain reaction (PCR) method with subsequent
DNA restriction and ligation. The standard PCR protocol is listed in the following (Roche,
Basel, Switzerland).
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10 ml 10¥ expand HF buffer (with MgCl2)
  8 ml dNTPs (2.5 mM)
10 ml upstream primer containing restriction site (5 mM)
10 ml downstream primer containing restriction site (5mM)
  3 ml cDNA from IL-2-stimulated or -deprived TS1ab cells (40 ng/ml)
  1 ml High fidelity enzyme mix (3.5 units/ml)
58 ml dd H2O
PCR-conditions:
first cycle 94°C   2 min
30 cycles 94°C 30 sec
65°C 30 sec
72°C   1 min
final cycle 72°C   7 min
The amplified PCR products were analyzed by agarose gel electrophoresis and
purified by Wizard PCR Preps DNA Purification System (Promega, Madison, WI)
according to the manufacturer’s recommendations. Purified PCR products and the target
vector were digested O.N. at 37°C in a 30 ml reaction volume containing the appropriate
10¥ restriction buffer and 1 ml of each restriction enzyme. DNA fragments were separated
by preparative agarose gel electrophoresis and purified from agarose slices by using
Ultrafree-DA filter. DNA ligations were carried out in a total volume of 15 ml. The
insert/vector molar ratio was adjusted to 3/1 for sticky end ligation and 10/1 for blunt end
ligation and was added to 1¥ T4 ligase buffer and one unit of T4 ligase. The reactions were
incubated O.N. at 16°C. 2 ml of the ligation reaction were used for transformation of
competent E. coli DH5a or XL1-Blue cells. Bacteria were incubated 30 min on ice,
followed by a heat shock for 70 sec at 42°C. After 2 min incubation on ice, cells were
resuspended in LB medium, incubated for one hour at 37°C and plated on LB agar plates
containing antibiotics for selection of transformants. On the next day single colonies were
picked, grown O.N. at 37°C and checked for bearing the desired plasmid construct by
performing minipreparations (Qiagen).
II.2.5 Site-directed mutagenesis
Site-directed mutagenesis was performed using the QuikChange mutagenesis kit
(Stratagene, La Jolla, CA) according to the manufacturer’s instructions. Briefly, PCR
reactions were carried out for single amino acid changes.  The critical leucine and aspartic
acid residue from the BH3 domain were mutated to glutamic acid and alanine,
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respectively. The PCR reaction was composed of double-stranded plasmid DNA as a
template, polymerase PFU turbo and a complementary set of sense and antisense primer.
Both primers had incorporated the desired mutations leading finally to a mutated plasmid.
The methylated, non-mutated parental strand was digested by treatment with the restriction
enzyme DpnI. Subsequently 1ml of the PCR reaction was transformed into supercompetent
E. coli XL1-Blue cells. Mutated ITM2BS sequence was confirmed by DNA sequencing.
II.2.6 Automated DNA Sequencing
The principle of automated DNA sequencing is based on excitation and detection of
fluorescent didesoxynucleotides that lead to termination of DNA synthesis. In parallel,
DNA is labelled at different positions by means of PCR (Sanger et al., 1977). Sequencing
was done with the automatic sequencer model 373A (Applied Biosystems, Foster City,
CA).
II.2.7 RNA isolation
Total RNA was isolated using Trizol reagent (GibcoBRL, Grand Island, NY)
according to the manufacturer’s recommendations. After washing with PBS, cells were
lysed in Trizol reagent, incubated for 5 min at R.T., mixed with chloroform and
centrifuged at 12,000 g for 10 min at 4°C. The RNA located in the upper aqueous phase
was precipitated with isopropyl alcohol, incubated for 10 min at R.T. and centrifuged at
12,000 g for 10 min at 4°C. After washing with 75% ethanol, the RNA pellet was
resuspended in RNase-free water and incubated for 10 min at 55°C.
II.2.8 Denaturing gel electrophoresis for RNA
A total of 10 ml of 5¥ RNA loading buffer were added to each RNA sample, incubated
for 5 min at 65°C, chilled on ice and loaded onto a formaldehyde denaturing gel as
described (Sambrook et al., 1989). After electrophoresis, gels were visualized and
transfered O.N. to nitrocellulose filter (see Northern blot).
® 10¥ FA gel buffer (pH 7.0): 200 mM MOPS
  50 mM sodium acetate
  10 mM EDTA
® 1¥ FA running buffer: 100 mM 10¥ FA gel buffer
                                                      20 mM 37% (12.3 M) formaldehyde
880 mM RNase-free water
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® 1¥ RNA loading buffer:   16  ml saturated bromophenol blue solution
  80  ml 500 mM EDTA, pH 8.0
720  ml 37% (12.3 M) formaldehyde
    2 ml 100% glycerol
 3.1 ml formamide
    4 ml 10¥ FA gel buffer
100  ml RNase-free water
II.2.9 Northern blotting and random primed labelling
To confirm the results obtained by RDA, northern blot analyses were performed
following the protocol of Sambrook et al. (1989). 15 m l of RNA sample were
electrophoresed in a 1% agarose gel in the presence of formaldehyde and transferred to
nitrocellulose filter. RNA was covalently immobilized on the filter by UV-crosslinking for
2 min. DNA products were labelled with radioactive [a-32P]-dCTP (Feinberg and
Vogelstein, 1983) by using random prime labelling system (Amersham Pharmacia Biotech,
Piscataway, NJ) or Prime-it II Random Primer Labelling Kit (Stratagene, La Jolla, CA).
Subsequently, filter was prehybridized, hybridized with the 32P labelled probe, stringently
washed several times and exposed to X-ray film at -70°C with intensifying screen.
II.2.10 Representational difference analysis (RDA)
To search for genes that are transcriptionally upregulated upon IL-2 withdrawal, we
performed a representational difference analysis as described (Hubank and Schatz, 1994;
Louahed et al., 1999) (Fig. II.1). Total RNA was prepared from IL-2-stimulated (driver) or
-deprived (tester) TS1ab cells using Trizol reagent. Polyadenylated RNA was purified
from total RNA with oligo (dT) cellulose columns (GibcoBRL, Grand Island, NY).
Double-stranded cDNA was generated from 5 mg poly (A)+ RNA using oligo (dT) primer
and the Super Script Choice System for cDNA synthesis following the manufacturer’s
instructions (Life Technologies, Rockville, MD). Adapters of known sequence were
ligated to the ends of both populations. After PCR amplification and restriction of driver
and tester population, new different adapters were only ligated to the tester population. The
two cDNAs populations were melted and hybridized at a high driver/tester ratio. Three
populations of double-stranded hybrids are possible: tester/tester, driver/driver,
tester/driver. PCR primers complementary to the adapters of the tester population were
used to amplify specifically the tester/tester hybrids. In this way transcripts that are
induced in IL-2 deprived cells were enriched. The other two hybrid groups contain
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sequences common to both RNA populations, but lack adapter sequences at both ends
preventing their exponential amplification by PCR. The first difference product (DP1) was
digested, ligated to new adapters, hybridized again with the driver and amplified by PCR
generating the second difference product (DP2). After three rounds of subtraction, the PCR
products of the DP3 were digested with DpnI and cloned into the BamHI site of pTZ19R.
Sequence comparisons were performed with the BLAST search program.
II.2.11 Two-hybrid screen
Bcl-xL cloned into the pGAD vector was used as a bait to screen a cDNA library from
TS1ab  cells in the Saccharomyces cerevisae L40 strain (MATa trp1 leu2 his3
LYS2::lexA-His3, URA3::lexA-LacZ) using standard procedures (Fields and Bartel,
2001). Sequencing of inserts from positive clones of the two-hybrid screen was performed
on both strands with an automatic sequencer and sequences were compared using BLAST
program.
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II.3 Methods of cell biology
II.3.1 Cell culture
The murine T cell line TS1ab can be propagated independently in IL-2, IL-4 or IL-9
(Pitton et al., 1993). Cells were cultured in RPMI supplemented with 5% heat-inactivated
fetal calf serum, 2 mM L-glutamine, 10 mM HEPES, 0.55 mM arginine, 0.24 mM
asparagine, 50 mM 2-ME and 5 ng/ml of IL-2. Murine rIL-4 or supernatant of a HeLa
subline transfected with pKCR-IL-4.neo was used as a source of murine IL-4. COS-7 cells
are adherent cells derived from monkey kidney (ATCC, CRL-1651). Cells were grown in
DMEM medium supplemented with 10% heat-inactivated fetal calf serum, 2 mM L-
glutamine, 100 mg/ml penicillin/streptomycin, 10 mM HEPES and 1 mM sodium pyruvate.
II.3.2 Transient transfection
TS1ab  cells were transiently transfected using the DEAE-dextran method.
Exponential growing cells (10¥ 106) were washed with TS buffer (25 mM Tris-HCl, 137
mM NaCl, 5 mM KCl, 0.7 mM CaCl2, 0.5 mM MgCl2, 0.6 mM Na2HPO4, pH 7.4). Cells
were transfected with 5 mg of the corresponding expression vector. 750 ml of TS buffer and
750 ml of freshly prepared DEAE-dextran (1 mg/ml in TS buffer) solution were mixed
successively with the cells and incubated for 20 min at R.T., after which 13 ml of RPMI
1640/5% FCS were added. Cells were incubated for 1 h at 37°C, centrifuged, and
resuspended in 12 ml of RPMI 1640/5% FCS alone or supplemented with the appropriate
interleukin.
II.3.3 Cell lysates and immunoprecipitation
Cells were lysed for 20 min at 4°C in NP-40 (20 mM Tris-HCl pH8, 1% NP-40, 137
mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 10% glycerol and protease inhibitors cocktail) or
RIPA-buffer (20 mM Tris-HCl pH8, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS,
137 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 10% glycerol as well as protease inhibitors
cocktail). Lysates were centrifuged (20 min, 13,000 rpm, 4°C) and immunoprecipitated
with the corresponding antibody. Protein A sepharose was added for 1 h at 4°C and after
three washing steps, immunoprecipitates were resuspended in Laemmli sample buffer and
separated by SDS-PAGE.
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II.3.4 SDS polyacrylamide gel electrophoresis (SDS-PAGE)
Cells (1 ¥  107) were IL-2/IL-4 stimulated or deprived for 6, 12 and 24 h. The
concentration of cell lysates was determined using the DC protein assay kit (Biorad,
Hercules, CA). Samples were prepared by addition of 2¥ Laemmli sample buffer (2%
SDS, 0.72 M b-mercaptoethanol, 60 mM Tris-HCl pH 6.8, 10% glycerol, 0.001 %
bromophenol blue. After incubating for 5 min at 95°C, protein extracts were separated by
SDS-PAGE under denaturing, reducing conditions (Laemmli, 1970)Laemmli, 1970).
Electrophoresis was carried out in 1¥ running buffer (30 mM Tris-HCl, 190 mM glycine,
0.1% SDS).
II.3.5 Western blot
Immunoblotting was performed as described (Towbin et al., 1979). Briefly, proteins
were separated by SDS-PAGE and transferred to nitrocellulose in a tank blot system
(Biorad, Hercules, CA) containing 1¥ transfer buffer (30 mM Tris-HCl, 190 mM glycine
and 20% methanol). Blots were blocked with 5% nonfat milk for 1 h at R.T. in Tris-
buffered saline (TBS: 10 mM Tris-HCl pH 8.0, 150 mM NaCl) and incubated with the
primary antibody (3 h at R.T. or O.N. at 4°C) in TBS/0.5% nonfat dry milk. Membranes
were washed with 0.05% Tween20 in TBS and incubated with peroxidase-conjugated
secondary antibody (1 h at R.T.). After three washing steps with 0.05% Tween 20/TBS,
proteins were detected by using the chemiluminescence kit ECL (Amersham, Piscataway,
NJ) followed by exposure to X-ray films.
II.3.6 Antibody production
A peptide of ITM2BS spanning amino acid sequence 39-55 was synthesized on an
automated multiple peptide synthesizer using the solid phase procedure and standard Fmoc
chemistry. The peptide, glutaraldehyde-coupled to KLH via N-terminal, was injected into
outbread New Zealand rabbits. Sera were collected between seven and ten days after the
last injection. This antibody recognizes ITM2BS and ITM2BL that can be distinguished by
their molecular weight.
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II.3.7 Protein-peptide binding studies
Peptides comprising the R/K-X-V/I-X-F (R) or F-X-X-R-X-R (F) motif of Bcl-w and
Bcl-xL as well as their corresponding mutated peptides were prepared by automated spot
synthesis onto an aminoderivatized cellulose membrane. Membrane was blocked,
incubated with purified PP1a (Calbiochem, La Jolla, CA) and after several washing steps,
incubated with anti-PP1a antibody followed by PO-conjugated secondary antibody. Spots
were developed using the ECL system.
II.3.8 Protein-protein interaction competition
Lysates from IL-4-stimulated cells were immunoprecipitated with anti-Bad antibody,
and protein A sepharose was added. The interactions Bcl-w/PP1a and Bcl-xL/PP1a were
competed by incubation with R, F or R* peptides (30 min at R.T.). After washing,
immunoprecipitates were either assayed for protein phosphatase activity or transferred to
nitrocellulose and blotted with the corresponding antibody.
II.3.9 In vitro phosphatase assay
IL-4-stimulated cells (1¥ 107) were lysed in NP-40 lysis buffer (20 mM Tris-HCl pH8,
1% NP-40, 137 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 10% glycerol, protease inhibitors
cocktail). Supernatants were immunoprecipitated with the corresponding antibody
followed by incubation with protein A sepharose. Immunoprecipitates were washed with
phosphatase buffer (50 mM Tris-HCl pH 7.5, 0.1% b-mercaptoethanol, 0.1 mM EDTA and
1 mg/ml BSA) and mixed with [32P] phosphorylase a, diluted in phosphatase buffer
supplemented with caffeine. The reaction was incubated for 40 min at 30°C, stopped with
200 ml of 20% TCA and centrifuged. A total of 185 ml of the supernatant were used to
estimate the generation of free phosphate liberated from [32P] phosphorylase a.
II.3.10 Cholesterol depletion
IL-4-stimulated serum-deprived cells (1¥ 106) were treated for 30 min at 37°C with 10
mM methyl-b-cyclodextrin (Sigma, Louis, MO) leading to cholesterol depletion up to 40%
in the plasma membrane and raft disruption (Kabouridis et al., 2000). Cells were washed
and utilized for CTx-FITC labelling or apoptosis quantification by cell cycle analysis.
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II.3.11 Immunofluorescence
Non-transfected or transfected IL-2-stimulated or -deprived cells were loaded with
freshly prepared 100 nM Mitotracker Red (Molecular Probes, Eugene, OR) in the
appropriate culture medium for 45 min at 37°C in the dark. For immunofluorescence, cells
were washed twice with PBS, fixed in 4% paraformaldehyde for 15 min at R.T., blocked in
PBS with 5% BSA and incubated for 2 h with anti-ITM2B and/or anti-mitochondrial
serum in PBS containing 0.5% BSA and 0.1% Triton X-100. After two washing steps, cells
were incubated for 1 h with Cy2-conjugated anti-human and Cy3-conjugated anti-rabbit
(Jackson Immunoresearch, West Grove, PA) or Alexa488-conjugated anti-rabbit
(Molecular Probes, Eugene, OR) secondary antibodies. In case of triple staining
experiments, anti-ITM2B was detected by anti-rabbit biotin, followed by Cy5-conjugated
streptavidin (Jackson Immunoresearch, West Grove, PA). Samples were analyzed by using
an Ar-Kr laser and a TCS-NT Leica confocal imaging system (Leica, Lasertechnik,
Heidelberg, Germany).
II.3.12 CTx-labelling
IL-4-stimulated or -deprived cells (1¥ 106) were fixed with PBS containing 1%
paraformaldehyde for 5 min on ice, washed with PBS/0.2% BSA, blocked with PBS-
staining (PBS/10% FCS) for 1 h at 4°C and incubated with Cholera toxin (CTx)-FITC (20
min, 6 mg/ml). CTx binds to the ganglioside GM1 present in the rafts. Following steps
were performed at 4°C and samples were protected from light. After two washing steps,
cell permeabilization was carried out by using phosphatidylcholine (50 mg/ml in PBS) for 2
min and cells were washed. Samples were incubated with the primary antibody anti-Bad or
anti-Lck for 1 h in PBS/0.2% BSA, washed and incubated with the Cy3-labeled secondary
antibody for 1 h. Finally, after several washing steps, cells were exposed to methanol for
10 min at -20°C, mounted with Vectorshield medium (Vector Laboratories, Burlingame,
CA) and analyzed by confocal microscopy. The program used for quantification of
samples was Leica TSC NT version 1.5.451 (Leica, Lasertechnik, Heidelberg).
II.3.13 Subcellular fractionation
Subcellular fractionation was performed as described (Hacki et al., 2000; Millan and
Alonso, 1998). Briefly, IL-4-stimulated or -deprived cells were washed in PBS and then
resuspended for 2 min in extraction buffer STE (10 mM HEPES pH 7.4, 1 mM EDTA,
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0.25 mM sucrose, 2 mg/ml aprotinin, 10 mg/ml leupeptin, 1 mM PMSF, 1 mg/ml pepstatin).
The extract was inspected under the microscope and more than 95% of the cells were
lysed. The homogenates were applied to a linear gradient sucrose (0.73 to 1.9 M) and
ultracentrifuged O.N. at 20,000 g. The banded organelles were recovered by syringe,
diluted with an equal volume of 10 mM HEPES buffer and sedimented at the speed
appropriated for the respective organelles. The purity of the organelles was determined by
western blot using antibodies against specific markers: anti-cytochrome c  for
mitochondria, anti-Lck and CTx-Biotin for rafts, anti-Calnexin for endoplasmic reticulum
(ER) and anti-Caspase-3 for cytosol. For preparation of cytosol, the homogenate was
precentrifuged for 10 min at 750 g to remove nuclei and unbroken cells, followed by a
centrifugation (100,000 g) for 1 h to clear off the membranes.
II.3.14 Triton X-100 flotation
10¥ 106 IL-4-stimulated or -deprived cells were washed with PBS and lysed in TXNE
buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.2% Triton X-100)
containing protease inhibitors cocktail. Detergent insoluble membranes (rafts) were
isolated by ultracentrifugation (17,000 g, 4 h, 4°C) in a 30-35% gradient of Optiprep
(Nycomed Pharma, Oslo, Norway) as described (Manes et al., 1999). Different fractions
were collected from the top to the bottom of the gradient and precipitated with
trichloroacetic acid. Normalized protein amounts were analyzed by SDS-PAGE and
western blot.
II.3.15 Isolation of mitochondria and S-100 fraction
Mitochondria were isolated using a modification of Yang et al. (1997). Briefly, 2x 107
cells were IL-2/IL-4-stimulated or -deprived, harvested and washed with ice-cold PBS.
Cell pellet was resuspended in 5 volumes of ice-cold buffer A (20 mM HEPES-KOH pH
7.5, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 0.1 mM PMSF
and 250 mM sucrose) supplemented with protease inhibitors. Cells were disrupted in a
Dounce homogenizer, the nuclei centrifuged (1000 g, 10 min, 4°C) and the supernatant
further centrifuged (10,000 g, 15 min, 4°C). The resulting mitochondrial pellet was
resuspended in buffer A and stored at -80°C. The supernatant was centrifuged (100,000 g,
1 h, 4°C) and the resulting S-100 fraction stored at -80°C.
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II.3.16 Nuclear extracts
IL-2-stimulated or -deprived cells (3x 107) were resuspended for 2 min in 1 ml of
buffer A (50 mM NaCl, 10 mM HEPES pH 8.0, 0.5 M sucrose, 1 mM EDTA, 0.5 mM
spermidine, 0.15 mM spermine and 0.2% Triton X-100). Lysates were centrifuged (4500 g,
3 min, 4°C). Nuclei were resuspended in 1 ml buffer B (50 mM NaCl, 10 mM HEPES pH
8.0, 25% glycerol, 0.1 mM EDTA, 0.5 mM spermidine and 0.15 mM spermine) and
centrifuged (4500 g, 3 min, 4°C). Nuclear proteins were extracted at 4°C for 30 min in 60
ml of buffer C (350 mM NaCl, 10 mM HEPES pH 8.0, 25% glycerol, 0.1 mM EDTA, 0.5
mM spermidine and 0.15 mM spermine). Supernatants were cleared by centrifugation and
stored at -80°C. All buffers were supplemented with protease inhibitors.
II.3.17 Estimation of apoptosis by propidium iodide
A total of 2¥ 105 cells were washed with PBS, permeabilized with 0.1% NP-40 and
stained with 50 mg/ml propidium iodide. Samples were analyzed using an EpicsXL flow
cytometer. Apoptosis was measured as the percentage of cells in the subG1 region of the
fluorescence scale having a hypodiploid DNA content (Nicoletti et al., 1991).
II.3.18 Apoptosis detection by annexin
Apoptosis was also measured using the Annexin V-FITC kit (Immunotech, Marseille,
France) based on the binding properties of annexin V to phosphatidylserine and on the
DNA-intercalating capabilities of propidium iodide (Koopman et al., 1994). 5¥ 105 cells
were washed with ice-cold PBS, diluted in ice-cold binding buffer and stained with
annexin V-FITC (0.05 mg/ml) and propidium iodide (2.5 mg/ml). Samples were maintained
for 10 min on ice and then analyzed by flow cytometry.
II.3.19 Detection of caspase-3-like activity in vivo
Caspase-3 like activity in vivo was analyzed using the PhiPhiLux G1D2 kit
(OncoImmunin, Gaithersburg, MD). Cells (5¥ 105) were centrifuged and supernatant was
discarded. A total of 50 ml of 10 mM substrate solution (peptide sequence: GDEVDGI) and
2.5 ml of FCS were added to each sample. Cell suspension was incubated for 60 min at
37°C protected from light, washed with 1 ml of dilution buffer and the pellet were
resuspended in ice-cold dilution buffer. Fluorescence emission was determined using the
FL2 channel of the flow cytometer.
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II.3.20 Measurement of caspase-3-like and -9 activity in vitro
Cells were washed with ice-cold PBS and resuspended in extraction buffer (50 mM
Tris-HCl pH7.6, 150 mM NaCl, 0.5 mM EDTA, 10 mM NaH2PO4, 10 mM Na2HPO4, 1%
NP-40, 0.4 mM Na3VO4, 1 mM PMSF and protease inhibitor cocktail). Cell lysate was
centrifuged (20,000 g, 30 min) and 5 mg of cytosolic protein was diluted five-fold in
caspase buffer (25 mM HEPES pH 7.5, 0.1% CHAPS, 10% sucrose, 10 mM dithiothreitol
and 0.1 mg/ml ovalbumin) and incubated for 1 h at 37°C with the fluorescent substrate for
caspase-3 Ac-DEVD-AMC (10 mM) or for caspase-9 Ac-LEHD-AMC (10 mM). The
reaction was stopped by adding HPLC buffer (water/acetonitrile 75/25, 0.1%
trifluoroacetic acid). Cleaved substrate fluorescence was determined by C18 reverse phase
HPLC using fluorescence detection (338 nm excitation, 455 nm emission) (Ruiz-Vela et
al., 1999).
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III Results
Our group has established a lymphokine-dependent cellular model to study apoptosis
signalling pathways upon growth factor deprivation. The murine T-lymphocyte cell line
TS1ab is able to proliferate independently in the presence of IL-2, IL-4 or IL-9. Following
interleukin deprivation, TS1ab cells cease to proliferate and undergo apoptosis, as detected
by annexin staining. As early as 4 h after IL-2 deprivation, about 14% of cells are
apoptotic, reaching 44% at 24 h, whereas control cells maintained in the presence of IL-2
show no signs of apoptosis (Fig. III-1). Similar percentage of apoptotic cells are reached
following IL-4 or IL-9 withdrawal.
Figure III-1. Effect of interleukin withdrawal on apoptosis. TS1ab cells were cultured in the presence or absence of IL-2
and harvested at distinct times. To analyze apoptosis, cells were stained with annexin and propidium iodide and the
percentage of dying cells was estimated using flow cytometry. Region G corresponds to apoptotic cells. The percentage
of apoptosis in each sample is superimposed. Similar results were obtained in TS1ab cells after IL-4 or IL-9 deprivation.
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III.1 The BH3-only protein ITM2BS, upregulated upon IL-2
deprivation, triggers apoptosis by inducing loss of mitochondrial
membrane potential
III.1.1 Identification of ITM2BS as an upregulated gene in response to IL-2
withdrawal
To identify proteins that could be involved in the induction of apoptosis, a
representational difference analysis (RDA) of gene expression was performed in IL-2-
deprived TS1ab cells as previously described (Hubank and Schatz, 1994; Louahed et al.,
1999). Cells were IL-2-stimulated or -deprived for 20 h before mRNA extraction. After
three rounds of subtractive hybridization, the third product was cloned. Over 500 clones
were analyzed by the Blast program. Among the different IL-2 deprivation-induced genes,
several transcripts have already been involved in promoting apoptosis such as the
retinoblastoma suppressor-associated protein 46 (RbAp46), the basic transcription factor 3
(BTF3), the 78 kDa glucose-regulated protein (GRP78) or the proliferation-associated gene
product (PAG) (Aoki et al., 1997; Brockstedt et al., 1999; Guan et al., 2001; Mu et al.,
2002). One of the sequenced clones consisted of a 190 nt DpnII fragment showing a 100%
match to a cDNA encoding the integral membrane protein 2B (ITM2B). The kinetic of
ITM2B expression was further analyzed by northern blot after IL-2 deprivation for
different time periods. As shown in figure III-2, a transcript of 1.1 kb corresponding to
ITM2BS was upregulated within 3 h of IL-2 deprivation and reached its maximal
expression upon 20 h of lymphokine deprivation. A non-upregulated 1.4 kb transcript that
corresponds to the long isoform of the protein, ITM2BL, was also observed (Fig. III-2).
The upregulation of ITM2BS expression was confirmed using a probe of the 5' untranslated
region of ITM2BS that is absent in ITM2BL (data not shown). As internal control of equal
RNA loading, ribosomal 28S and 18S signals are shown.
The full length ITM2BS was cloned by PCR and encodes a 210 amino acid protein
(Fig. III-3A). Using the Expasy database, no domains of known protein families could be
detected. However, scrutiny of its sequence revealed a stretch of six amino acids at
position 35-40 aa with high homology to the BH3 motif (Fig. III-3B), but lacks conserved
BH1, BH2 and BH4 domains. This conserved motif is shared by the BH3-only members of
the Bcl-2 family such as Bad, Bid, Bik, Bim, Harakiri, Noxa and Puma (Fig. III-3B)
(Chittenden et al., 1995a; Zha et al., 1996a). The mouse genomic database revealed a clone
from chromosome 14 containing the ITM2BS gene.
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Figure III-2. Transcriptional induction of ITM2BS mRNA upon IL-2 deprivation. Total RNA was isolated from 30¥ 106
IL-2-stimulated (C, 5 ng/ml) or -deprived TS1ab cells for different time periods. RNA (15 mg/lane) was electrophoresed
in 1% agarose/formaldehyde, blotted and hybridized in high stringency conditions with a 32P-labelled ITM2BS probe.
Two transcripts of 1.1 kb, corresponding to ITM2BS and 1.4 kb corresponding to ITM2BL were detected. DNA probe was
labelled by random priming. Both 28S and 18S rRNA bands serve as internal control of RNA loading.
Comparison with the cDNA sequence suggests a five exon structure (Fig. III-3C) for
ITM2BS gene. Protein homology searches in the GenBank database detected a strong
amino acid identity among ITM2BS sequence from human, mouse, chicken, fly, C.
elegans, xenopus, zebra fish, bovine and rat (Fig. III-3D). The highest identity is observed
at the C-terminal.
B
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Figure III-3. ITM2BS is a novel BH3-containing protein. (A) Predicted amino acid sequence of ITM2BS. The BH3
domain of ITM2BS is underlined and the conserved BH3 core element is marked in bold. (B) Alignment of the ITM2BS
BH3 motif with other BH3 domains of Bcl-2 family proteins: pro-apoptotic murine Bad, Bid, Bik, Bim, Harakiri, Puma
and Noxa with two BH3 domains. Conserved leucine (L) and aspartic acid (D) residues are shaded. (C) Exon-intron
organization of the ITM2BS gene. Murine ITM2BS contains five exons spanning a 5.6 kb region of murine chromosome
14. Positions of the start and termination codons are indicated, with coding regions in grey blocks. The BH3 domain is
located in exon 2. (D) Alignment of protein sequences of mouse, human, chicken, C. elegans, fly, zebra fish, bovine and
rat ITM2Bs. ITM2A and ITM2C are also included in the alignment. Residues sharing identity among each other are
coloured. Alignment was generated using Belvu program.
To study the effect of IL-2 deprivation on ITM2BS protein expression, cells were IL-2
stimulated or deprived for different periods of time and total ITM2BS expression was
analyzed by western blot. Weak expression of ITM2BS was observed in control IL-2-
stimulated cells, increasing upon IL-2 deprivation (Fig. III-4A). Reprobing the membrane
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with anti-pan-Ras as an internal control of protein loading showed similar levels of Ras
expression throughout the kinetic. The specificity of the generated ITM2BS antibody was
estimated by competition with increasing concentrations of the peptide used for generation
of the antibody (Fig. III-4B). This antibody recognizes both, ITM2BS and ITM2BL, which
can be differentiated by their molecular weights. These results suggest that the different
induction kinetics at the mRNA and protein level may be attributed to specific function
acquired after IL-2 deprivation.
Figure III-4. Upregulation of ITM2BS expression at the protein level. (A) TS1ab cells were IL-2-stimulated (C, control)
or -deprived for the times indicated and lysed. Proteins were separated by SDS-PAGE, transferred to nitrocellulose and
probed with anti-ITM2B antibody. Protein bands were detected using the ECL system. The blot was reprobed with pan-
Ras antibody as internal control of protein loading. Similar results were obtained in three independent experiments.
Molecular weights of the corresponding proteins are shown. (B) TS1ab cells were lysed, proteins separated by SDS-
PAGE and transferred to nitrocellulose. Anti-ITM2B antibody was pre-incubated with increasing concentrations of the
peptide used for the immunization and then incubated with the blot.
III.1.2 Overexpression of ITM2BS induces apoptosis, which is repressed by Bcl-2
The effect of ITM2BS on cell survival was examined in TS1ab cells using transient
transfection assays. Expression of ITM2BS in IL-2-stimulated cells resulted in strong
induction of apoptosis 20 h after transfection compared with the level of apoptosis
observed in IL-2-stimulated cells transfected with the empty vector (mock transfectants)
(Fig. III-5A). Transfection of ITM2BS into IL-2-deprived cells also led to dramatic
induction of apoptosis compared with the level observed in IL-2-deprived mock
transfected cells (Fig. III-5A). Overexpression of ITM2BL in IL-2-stimulated or -deprived
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cells had not effect on apoptosis (data not shown). The level of apoptosis observed in non-
transfected cells is also shown. Expression of transfected ITM2BS was confirmed by
western blot. Ras expression is shown as internal control of protein loading.
Figure III-5. Expression of ITM2BS induces apoptosis, which is abolished by the pro-survival Bcl-2. (A) Cells were
transfected with or without ITM2BS using the DEAE-dextran method and maintained after transfection with or without
IL-2 for 20 h. Cells were washed, permeabilized and stained with propidium iodide. Samples were analyzed by flow
cytometry. Non-transfected cells maintained in the presence or absence of IL-2 were used as control. Standard deviation
(SD) was n = 3 (IL-2 stimulation, white bars; IL-2 deprivation, shaded bars). Expression of the transiently transfected
ITM2BS was confirmed by direct comparison of protein level in mock and ITM2BS transfected cells. The blot was probed
with anti-pan-Ras as internal control of protein loading. (B) Cells were transfected with or without ITM2BS as in A and
maintained after transfection with or without IL-4 for 24 h. Samples were analyzed by flow cytometry. Non-transfected
cells, maintained in the presence or absence of IL-4, were used as control. Standard deviation (SD) was n = 3 (IL-4
stimulation, white bars; IL-4 deprivation, shaded bars). Expression of the transiently transfected ITM2BS was confirmed
by western blot. The blot was reprobed with anti-pan-Ras as internal control for protein loading. (C) Cells were co-
transfected with or without ITM2BS or ITM2BS and Bcl-2 as in A and cultured after transfection in the presence or
absence of IL-2 for 24 h. Samples were analyzed by flow cytometry. Expression of the transfected ITM2BS was
confirmed by western blot. The blot was rehybridized with anti-pan-Ras as internal control for protein loading (IL-2
stimulation, white bars; IL-2 deprivation, shaded bars). Similar results were obtained in three independent experiments.
Interestingly, expression of ITM2BS in IL-4-stimulated or -deprived cells did not have
any effect on apoptosis, compared with the level of apoptosis observed in IL-4-stimulated
or -deprived mock transfectants (Fig. III-5B). The level of apoptosis in non-transfected
cells is also illustrated. Co-expression of ITM2BS and the anti-apoptotic protein Bcl-2
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strongly inhibited the cell death-inducing activity of ITM2BS in IL-2-stimulated or -
deprived cells, compared with the high level of apoptosis observed in ITM2BS transfected
cells (Fig. III-5C). Expression of transiently transfected ITM2BS or Bcl-2 in IL-2 or IL-4-
stimulated or -deprived cells was confirmed by direct comparison of ITM2BS or Bcl-2
protein level in transfected cells and mock controls. Unaltered Ras expression under all
transfection conditions was used as an internal control of protein loading.
III.1.3 The BH3 domain of ITM2BS is required for its ability to promote apoptosis
To determine if the BH3 domain of ITM2BS is required to induce apoptosis, the
apoptotic activity of wild-type ITM2BS and a BH3 domain mutant of ITM2BS protein
(ITM2BS*) was compared. In ITM2BS*, the critical leucine (L) and aspartic acid (D)
residues at amino acid position 35 and 40 were mutated to glutamic acid (E) and alanine
(A), respectively. Transient transfection showed that mutation of BH3 domain inhibited
apoptosis, when compared with the ability of wild-type ITM2BS to induce apoptosis in IL-
2-stimulated or -deprived TS1ab cells (Fig. III-6A). Expression of ITM2BS* had not effect
on apoptosis in IL-4-stimulated or -deprived transfected cells compared to mock
transfectants (Fig. III-6B).
Figure III-6. . The BH3 domain of ITM2BS is essential for induction of apoptosis. (A) TS1ab cells were transfected with
or without ITM2BS or ITM2BS mutant (ITM2BS*), in which the critical L and D residues within its BH3 motif were
mutated to E and A, respectively. Cells were maintained after transfection in the presence or the absence of IL-2 for 24h.
Samples were analyzed by flow cytometry. Expression of the transfected ITM2BS was confirmed by western blot.
Hybridization with anti-pan-Ras was used as internal control of protein loading (IL-2 stimulation, white bars; IL-2
deprivation, shaded bars). Similar results were obtained in two independent experiments. (B) Cells were transfected with
or without ITM2BS or ITM2BS containing a mutated BH3 domain (ITM2BS*) as in A and maintained after transfection in
the presence or absence of IL-4 for 24h. Samples were analyzed as in A. Expression of the transfected proteins was
analyzed by western blot (IL-4 stimulation, white bars; IL-4 deprivation, shaded bars).
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Expression of transiently transfected proteins in IL-2- or IL-4-stimulated or -deprived
cells was confirmed by direct comparison of protein level in transfected cells and mock
controls. This result suggests that integrity of ITM2BS BH3 domain is necessary for the
induction of apoptosis in T-lymphocytes, since mutation of the critical amino acids leucine
and aspartic acid within this motif abolishes its pro-apoptotic activity.
III.1.4 ITM2BS interacts with Bcl-2 in vivo
To determine the ability of ITM2BS to associate with anti-apoptotic members of the
Bcl-2 family, co-immunoprecipitation experiments were performed using ITM2BS- and
Bcl-2-specific antibodies. ITM2BS was detected by western blot in anti-Bcl-2
immunoprecipitates of IL-2-stimulated cells and was not observed in anti-Bad
immunoprecipitates (Fig. III-7A). However, ITM2BS was not detected in anti-Bcl-2 or
anti-Bad immunoprecipitates of IL-2-deprived cells. Reprobing the membrane with anti-
Bcl-2 and anti-Bad antibodies showed both proteins in IL-2-stimulated cells and only Bad
expression in IL-2-deprived cells.
Figure III-7. ITM2BS interacts with Bcl-2 in vivo. (A) Cytoplasmic lysates from IL-2-stimulated or -deprived (20 h) cells
were immunoprecipitated with anti-ITM2BS antibody, transferred to nitrocellulose and immunoblotted with anti-Bcl-2,
anti-Bad and anti-ITM2BS, the latter as internal control. Molecular weights of the corresponding proteins are shown.
Similar results were obtained in three independent experiments. Alternatively, cytoplasmic lysates from IL-2-stimulated
or -deprived cells were immunoprecipitated with anti-Bcl-2 or anti-Bad antibodies, transferred to nitrocellulose and
immunoblotted with anti-ITM2BS, anti-Bcl-2 or anti-Bad, the two latter as internal control. Similar results were obtained
in three independent experiments. As negative control, cytoplasmic lysates from IL-2-stimulated or -deprived cells were
immunoprecipitated with anti-IL-2 antibody and blotted with anti-ITM2BS. (B) Cells were IL-2-stimulated or -deprived
for different time periods and then lysed. Protein extracts were separated by SDS-PAGE, transferred to nitrocellulose and
probed with anti-Bad, anti-Bcl-2 and anti-pan-Ras, the latter as internal control of protein loading. Similar results were
obtained in three independent experiments.
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To confirm this interaction, reciprocal experiments were performed. Bcl-2 was
detected in anti-ITM2BS immunoprecipitates of IL-2-stimulated cells (Fig. III-7A) and was
not observed in anti-ITM2BS immunoprecipitates of IL-2-deprived cells. No association of
Bad with ITM2BS could be detected upon ITM2BS immunoprecipitation (Fig. III-7A).
Reprobing the membrane with anti-ITM2BS showed the presence of the protein. The
specificity of the described interaction was confirmed by immunoprecipitation of
cytoplasmic lysates with an irrelevant antibody, anti-IL-2. To explore the effect of IL-2-
deprivation on Bad and Bcl-2 expression, TS1ab cells were IL-2 stimulated or deprived
for different periods of time and total protein expression was analyzed by western blot.
Expression of Bad was observed in IL-2-stimulated cells and was not modified throughout
the starvation period (Fig. III-7B). Bcl-2 expression was observed in IL-2-stimulated cells,
decreasing throughout lymphokine deprivation (Fig. III-7B). Taken together, these results
suggest that ITM2BS associates to Bcl-2, but not to the pro-apoptotic BH3-only protein
Bad. Low level of Bcl-2/ITM2BS interaction was observed in IL-2-deprived TS1ab cells
because Bcl-2 was downregulated, being the limiting molecule in the formation of this
complex.
III.1.5 Mitochondrial localization of ITM2BS increases upon IL-2 deprivation
To determine the subcellular localization of ITM2BS, cellular fractions such as
nuclear, mitochondrial, cytosolic and cytoplasmic proteins were isolated from IL-2-
stimulated or -deprived TS1ab cells. ITM2BS was detected by western blot in cytoplasmic
extracts, but not in nuclear extracts of IL-2-stimulated or -deprived cells (Fig. III-8).
Moreover, mitochondrial localization of ITM2BS was observed under both conditions. The
amount of protein associated to mitochondria significantly increased upon IL-2
deprivation. ITM2BS could not be detected in the cytosolic fraction of IL-2-stimulated or -
deprived cells (Fig. III-8). As internal control of protein fractionation, the blot was
reprobed with anti-pan-Ras (cytoplasmic marker), anti-Caspase-3 (cytosolic marker), anti-
Mito 2813 (pyruvate dehydrogenase, mitochondrial marker) and anti-Histones (nuclear
marker) antibodies.
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Figure III-8. ITM2BS localizes to mitochondria, increasing upon IL-2 deprivation. Nuclear, cytoplasmic, mitochondrial
and cytosolic proteins were isolated from IL-2-stimulated or -deprived cells, separated by SDS-PAGE, transferred to
nitrocellulose and immunoblotted sequentially with anti-ITM2B, anti-pan-Ras (cytoplasmic marker), anti-caspase-3
(cytosolic marker) and anti-Histones (nuclear marker) antibodies. Similar results were obtained in two independent
experiments.
III.1.6 Expression of ITM2BS promotes cytochrome c release
As ITM2BS is associated to mitochondria, the hypothesis was tested, whether ITM2BS
could be involved in cytochrome c release and as a consequence, in the mitochondria-
mediated apoptotic pathway. For this purpose, mitochondrial and cytosolic proteins were
isolated from IL-2-stimulated and -deprived mock- or ITM2BS-transfected TS1ab cells.
Figure III-9. ITM2BS expression induces release of cytochrome c. (A) TS1ab cells were transfected with ITM2BS or the
empty vector (mock transfectants) and maintained with or without IL-2. After transfection, mitochondrial and cytosolic
proteins were separated and blotted with anti-cytochrome c, anti-caspase-3 (cytosolic marker) and anti-Mito 2813
(pyruvate dehydrogenase, mitochondrial marker). (B) Cytosolic and mitochondrial proteins were isolated from IL-2-
stimulated or -deprived cells and blotted with anti-cytochrome c. (C) TS1ab cells were IL-2-stimulated or -deprived for
the indicated times and lysed. Blots were probed with anti-cytochrome c antibody. Similar results were obtained in three
independent experiments.
Results
55
Mock-transfected IL-2-stimulated cells showed cytochrome c in mitochondrial
extracts, decreasing in mock-transfected IL-2-deprived cells. Traces of cytochrome c were
detected in S-100 fraction of both IL-2-stimulated and -deprived mock transfectants (Fig.
III-9A). Interestingly, only a small part of cytochrome c was observed in mitochondrial
extracts of IL-2-stimulated or -deprived ITM2BS-transfected cells. The level of cytochrome
c detected in S-100 fraction of ITM2BS-transfected cells was significant higher than in
mock-transfectants (Fig. III-9A). The blot was rehybridized with anti-Caspase-3 (cytosolic
marker) or anti-Mito 2813 (mitochondrial marker). Moreover, control studies demonstrated
that cytochrome c was also released into the cytosol in apoptotic non-transfected IL-2-
deprived cells (Fig. III-9B), but total expression of cytochrome c was not altered
throughout the IL-2 starvation period (Fig. III-9C). As internal control of protein loading,
the blot was reprobed with anti-pan-Ras antibody. These observations suggest that
cytochrome c progressively accumulates in the cytosol of ITM2BS-transfected cells,
correlating with apoptosis induction and also indicate that mitochondrial localization of
ITM2BS is the critical event that triggers the apoptotic pathway.
III.1.7 Mitochondrial localization of ITM2BS correlates with loss of mitochondrial
membrane potential
To further analyze the role of mitochondria in ITM2BS-induced cell death, the
hypothesis was tested, whether mitochondrial localization of ITM2BS causes loss of
mitochondrial membrane potential using MitoTracker fluorochrome that accumulates in
active mitochondria. ITM2BS association to mitochondria was analyzed in intact cells by
confocal microscopy (Fig. III-10A). IL-2-stimulated or -deprived cells were incubated with
anti-mitochondria antibody (anti-Mito 2813) and anti-ITM2BS or anti-mitochondria
antibody and MitoTracker before secondary labelling. Double immunofluorescence
analysis showed strong co-localization of ITM2BS with mitochondria in IL-2-deprived
cells, confirming biochemical results (Fig. III-10A). In contrast to apoptotic cells, a weak
co-localization of ITM2BS with mitochondria was observed in IL-2-stimulated cells (Fig.
III-10A). Interestingly, association of ITM2BS to mitochondria in IL-2-deprived apoptotic
cells correlates with loss of MitoTracker staining, strongly suggesting failure of
mitochondrial membrane potential (Fig. III-10A). To conclusively confirm the implication
of ITM2BS in loss of mitochondrial membrane potential, ITM2BS transfected TS1ab cells
were analyzed. IL-2-stimulated mock transfected cells showed weak co-localization of
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ITM2BS with the mitochondria-specific antibody and they retained MitoTracker staining,
suggesting active mitochondria (Fig. III-10B). The level of ITM2BS and mitochondrial
marker co-localization strongly increased in IL-2-stimulated ITM2BS transfected cells, but
these cells did not retain MitoTracker labelling, showing loss of mitochondrial membrane
potential (Fig. III-10B). In addition, double immunofluorescence analysis of IL-2-
stimulated mock transfected cells demonstrated association of endogenous ITM2BS to
active mitochondria, as detected by MitoTracker staining, whereas there was no
fluorescence overlapping in IL-2-stimulated ITM2BS transfected cells because membrane
potential was lost (Fig. III-10C).
Finally, triple staining experiments were performed with anti-ITM2BS (violet), anti-
mitochondria (green) and MitoTracker (red) of IL-2-stimulated mock or ITM2BS
transfected cells. Figure III-10D shows regions of triple co-localization with punctate
staining of endogenous ITM2BS, mitochondria and MitoTracker (white colour) in IL-2-
stimulated mock transfected cells, indicating that endogenous ITM2BS is localized, at least
in part, in active mitochondria. Intact mitochondria were detected in mock transfectants by
overlapping of anti-mitochondria and MitoTracker markers (yellow colour). On the other
hand, ITM2BS co-localized with mitochondria (blue colour) in ITM2BS transfected cells,
but MitoTracker fluorescence was not detected due to loss of mitochondrial membrane
potential induced by overexpression of ITM2BS (Fig. III-10D).
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Figure III-10. ITM2BS expression triggers loss of mitochondrial membrane potential. (A) IL-2-stimulated or -deprived
cells were stained with either anti-mitochondria Mito 2813 and anti-ITM2B or anti-mitochondria and MitoTracker
followed by Cy3/Cy2-labelled secondary antibodies and analyzed by confocal microscopy. Similar results were obtained
in three independent experiments. Single confocal sections show fluorescence in green and red. Fluorescence co-
localization is shown in yellow. (B) IL-2-stimulated mock or ITM2BS transfected cells were stained with either anti-
mitochondria and anti-ITM2B or anti-mitochondria and MitoTracker followed by Cy3/Cy2-labelled secondary
antibodies. Cells were analyzed as in A. Similar results were obtained in three independent experiments. (C) Cells were
treated as in B and stained with MitoTracker and anti-ITM2B, followed by Cy2-labelled secondary antibodies and were
analyzed by confocal microscopy. Similar results were obtained in three independent experiments. (D) Cells, treated as in
B, were triple labelled with anti-mitochondria, anti-ITM2B and MitoTracker, followed by Cy2 and Cy5-streptavidin-
labelled secondary antibodies and were analyzed by confocal microscopy. Similar results were obtained in three
independent experiments. Overlay of red and green fluorescence is shown as yellow colour, overlay of violet and red
fluorescence is shown in pink, overlay of violet and green fluorescence is shown in blue and triple overlay is shown in
white colour.
C
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III.1.8 Caspase activity is required to execute ITM2BS-induced apoptosis
To test the involvement of upstream and downstream caspases in ITM2BS-induced
apoptosis, specific antibodies were used together with measurement of caspase activity in
cell extracts and intact cells. Western blot analysis of IL-2-stimulated ITM2BS transfected
cells revealed lower level of procaspase-9 compared with the level detected in IL-2-
stimulated mock transfected cells (Fig. III-11A), suggesting that ITM2BS expression
induces procaspase-9 cleavage and, as a consequence, its activation. The cleaved products
of pro-caspase-9 (catalytic subunits) increased in ITM2BS transfected cells (data not
shown). Caspase-9 activity was also analyzed in cell extracts. Higher level of caspase
activity was detected in extracts of IL-2-stimulated or -deprived ITM2BS transfected cells
(Fig. III-11B) compared to the level of mock transfected cells in the presence or absence of
IL-2, respectively.
The level of caspase-3 activation was determined by western blot, demonstrating that
the amount of procaspase-3 decreased upon ITM2BS transfection in IL-2-stimulated cells
compared to the level of procaspase-3 detected in mock transfected cells, suggesting that
ITM2BS expression induces procaspase-3 cleavage (Fig. III-11C). The cleaved products
were detected in ITM2BS transfected cells (data not shown). Caspase-3 activity was also
detected upon incubation of transfected cells with PhiPhiLux, a fluorogenic substrate
(amino acid sequence D-E-V-D-G-I) for the detection and measurement of caspase-3 and
caspase-3-like activities in living cells. Very few cells produced fluorescence emission
upon mock transfection (Fig. III-11D), whereas ITM2BS expression induced a strong
increase in fluorescence, indicating the induction of caspase-3 activity (Fig. III-11D). The
cleaved products of pro-caspase-9 and -3 were also detected in 24 h IL-2-deprived cells
(Fig. III-11E). Given that anti-apoptotic members of the Bcl-2 family stabilize the
mitochondrial membrane barrier that regulates the release of cytochrome c, the question
was addressed whether active caspases could cleave the pro-survival protein Bcl-2, which
is expressed in IL-2-stimulated cells, to cause mitochondrial damage. For this purpose, the
ability of ITM2BS to induce Bcl-2 cleavage was analyzed. Figure III-11F shows that
overexpression of ITM2BS did not induce cleavage of mitochondria-associated Bcl-2.
Taken together, ITM2BS overexpression results in cleavage of caspase-3 and caspase-9,
thereby activating the caspase cascade in T-lymphocytes.
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Figure III-11. Effect of ITM2BS expression on caspase activation. (A) Mock or ITM2BS transfected IL-2-stimulated
cells were lysed and proteins blotted with anti-caspase-9 and p53, the latter as internal control of protein loading. Similar
results were obtained in four independent experiments. (B) Cells treated as in A and caspase-9 activity was determined as
the fluorescence emission of cleaved substrate. (C) Cells were treated as in A and protein blotted with anti-caspase-3 and
anti-p53. Similar results were obtained in three independent experiments. (D) Cells were treated as in A and caspase-3
activation was analyzed in living cells by flow cytometry using PhiPhiLux fluorescence peptide. Results show a typical
experiment out of four. (E) Cells were IL-2-stimulated or -deprived and caspase-9, as well as caspase-3, activation was
analyzed by western blot. (F) Cells were transfected with ITM2BS or empty vector (mock) and maintained in IL-2. After
transfection, proteins were blotted with anti-Bcl-2 and anti-p53.
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III.2 The pro-survival Bcl-2 family member Bcl-xL and Bcl-w target
protein phosphatase 1a to the pro-apoptotic molecule Bad
III.2.1 Bcl-xL and Bcl-w interact with the phosphatase PP1a
Our group had previously demonstrated that the anti-apoptotic molecule Bcl-2 is a
targeting subunit of the serine/threonine phosphatase PP1a in IL-2-stimulated TS1ab cells.
Furthermore, the Bcl-2 sequence (R/K-X-V/I-X-F) responsible for interaction with PP1a
(Ayllon et al., 2001) had been delineated. Given that Bcl-xL and Bcl-w also contain the
well conserved R/K-X-V/I-X-F motif, the possibility was explored, if the anti-apoptotic
molecules Bcl-xL and Bcl-w may be as well associated to PP1a in IL-4-stimulated TS1ab
cells that do not express Bcl-2, but do express Bcl-xL and Bcl-w. Reciprocal co-
immunoprecipitation experiments of cytoplasmic proteins were performed under IL-4-
stimulation or -deprivation conditions using specific antibodies. PP1a and Bad were
detected by western blot in anti-Bcl-xL immunoprecipitates of IL-4 stimulated cells,
decreasing throughout the starvation period (Fig. III-12A). Probing the membrane with
anti-Bcl-xL antibody showed similar protein levels in all analyzed conditions. PP1a and
Bad were also detected in anti-Bcl-w immunoprecipitates of IL-4-stimulated cells,
diminishing after lymphokine deprivation (Fig. III-12A). Membrane was also probed with
anti-Bcl-w antibody, showing similar protein levels. Immunoprecipitation of cytoplasmic
lysates with an irrelevant antibody, anti-p55 IL-2R chain, was not able to detect those
associations (Fig. III-12B). Similarly, Bcl-xL, Bcl-w and PP1a were detected in Bad
immunoprecipitates and the interaction among these proteins was also observed by
immunoprecipitation of detergent-free lysates as well as in cytoplasmic proteins isolated
by digitonin lysis (data not shown). In addition, these associations were identified in
freshly isolated thymocytes (Fig. III-12C).
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Figure III-12. Association of Bcl-xL and Bcl-w to PP1a and Bad. (A) Cytoplasmic extracts from IL-4-stimulated (60
U/ml) or -deprived cells were immunoprecipitated with anti-Bcl-xL or anti-Bcl-w antibodies, transferred to nitrocellulose
and blotted with anti-Bad, anti-PP1a, anti-Bcl-xL and anti-Bcl-w antibodies. Protein bands were detected using ECL
system. Molecular weights of the corresponding proteins are shown. Similar results were obtained in three independent
experiments. (B) Cytoplasmic extracts from IL-4-stimulated cells were immunoprecipitated with anti-p55 IL-2R chain
antibody, transferred to nitrocellulose and blotted with anti-Bcl-w, Bcl-xL or anti-p55 IL-2R antibodies. Protein bands
were detected using the ECL system. (C ) Cytoplasmic extracts from freshly isolated thymocytes were
immunoprecipitated with anti-Bad, anti-PP1a or an irrelevant serum (I) and blotted with anti-Bcl-2, anti-Bcl-xL, anti-Bad
and anti-PP1a. Proteins were detected as in A. Similar results were obtained in three independent experiments.
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III.2.2 Serine phosphorylation of Bcl-xL and Bcl-w affects binding to PP1a
Given that the number of Bcl-xL/PP1a/Bad and Bcl-w/PP1a/Bad complexes decreases
after IL-4 deprivation, further studies were carried out to determine whether down-
regulation of the expression of any of the proteins involved in the formation of the
complex may explain the previous result. Total expression of Bcl-xL, Bcl-w, PP1a and Bad
was analyzed in IL-4-stimulated or -deprived TS1ab cells. All proteins were expressed in
IL-4-stimulated or -deprived cells (Fig. III-13A). As the number of aggregates decreases
after IL-4 deprivation without modification of total expression of proteins of the complex,
post-translational modifications of Bcl-xL or Bcl-w may influence the formation of the
trimolecular complex. Therefore, the status of serine phosphorylation of Bcl-xL and Bcl-w
was examined. Cytoplasmic extracts from IL-4-stimulated or -deprived cells were
immunoprecipitated with anti-Bcl-xL or anti-Bcl-w and blotted with anti-Pser, anti-Bcl-w
and anti-Bcl-xL specific antibodies (Fig. III-13B). Serine phosphorylation of Bcl-xL and
Bcl-w was observed in control IL-4-stimulated cells, decreasing after IL-4 deprivation.
This result suggests a correlation between serine phosphorylation of Bcl-xL and Bcl-w and
the formation of trimolecular complexes.
We have recently shown that IL-2, as well as IL-3, induces serine phosphorylation of
Bad (Ayllon et al., 2000). Figure III-13C shows that IL-4 induced Bad phosphorylation at
serine 136 but not at serines 112 and 155. Moreover, IL-4 deprivation triggered serine 136
dephosphorylation of Bad. IL-2-stimulated cells (C, ser 112 and 136 phosphorylation) and
COS (C, ser 155 phosphorylation) cells overexpressing Bad were used as positive controls.
IL-3-induced serine phosphorylation of Bad results in its association to the 14-3-3 protein,
abolishing interaction with Bcl-xL (Zhou et al., 2000). Figure III-13D demonstrates that
serine phosphorylation of Bad in response to IL-4 did not result in binding to 14-3-3
protein. This protein was detected in total extracts from control IL-4 stimulated cells (lane
T), but was not observed neither in PP1a, nor in Bcl-xL or Bad immunoprecipitates of IL-
4-stimulated or -deprived cells. As internal control, the interaction of Raf and the 14-3-3
protein is demonstrated upon Raf immunoprecipitation (Fig. III-13D).
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Figure III-13. Effect of IL-4 deprivation on serine phosphorylation of Bcl-xL and Bcl-w and on association to 14-3-3
protein. (A) TS1ab cells were IL-4-stimulated or -deprived for the indicated times and lysed. Proteins were transferred to
nitrocellulose and probed with anti-Bcl-xL, anti-Bcl-w, anti-Bad and anti-PP1a antibodies. Similar results were obtained
in two independent experiments. (B ) Cytoplasmic extracts from IL-4-stimulated or 24 h-deprived cells were
immunoprecipitated with anti-Bcl-xL or anti-Bcl-w, separated in a gradient SDS-PAGE gel and blotted with anti-Pser and
as internal control, with anti-Bcl-xL and anti-Bcl-w. Similar results were obtained in three independent experiments. (C)
Cytoplasmic extracts from control, IL-4-stimulated or -deprived cells (1x 107) were immunoprecipitated with anti-Bad
antibody and blotted with anti-Bad serine 112, serine 136 and serine 155 antibodies. As internal control, the blot was
developed with anti-Bad antibody. Similar results were obtained in two independent experiments. IL-2 stimulated cells
served as positive control for serine 112 and 136 phosphorylation of Bad (lane C). Bad-transfected COS cells were
utilized as positive control for serine 155 phosphorylation of Bad (lane C). (D) Total extracts (T) of cytoplasmic lysates
from IL-4-stimulated or -deprived cells (1x 107) were immunoprecipitated with anti-PP1a, anti-Bcl-xL or anti-Bad
antibodies and blotted with anti-14-3-3, anti-PP1a, anti-Bcl-xL and anti-Bad. Similar results were obtained in two
independent experiments.
III.2.3 Detection of phosphatase activity in Bcl-xL and Bcl-w immunoprecipitates
Figure III-14A shows phosphatase activity in Bcl-xL, Bcl-w and Bad
immunoprecipitates of IL-4-stimulated cells. The enzymatic activity in the
immunoprecipitates was measured using 32P-labeled phosphorylase a as substrate. It is
interesting to notice that phosphatase activity detected in Bcl-xL and Bcl-w
immunoprecipitates nearly corresponds to the phosphatase activity observed in Bad
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immunoprecipitates. To confirm that this phosphatase activity was due to PP1a, enzymatic
activity was estimated in Bad or Bcl-w immunoprecipitates from IL-4-stimulated cells in
the presence of different ocadaic acid (OA) concentrations (Fig. III-14B). OA
concentrations that inhibit type 2A activity (10-9 M) had no effect on Bad- or Bcl-w-
associated phosphatase activity in vitro. Addition of 10-8 M of OA to Bcl-w or Bad
immunoprecipitates resulted in about 50% inhibition of phosphatase activity that was
strongly reduced after addition of 10-6 M OA (Fig. III-14B).
Figure III-14. Measurement of serine/threonine phosphatase activity in control or OA-treated Bcl-xL, Bad and Bcl-w
immunoprecipitates. (A) Phosphatase activity was estimated in Bad, Bcl-xL and Bcl-w immunoprecipitates from IL-4-
stimulated cells using 32P phosphorylase a as substrate. (B) Different concentrations of OA were added to Bad or Bcl-w
immunoprecipitates from IL-4 stimulated cells. Phosphatase activity was estimated as in A. Similar results were obtained
in three independent experiments. Phosphatase activity is represented as the percentage of maximal activity in untreated
supernatants.
Results
67
The effect of OA on phosphatase activity was also measured in supernatants from Bad
and Bcl-w immunoprecipitates. OA concentrations that had no effect on enzymatic activity
in Bad and Bcl-w immunoprecipitates (10-9 M) showed 50% inhibition in the supernatant,
as expected from an association of type 1 and type 2A activities (Fig. III-14B). The
selective effect of OA suggests that the observed phosphatase activity in Bad and Bcl-w
immunoprecipitates derives from phosphatase PP1a..
III.2.4 Bcl-w and Bcl-xL are novel targeting subunits of PP1a
Our group has recently shown that Bcl-2 is a targeting subunit of PP1a (Ayllon et al.,
2001). Given that Bcl-w and Bcl-xL are also associated to PP1a and that sequence of the
binding site of Bcl-2 to PP1a is conserved in Bcl-xL and Bcl-w, it is conceivable that these
anti-apoptotic molecules may be new targeting subunits of PP1a. To test this hypothesis,
depletion of Bcl-xL and Bcl-w was performed by sequential anti-Bcl-xL+Bcl-w
immunoprecipitation of cytoplasmic extracts of IL-4-stimulated cells. Supernatant from the
fourth anti-Bcl-xL/Bcl-w immunoprecipitation was immunoprecipitated with anti-Bad
antibody (5th) and phosphatase activity was estimated (Fig. III-15A). Traces of Bad-
associated phosphatase activity were detected in Bcl-xL/Bcl-w-depleted extracts compared
to high level of activity observed in control anti-Bad immunoprecipitates of IL-4-
stimulated cells. Given that insignificant Bad-associated phosphatase activity was detected
in the absence of Bcl-xL and Bcl-w, the possibility was examined, if these anti-apoptotic
molecules may control targeting of PP1a  to Bad. For this purpose, anti-Bad
immunoprecipitations were carried out in cytoplasmic extracts of IL-4-stimulated cells or
in extracts depleted of Bcl-xL and Bcl-w (5th). PP1a, Bcl-xL and Bcl-w were detected in
control anti-Bad immunoprecipitates, but were not observed in anti-Bad
immunoprecipitates from extracts depleted of Bcl-xL and Bcl-w (Fig. III-15B). In
reciprocal experiment, Bad, Bcl-xL and Bcl-w were detected in anti-PP1a
immunoprecipitates of control cells, but were not observed in PP1a immunoprecipitates
from extracts depleted of Bcl-xL and Bcl-w (Fig. III-15B). This result suggests that Bcl-xL
and Bcl-w seem to be necessary for association of PP1a to Bad.
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Figure III-15. Determination of serine/threonine phosphatase activity after Bcl-xL and Bcl-w depletion. (A) Bcl-xL and
Bcl-w were depleted from cytoplasmic lysates of IL-4-stimulated cells by four sequential immunoprecipitations.
Phosphatase activity was estimated in Bad immunoprecipitates from control IL-4-stimulated cells or in Bad
immunoprecipitates depleted of Bcl-xL and Bcl-w. Phosphatase activity is represented as the percentage of the maximal
activity detected in control anti-Bad immunoprecipitates. (B) The effect of Bcl-xL and Bcl-w depletion in PP1a/Bad
association was analyzed. Cytoplasmic extracts from control IL-4-stimulated cells or Bcl-xL/Bcl-w-depleted cytoplasmic
extracts were immunoprecipitated with anti-Bad or anti-PP1a antibody and blotted with anti-Bad, anti-Bcl-w, anti-Bcl-xL
and anti-PP1a antibodies. Similar results were obtained in three independent experiments.
III.2.5 Determination of Bcl-xL and Bcl-w binding sites to PP1a
It has been described that R/K-X-V/I-X-F motif is shared by most of the PP1a
targeting subunits (Egloff et al., 1997). We have shown that PP1a targeting subunit Bcl-2
also shares this conserved motif (Ayllon et al., 2001). Interestingly, sequences of Bcl-xL
and Bcl-w also contain this motif (Fig. III-16B). To analyze whether this sequence of Bcl-
xL and Bcl-w is involved in binding to PP1a, nitrocellulose-immobilized peptides of Bcl-xL
and Bcl-w containing this motif were generated. Membrane was incubated with purified
PP1a protein followed by anti-PP1a antibody exposure. Figure III-16B shows PP1a
binding to Bcl-xL and Bcl-w peptide sequences with different affinity. The R/K-X-V/I-X-F
motif, present in Bcl-xL and Bcl-w, interacted with PP1a and its mutation in critical valine
(V) and phenylalanine (F) residues strongly reduced binding of Bcl-xL and Bcl-w to PP1a
(Fig. III-16B). Analysis of the Bcl-2 binding sites to PP1a exhibited, in addition to R/K-X-
V/I-X-F motif, two other sequences (F-S-R-R-Y-R and F-T-A-R-G-R) that bind to PP1a.
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Interestingly, similar sequences were as well observed in Bcl-xL and Bcl-w (Fig. III-16A).
F-E-L-R-Y-R and F-E-T-R-F-R sequences of Bcl-xL and Bcl-w respectively were also able
to interact with PP1a and its mutation inhibited binding to PP1a, although the affinity
depended on the type of point mutation (Fig. III-16B). The interacting consensus F-X-X-R-
X-R motif was determined by sequence comparison of Bcl-2, Bcl-xL and Bcl-w (Fig. III-
16A).
Figure III-16. PP1a binding assay on cellulose-bound Bcl-xL or Bcl-w peptides. (A) Sequence of F-X-X-R-X-R motif of
Bcl-2, Bcl-xL and Bcl-w. (B) Membrane with Bcl-xL or Bcl-w peptides containing the R/K-X-V/I-X-F or F-X-X-R-X-R
motif, as well as peptides containing mutated motifs were incubated with purified PP1a, followed by anti-PP1a antibody
and PO-conjugated secondary antibody. Spots were detected using ECL system. Similar results were obtained in two
independent experiments. The R/K-X-V/I-X-F and F-X-X-R-X-R motifs are in bold. Mutated amino acids within the
motif are in bold and underlined. Peptide 1 corresponds to the PP1-binding motif of Bcl-xL and Bcl-w. Peptide 2
corresponds to the mutated PP1-binding site, where V and F residues were mutated to A.
To conclusively confirm that R/K-X-V/I-X-F and F-X-X-R-X-R motifs were
implicated in binding of Bcl-xL and Bcl-w to PP1a , competition experiments in
trimolecular complexes were performed. Lysates from IL-4-stimulated cells were
immunoprecipitated with anti-Bad antibody and the interaction Bcl-xL/PP1a and Bcl-
w/PP1a was competed using R* (N-W-G-R-I-A-A-A-F-S-F), R (N-W-G-R-I-V-A-F-F-S-
F) or F (G-D-E-F-E-L-R-Y-R-R-A-F) peptides (Fig. III-17A). Bcl-xL, Bcl-w and PP1a
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were detected in control anti-Bad immunoprecipitates, as well as in anti-Bad
immunoprecipitates treated with R* peptide. The amount of Bcl-xL, Bcl-w and PP1a
associated to Bad decreased after competition with F or R peptide, being almost
undetectable upon competition of Bad immunoprecipitates with F+R peptides (Fig. III-
17A). Similar level of Bad was observed in control or peptide-treated anti-Bad
immunoprecipitates. To confirm that Bcl-xL and Bcl-w are targeting subunits of PP1a, we
estimated phosphatase activity in control or peptide-treated Bad immunoprecipitates.
Phosphatase activity was detected in control or R* peptide-treated immunoprecipitates
(Fig. III-17B), diminishing upon competition of the interaction with F or R peptides.
Enzymatic activity was strongly decreased upon competition with both R and F peptides.
Figure III-17C illustrates the phosphatase activity in control or peptide-treated Bad
immunoprecipitates. The concentration of F or R peptide used was twice the concentration
used in F+R peptide-treated immunoprecipitates.
Figure III-17. Competition of the interaction Bcl-xL/PP1a/Bad and Bcl-w/PP1a/Bad with R, R*, F and R+F peptides.
(A) Cytoplasmic extracts from control IL-4-stimulated cells were immunoprecipitated with anti-Bad antibody. The
interaction Bcl-xL/PP1a/Bad and Bcl-w/PP1a/Bad was competed with 1.5 mM of R, R*, F or R+F peptides for 30 min at
room temperature. Immunoprecipitates were washed, transferred to nitrocellulose and blotted with anti-Bad, anti-PP1a,
anti-Bcl-xL and anti-Bcl-w. Similar results were obtained in two independent experiments. (B) Cytoplasmic lysates from
IL-4-stimulated cells were immunoprecipitated with anti-Bad antibody. Immunoprecipitates were treated with 1.5 mM of
R, R*, F or R+F peptides for 30 min at room temperature. Immunoprecipitates were washed and phosphatase activity
estimated using 32P phosphorylase a as substrate. Similar results were obtained in two independent experiments. (C)
Cytoplasmic lysates from IL-4-stimulated cells were immunoprecipitated with anti-Bad antibody and then treated with
1.5 mM of R+F peptide or 3 mM of R or F peptide (30 min, room temperature). Immunoprecipitates were washed and
phosphatase activity was estimated as in B.
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As shown in figure III-17B, phosphatase activity was drastically reduced upon
treatment of Bad immunoprecipitates with F+R peptides. Taken together, these results
suggest that Bcl-xL and Bcl-w, as well as Bcl-2, are PP1a targeting subunits.
III.2.6 Suppression of PP1a activity prevents induction of apoptosis
As IL-4 deprivation correlates with Bad dephosphorylation and apoptosis, inhibition
of phosphatase activity by OA treatment might block these events. In fact, treatment of
TS1ab cells with 1 mM of OA prevented Bad dephosphorylation at Ser 136 in the absence
of IL-4 (Fig. III-18A). No changes in total Bad expression were observed after OA
treatment, suggesting that OA does not affect protein expression. Moreover, IL-4-deprived
cells incubated with 1 mM of OA for 6 h showed significant reduction of apoptotic cells
compared to untreated cells (Fig. III-18B). Finally, inhibition of Bcl-xL and Bcl-w
expression through antisense oligonucleotide treatment also promoted apoptosis in IL-4-
stimulated cells (Fig. III-18C). Suppression of Bcl-xL and Bcl-w translation upon antisense
oligonucleotide treatment was demonstrated by western blot.
Figure III-18. Effect of OA on serine 136 phosphorylation of Bad and effect of antisense oligonucleotides on apoptosis.
(A ) Cells were treated with or without 1 mM OA in the presence or absence of IL-4. Cytoplasmic lysates were
immunoprecipitated with anti-Bad antibody, transferred to nitrocellulose and probed with phospho-Bad Ser 136 and anti-
Bad antibodies; the latter to verify that OA treatment in vivo does not affect Bad expression. Protein bands were detected
using ECL. Similar results were observed in three independent experiments. (B) Cells were treated for 6 h with or
without 1 mM OA in the presence or absence of IL-4 and then washed, stained with propidium iodide and analyzed by
flow cytometry. (C) Cells were treated for 24 h with or without 15 mM sense or antisense oligonucleotide in the presence
or the absence of IL-4. Oligonucleotides were added at 0, 12 and 18 h and cells were then treated as in B. The expression
of Bcl-xL and Bcl-w upon sense and antisense treatment were analyzed by western blot. Similar results were obtained in
two independent experiments.
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III.3 Transcription factor Aiolos binds to Bcl-xL and blocks its anti-
apoptotic function
III.3.1 Bcl-xL is unable to prevent IL-4-induced apoptosis
It has recently been described that Bcl-2 is expressed in IL-2-stimulated cells and IL-
4-cultured cells express Bcl-xL (Gomez et al., 1998). To study the effect of IL-4
deprivation on Bcl-xL expression, TS1ab cells were IL-4-stimulated or -deprived for
distinct time periods, and total Bcl-xL expression was analyzed by western blot. Bcl-xL
expression was observed in control IL-4-stimulated cells and showed a similar pattern
throughout the analyzed IL-4 starvation period (Fig. III-19). Despite the similar Bcl-xL
levels, IL-4 withdrawal induces a strong increase in apoptosis suggesting that Bcl-xL
cannot inhibit apoptosis under this condition.
Figure III-19. Bcl-xL expression in the presence and absence of IL-4. TS1ab cells were IL-4 stimulated or deprived for
the indicated time periods, harvested and lysed. Protein extracts were separated by SDS-PAGE, transferred to
nitrocellulose and hybridized with anti-Bcl-xL and anti-pan-Ras antibodies, the latter as internal control of protein
loading. Protein bands were detected using the ECL system. Molecular weights of the corresponding proteins are
indicated.
III.3.2 Interaction between Bcl-xL and Aiolos in vitro
To explore the mechanism, by which Bcl-xL is unable to promote cell survival in the
absence of IL-4, Bcl-xL-interacting proteins were searched. For this purpose, a yeast two-
hybrid screen was carried out using a cDNA library from TS1ab cells and Bcl-xL as bait.
Among the screened yeast transformants, 41 clones were identified that associated to Bcl-
xL fusion protein. Seven clones were Aiolos, 24 clones were Bad, six clones were Bcl-G
and four were Harakiri. Further studies were focused on the interaction between Aiolos and
Bcl-xL, as this association had not yet been reported. Aiolos binding to Bcl-xL is indicated
by the induction of LacZ expression (Fig. III-20). Neither Aiolos nor Bcl-xL alone restored
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LacZ expression. Ras/Bcl-xL or Aiolos/Raf interaction could not be detected. Deletion of
the BH3 and BH4 domain of Bcl-xL abolished its association to Aiolos (Fig. III-20). Ras-
Raf interaction served as positive control.
Figure III-20. Interaction of Aiolos and Bcl-xL in the two-hybrid system. The S. cerevisiae L40 reporter strain was co-
transfected with the indicated plasmids. The association between the two-hybrid proteins is indicated by induction of
LacZ expression (blue patches). L40 carrying Ras and Raf was used as positive control (BD: fusion with the DNA-
binding domain of Lex10; AD: fusion with the activation domain of Gal4).
III.3.3 Cellular localization of Aiolos in the presence or absence of IL-4
To analyze the cellular distribution of Aiolos, total, nuclear and cytoplasmic
expression of Aiolos were studied in IL-4-stimulated and -deprived TS1ab cells. Total
Aiolos expression was not modified throughout the analyzed starvation period compared to
IL-4-stimulated cells (Fig. III-21A). To examine the distribution of Aiolos, its expression
was analyzed in nuclear and cytoplasmic extracts of IL-4-stimulated or -deprived cells.
Similar levels of Aiolos were detected in cytoplasmic extracts in both conditions (Fig. III-
21B). As internal control of protein fractionation, hybridization with anti-pan-Ras
(cytoplasmic marker) is shown, using nuclear proteins as negative control (Fig. III-21B,
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lane N). Detection of Histone expression served as control of purity of fractions. Similarly,
Aiolos was detected in nuclear extracts of IL-4-stimulated or -deprived TS1ab cells (Fig.
III-21C), suggesting that IL-4 withdrawal does not trigger translocation of Aiolos from the
cytoplasm to the nucleus. Purity of protein fractionation was checked by reprobing the
membrane with anti-Histones antibody (nuclear marker). Cytoplasmic proteins were used
as negative control (Fig. III-21C, lane C). As expected, Bcl-xL did not localize to the
nucleus both in IL-4-stimulated and -deprived cells.
Figure III-21. Analysis of Aiolos expression upon IL-4 deprivation. (A) Cells were cultured in the presence of IL-4,
deprived for the indicated times, harvested and lysed. Protein lysates were separated by SDS-PAGE, transferred to
nitrocellulose and probed with anti-Aiolos and anti-pan Ras. Molecular weights of the corresponding proteins are
indicated. Similar results were obtained in three independent experiments. (B) Cytoplasmic lysates from IL-4-stimulated
or -deprived cells were separated by SDS-PAGE, transferred to nitrocellulose and blotted with the same antibodies as
described above. Anti-Histones antibody was used as nuclear marker (N, nuclear extracts). Similar results were obtained
in three independent experiments. (C) Nuclear proteins were isolated from IL-4-stimulated or -deprived cells. Proteins
were resolved by SDS-PAGE, transferred to nitrocellulose and blotted as in B (C, cytoplasmic extracts). Similar results
were obtained in two independent experiments.
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III.3.4 In vivo association of Bcl-xL and Aiolos
To analyze whether interaction between Bcl-xL and Aiolos could be confirmed in vivo,
reciprocal co-immunoprecipitation experiments of cytoplasmic proteins were carried out
under IL-4 stimulation and deprivation. Bcl-xL was detected in anti-Aiolos
immunoprecipitates of IL-4-stimulated cells, increasing upon IL-4 deprivation (Fig. III-
22A). Densitometric analysis of Aiolos/Bcl-xL association exhibited a 4-fold increase in
IL-4-deprived TS1ab cells. Similar amounts of Aiolos were observed under both
conditions. The specificity of this interaction was confirmed by immunoprecipitation with
an irrelevant antibody anti-IL-2 (Fig. III-22A and B, lane I). Purity of protein fractionation
was demonstrated by hybridization with anti-Histones antibody using nuclear extracts as
positive control (Fig. III-22A, lane N). In reciprocal experiments, Aiolos was detected in
anti-Bcl-xL immunoprecipitates of IL-4-stimulated cells, increasing three-fold throughout
IL-4 withdrawal. The amount of Bcl-xL did not change during the analyzed starvation
period (Fig. III-22B). The specifity of the interaction was tested as above. Furthermore,
Aiolos/Bcl-xL interaction was also observed in freshly isolated thymocytes, confirming the
results obtained in TS1ab cells (Fig. III-22A). These results provide evidence that Aiolos
interacts with Bcl-xL and that this association increases during IL-4 deprivation. To
estimate the total amount associated to Aiolos, supernatant from Aiolos
immunoprecipitates (10¥ 106 cells) corresponding to 15% (1.5¥ 106 cells), 10% (1¥ 106
cells), 5% (0.5¥ 106 cells), 2.5% (0.25¥ 106 cells) and 1.25% (0.12¥ 106 cells) of total cells
were transferred to nitrocellulose and blotted with anti-Bcl-xL antibody. As shown in figure
III-22C, about 10% of the total amount of Bcl-xL was associated to Aiolos.
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Figure III-22. Reciprocal co-immunoprecipitation experiments of Aiolos and Bcl-xL. (A) Cytoplasmic lysates from IL-4-
stimulated or -deprived cells were immunoprecipitated with anti-Aiolos antibody, washed, transferred to nitrocellulose
and blotted with anti-Bcl-xL antibody. Control hybridizations were carried out with anti-Aiolos and anti-Histones
antibodies (I, Immunoprecipitation with an irrelevant antibody; N, nuclear extracts; T, cytoplasmic extracts from
thymocytes immunoprecipitated with anti-Aiolos). Densitometric analysis and SD of Bcl-xL western blot are shown. The
t-test shows following significances: p < 0.001 (24 h) and p < 0.01 (12 h). (B) Cytoplasmic lysates from IL-4-stimulated
or -deprived cells were immunoprecipitated with anti-Bcl-xL, washed and blotted with anti-Aiolos, anti-Bcl-xL and anti-
Histones antibodies. Similar results were obtained in three independent experiments. Densitometric analysis and SD of
Aiolos western blot are illustrated. The t-test revealed following significances: p < 0.0001 (24 h) and p < 0.005 (12 h).
(C) Cytoplasmic lysates from IL-4-stimulated or -deprived cells were immunoprecipitated with anti-Aiolos antibody,
transferred to nitrocellulose and blotted with anti-Aiolos and anti-Bcl-xL antibodies. Supernatant from Aiolos
immunoprecipitates corresponding to 1.5¥ 106 (1), 1¥ 106 (2), 0.5¥ 106 (3), 0.25¥ 106 (4) and 0.12¥ 106 (5) cells were
separated by SDS-PAGE, transferred to nitrocellulose and blotted with anti-Bcl-xL. Molecular weights of the
corresponding proteins are shown.
III.3.5 IL-4 triggers tyrosine phosphorylation of transcription factor Aiolos
To further elucidate the mechanism, by which Bcl-xL and Aiolos interact in the
cytoplasm of IL-4-deprived TS1ab  cells and the fact that IL-2 induces tyrosine
phosphorylation of Aiolos, the question was addressed, if IL-4 could induce Aiolos
phosphorylation. In fact, tyrosine-phosphorylated Aiolos was detected in Aiolos
immunoprecipitates of IL-4-stimulated cells, decreasing throughout the deprivation period
(Fig. III-23A). Cytoplasmic immunoprecipitated Aiolos was detected by reprobing the
membrane with anti-Aiolos antibody showing similar levels. To verify that Bcl-xL was
associated to unphosphorylated Aiolos, immunoprecipitates of Bcl-xL or Aiolos were
performed in cytoplasmic lysates of IL-4-stimulated or -deprived cells. Tyrosine-
phosphorylated Aiolos was detected in Aiolos immunoprecipitates of control IL-4-
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stimulated cells, but not in Bcl-xL immunoprecipitates of IL-4-stimulated or -deprived cells
(Fig. III-23B). Immunoprecipitated Aiolos and Bcl-xL were observed by reprobing the
membrane with anti-Aiolos and anti-Bcl-xL antibodies. Densitometric analysis of western
blot exhibited three times more Aiolos/Bcl-xL association in IL-4-deprived cells. This
result suggests that IL-4 triggers tyrosine phosphorylation of Aiolos, preventing its binding
to Bcl-xL or alternatively, IL-4 may influence the conformational state of Bcl-xL and
consequently its dissociation from Aiolos.
Figure III-23. Tyrosine phosphorylation of Aiolos. (A) Cytoplasmic lysates from IL-4-stimulated or -deprived TS1ab
cells were immunoprecipitated with anti-Aiolos, washed, transferred to nitrocellulose and probed with anti-PTyr
antibody. The blot was reprobed with anti-Aiolos. Similar results were obtained in two independent experiments. (B)
Cytoplasmic lysates from IL-4-stimulated or -deprived TS1ab cells were immunoprecipitated with anti-Bcl-xL or anti-
Aiolos (lane C) and probed with anti-PTyr and anti-Aiolos antibodies. To detect cytoplasmic Bcl-xL, the blot was
hybridized with anti-Bcl-xL antibody. Similar results were observed in two independent experiments. Densitometric
analysis of Aiolos western blot is shown.
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III.3.6 Association of Bcl-xL and Aiolos blocks the anti-apoptotic function of Bcl-xL
As IL-4 withdrawal in TS1ab cells correlates with induction of apoptosis without
modification of Bcl-xL expression and increased association of dephosphorylated Aiolos to
Bcl-xL, it is possible that Bcl-xL could not prevent apoptosis in IL-4-deprived cells because
this anti-apoptotic molecule is associated to unphosphorylated Aiolos in the cytoplasm.
Cells transfected with Bcl-xL and deprived of IL-4 for 24 h revealed a strong reduction in
the fraction of apoptotic cells compared with IL-4-deprived mock-transfected cells (Fig.
III-24A). Transfected cells showed two-fold induction of Bcl-xL expression. To confirm
that Aiolos interacts with Bcl-xL thereby preventing its anti-apoptotic role, cells were
transfected with pHook3 or pHook3, Bcl-xL and Aiolos, and then selected. Double
transfectants with Bcl-xL and Aiolos showed a similar apoptosis rate comparable to mock
transfectants under both conditions (Fig. III-24A). Expression of transiently transfected
Bcl-xL and Aiolos was confirmed by comparison of Bcl-xL and Aiolos protein levels in
transfected cells and mock controls (Fig. III-24B). Densitometric studies of western blot
showed an induction of Bcl-xL and Aiolos expression in transfected cells. To conclusively
demonstrate that association of Aiolos to Bcl-xL blocks its anti-apoptotic function, Bcl-xL
immunoprecipitations were carried out in Bcl-xL or Bcl-xL/Aiolos transfected cells. Figure
III-25 demonstrates a high level of Aiolos/Bcl-xL association in Aiolos/Bcl-xL-transfected
cells compared with mock or Bcl-xL transfectants, as observed by densitometric analysis of
the corresponding western blot.
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Figure III-24. Cell cycle analysis and western blot of TS1ab cells transfected with Bcl-xL or Bcl-xL and Aiolos. (A)
Cells were transfected with or without Bcl-xL or Bcl-xL/Aiolos and pHook using the DEAE-dextran method. After
transfection, cells were maintained with or without IL-4, then washed, selected using the capture-Tec kit, permeabilized
and stained with propidium iodide. Samples were analyzed by flow cytometry. Non-transfected cells propagated in the
presence or absence of IL-4 were used as control. SD is shown (n = 3). (B) Expression of the transiently transfected Bcl-
xL and Aiolos was confirmed by western blot. The blot was reprobed with anti-pan-Ras as internal control of protein
loading. Similar results were obtained in two independent experiments. Densitometric analysis of Bcl-xL and Aiolos
western blot is illustrated on the right side.
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Figure III-25. Interaction of Bcl-xL and Aiolos in Bcl-xL or Bcl-xL/Aiolos transfected cells. Cells were transfected with
or without Bcl-xL or Bcl-xL/Aiolos using DEAE-dextran method and maintained after transfection with or without IL-4.
Cytoplasmic lysates were immunoprecipitated with anti-Bcl-xL, transferred to nitrocellulose and probed with anti-Aiolos
and anti-Bcl-xL antibodies. Protein bands were detected using the ECL system. Molecular weights of the corresponding
proteins and densitometric analysis of Aiolos western blot are shown.
III.3.7 Downregulation of Aiolos expression enhances cell survival
Given that binding of Aiolos to Bcl-xL in IL-4-deprived cells inhibits the anti-
apoptotic function of Bcl-xL, the question arose whether downregulation of Aiolos
expression in IL-4-deprived cells would promote cell survival through Bcl-xL expression.
Figure III-26 shows that inhibition of Aiolos expression upon antisense oligonucleotide
treatment enhanced cell survival by Bcl-xL in the absence of IL-4. Aiolos downregulation
was checked by western blot (Fig. III-26). Taken together, these results suggest that Bcl-xL
is not able to act as a survival factor in IL-4-deprived cells because this anti-apoptotic
molecule is sequestered by unphosphorylated Aiolos and only cells overexpressing Bcl-xL
are able to prevent apoptosis in the absence of IL-4.
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Figure III-26. Antisense Aiolos causes apoptosis inhibition. Cells were treated for 24 h with or without 15 mM sense or
antisense oligonucleotides in the presence or absence of IL-4. Oligonucleotides were added at 0, 12 and 18 h. Cells were
washed, stained with propidium iodide, and analyzed by flow cytometry. Aiolos expression upon sense and antisense
oligonucleotide treatment was analyzed by western blot.
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III.4 Segregation of the pro-apoptotic molecule Bad from lipid rafts is
involved in the induction of apoptosis
III.4.1 IL-4 deprivation triggers Bad translocation from lipid rafts to mitochondria
It has been shown that Bad becomes phosphorylated after IL-3 stimulation leading to
its association to the cytoplasmic protein 14-3-3. However, our group had recently
demonstrated that IL-2 induces Bad phosphorylation without binding to 14-3-3 protein
(Ayllon et al., 2001). Similarly, neither IL-4 stimulation nor IL-4 deprivation resulted in
association of Bad to 14-3-3 protein (Fig. III-27). As internal control, the interaction of Raf
and the 14-3-3 protein is shown.
Figure III-27. Lack of association of Bad with 14-3-3 protein in TS1ab cells. Cytoplasmic extracts from 10x 106 IL-4-
stimulated or -deprived cells were immunoprecipitated with anti-Bad or anti-Raf antibodies and blotted with anti-14-3-3,
anti-Raf and anti-Bad antibodies. Total extracts (lane T) were used as a positive control of 14-3-3 and Raf expression.
Similar results were obtained in three independent experiments.
As 14-3-3 protein did not appear to play a role in regulation of Bad in IL-4-stimulated
or -deprived TS1ab, the hypothesis was addressed, whether subcellular localization of Bad
may be involved in the control of its pro-apoptotic role. For this reason, the subcellular
distribution of Bad was analyzed in IL-4-stimulated or -deprived cells (Fig. III-28). After
lysis, cells were fractionated over sucrose gradient. To estimate the purity of fractionation,
the distinct fractions were immunoblotted with markers for rafts (Lck and GM1
ganglioside), mitochondria (Cytochrome c), endoplasmic reticulum (Calnexin) and cytosol
(caspase 3). Nuclear fraction is not shown in the blot, since Bad was not observed in
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nuclei. Rafts were detected by western blot in fraction 1 using anti-Lck antibody and CTx-
Biotin that recognizes GM1 ganglioside (Fig. III-28A). Majority of Bad was found in rafts
(fraction 1), although a very small fraction was also present in mitochondria (fraction 4),
cytosol and endoplasmic reticulum (fraction 2). As internal control, Bad was observed in
total extracts of IL-4-stimulated cells.
Figure III-28. Subcellular localization of Bad in IL-4-stimulated or -deprived cells. (A) Anti-Bad, anti-Lck (rafts), CTx-
Biotin (GM1 ganglioside, rafts), anti-caspase-3 (cytosol), anti-Calnexin (endoplasmic reticulum, ER) and anti-
cytochrome c (mitochondria) immunoblot analysis of subcellular fractions from IL-4-stimulated or -deprived cells. The
fractions (1 to 4) were prepared by sucrose gradient ultracentrifugation and tested for their purity using antibodies against
mitochondria, rafts, ER and cytosol. Nuclear fraction is not shown in the blot (fraction 5). The protein amount loaded per
well in each gradient fraction corresponds to that of 5x 106 cells. Total extracts contained 30 mg protein. Similar results
were obtained in three independent experiments. (B) IL-4-stimulated or -deprived cells were Triton X-100 extracted and
fractionated in Optiprep flotation gradient. Fractions were collected from the top to the bottom of the gradient and were
analyzed by western blot. Only the first, insoluble proteins (I) and the last fraction, soluble proteins (S) are shown.
Similar results were obtained in two independent experiments.
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IL-4 deprivation induces disorganization of rafts (fraction 1) that were not detected in
the absence of IL-4 using either anti-Lck antibody or CTx-Biotin. The mitochondria, which
also contains other cellular structures with similar density, is observed in fraction 4 and
most of the caspase 3 was cleaved, given a new protein of lower molecular weight. More
interestingly, Bad is almost undetectable in cytosol and rafts and only observed in fraction
4 that corresponds to mitochondria and cellular structures with similar density (Fig. III-
28A). This result strongly suggests an IL-4-dependent association of Bad to rafts and
translocation to mitochondria upon IL-4-deprivation. To confirm these results, rafts were
isolated by Triton X-100 flotation gradient. As shown in figure III-28B, Bad and Lck were
detected in the detergent insoluble fraction (I) of IL-4-stimulated cells, which corresponds
to lipid rafts, whereas both proteins were found upon IL-4 withdrawal in the fraction
corresponding to soluble proteins (S).
The subcellular localization of Bad was also analyzed in mitochondrial and cytosolic
fractions of IL-4-stimulated or -deprived cells. Bad was detected in the mitochondrial
fraction of IL-4-stimulated cells (Fig. III-29A). The amount of Bad associated to
mitochondria increased upon IL-4 deprivation. Traces of Bad were found in the cytosolic
fraction of IL-4-stimulated or -deprived cells. The anti-apoptotic molecule Bcl-xL was
weakly detected in the mitochondrial fraction of IL-4-stimulated cells, increasing after IL-4
deprivation. As internal control of protein fractionation, the blot was probed with anti-
caspase 3 (cytosolic marker), anti-mitochondria Mito 2813 (pyruvate dehydrogenase,
mitochondrial marker) and anti-Calnexin to confirm the lack of endoplasmic reticulum
contamination in mitochondrial preparation. Total extracts (lane T) were used as positive
control of Calnexin expression. Finally, we explored the association of Bad to some Bcl-2
family members. We performed co-immunoprecipitation experiments of cytoplasmic
proteins under IL-4 stimulation or deprivation using specific antibodies. Bad was detected
by western blot in anti-Bcl-xL immunoprecipitates of IL-4-stimulated cells, decreasing
throughout the analyzed starvation period (Fig. III-29B). Probing the membrane with anti-
Bcl-xL antibody showed similar levels in all conditions.
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Figure III-29. Association of Bad with mitochondria and Bcl-xL. (A) Mitochondrial and cytosolic proteins were isolated
from IL-4-stimulated or -deprived cells, separated by SDS-PAGE, transferred to nitrocellulose and immunoblotted with
anti-Bad, anti-Bcl-xL, anti-caspase-3 (cytosolic marker), anti-mitochondria Mito 2813 (pyruvate dehydrogenase,
mitochondrial marker) and anti-Calnexin (marker for endoplasmic reticulum). Protein bands were detected using the ECL
system. Similar results were obtained in three independent experiments. (B) Cytoplasmic lysates from IL-4-stimulated or
-deprived cells were immunoprecipitated with anti-Bcl-xL, transferred to nitrocellulose and blotted with anti-Bad and
anti-Bcl-xL antibodies. Protein bands were detected as in A . Similar results were obtained in three independent
experiments.
Bad association to rafts was also analyzed in IL-4-stimulated cells by confocal
microscopy (Fig. III-30A). IL-4-stimulated or -deprived cells were incubated with the raft
marker cholera toxin B subunit (CTx-FITC) before secondary labelling with anti-Bad or
anti-Lck antibody. Double immunofluorescence analysis with anti-Bad and CTx-FITC
demonstrated rafts localization of Bad in the surface of IL-4-stimulated cells. In marked
contrast, disorganization of rafts was observed in IL-4-deprived cells and consequently, a
lack of Bad localization to rafts in IL-4-deprived cells (Fig. III-30A). Double
immunofluorescence analysis with anti-Lck and CTx-FITC was used as positive control
for Lck localization in membrane rafts of IL-4-stimulated cells. Furthermore, Lck was not
found to be associated with rafts in IL-4-deprived cells (Fig. III-30A). The profile of green
and red fluorescence co-localization was analyzed using the quantification software of
Leica (Leica TCS NT). As shown in figure III-30B, high number of green and red co-
localization peaks was observed in the membrane of IL-4-stimulated cells stained with
CTx-Lck or CTx-Bad. On the contrary, the level of co-localization of green and red
fluorescence was strongly reduced in IL-4-deprived cells (Fig. III-30B). This result
suggests that Bad is preferentially localized in lipid rafts in IL-4-stimulated cells and
segregates from the plasma membrane in IL-4-deprived cells. Similar results of co-
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localization of Bad with lipid rafts were observed using freshly isolated thymocytes from
mice (Fig. III-30C).
Figure III-30. Rafts localization of Bad in IL-4-stimulated cells. (A) IL-4-stimulated or -deprived cells were stained with
CTx-FITC and incubated either with anti-Lck or anti-Bad antibodies as indicated, followed by Cy3-labelled secondary
antibody and analyzed by confocal microscopy. Similar results were obtained in three independent experiments. Single
confocal sections show fluorescence in green (FITC) and red (Cy3). (B) The profile of green and red fluorescence co-
localization in the cell membrane was analyzed using the quantification software of Leica. The peaks of fluorescence co-
localization are labelled with stars. (C) Freshly isolated thymocytes from mice were stained as in A, followed by Cy3-
labelled secondary antibody and analyzed by confocal microscopy. Similar results were obtained in two independent
experiments.
Bad association to mitochondria in IL-4-deprived cells was also examined in intact
cells by confocal microscopy (Fig. III-31A). Double immunofluorescence analysis with
anti-Bad and anti-mitochondria antibodies shows weak association of Bad to mitochondria
in IL-4-stimulated cells, while there is a high fraction of Bad associated to mitochondria in
IL-4-deprived cells (Fig. III-31A). This separation of Bad from rafts correlates with its
translocation to mitochondria in IL-4-deprived cells, as revealed by cellular fractionation
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and confocal microscopy (Fig. III-28A). The profile of green and red fluorescence co-
localization was also analyzed using the quantification software of Leica. Figure III-31B
shows moderate green and red co-localization peaks in IL-4-stimulated cells stained with
anti-Bad and anti-mitochondria antibodies. The level of co-localization of both
fluorescences strongly increases in IL-4-deprived cells (Fig. III-31B).
Figure III-31. Mitochondrial localization of Bad. (A) IL-4-stimulated or -deprived cells were stained with anti-Bad and
anti-mitochondria antibodies, followed by FITC- and Cy3-labelled secondary antibodies and analyzed as above. Similar
results were obtained in three independent experiments. (B) The profile of green and red fluorescence co-localization in
the cell membrane was analyzed using the quantification software (Leica). The peaks of fluorescence co-localization are
labelled with stars.
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III.4.2 Bad localization in lipid rafts is required to prevent apoptosis
Depletion of cellular cholesterol impairs the ability of glycosyl phosphatidylinositol
(GPI)-anchored proteins to associate with lipid rafts.
Figure III-32. Methyl-b-cyclodextrin (M-b-CD) treatment prevents association of Bad to rafts. (A) IL-4-stimulated cells
were serum-starved for 30 min and then treated with or without 10 mM M-b-CD for 30 min at 37°C before incubation
with CTx-FITC and anti-Bad or anti-Lck antibodies, followed by Cy3-labeled secondary antibody. Subsequently, cells
were analyzed by confocal microscopy. Similar results were obtained in two independent experiments. Single confocal
sections show green (FITC) and red (Cy3) fluorescence. (B) The profile of green and red fluorescence co-localization in
the cell membrane was analyzed using the quantification software (Leica). The peaks of fluorescence co-localization are
labelled with stars. (C) Background staining with anti-rabbit Cy3 or anti-mouse Cy3.
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To examine whether there is a similar requirement of cholesterol for the association of
Bad to rafts, IL-4-stimulated cells were treated for 30 min with or without 10 mM methyl-
b-cyclodextrin (M-b-CD) in serum-free medium to deplete cellular cholesterol. Cells were
then incubated with CTx-FITC and labelled with anti-Bad or anti-Lck antibodies. Serum
depletion alone weakly disrupted the association of Lck or Bad to lipid rafts (Fig. III-32A).
Given that exclusion of Bad from rafts was also observed in apoptotic IL-4-deprived
cells (Fig. III-30A), the hypothesis was tested whether Bad association to rafts and its
integrity were necessary for prevention of apoptosis. For this purpose, IL-4-stimulated
cells were treated for 30 min with or without M-b-CD in serum-free medium, then washed,
resuspended in IL-4-supplemented complete medium and analyzed by flow cytometry for
induction of apoptosis at different times (Fig. III-33). M-b-CD treated cells showed
stronger level of apoptosis compared to control non-treated cells, reaching the highest level
five hours after M-b-CD treatment. Eight hours upon treatment, the amount of apoptotic
cells detected in treated and non-treated cells were similar, since addition of serum restored
the lipid composition of the membrane (data not shown). Taken together, these results
suggests that segregation of Bad from rafts is implicated in the induction of apoptosis.
Figure III-33. M-b-CD is able to induce apoptosis in the presence of IL-4. IL-4-stimulated cells were serum-starved for
30 min and then treated with or without 10 mM M-b-CD for 30 min at 37°C, then washed and transferred to complete
medium supplemented with IL-4. At different times, apoptosis was measured by flow cytometry. Sub-G1 region of the
fluorescence scale was used to determine the percentage of cells present in the initial step of apoptosis. Similar results
were obtained in two independent experiments (white bars, control cells; grey bars, M-b-CD-treated cells).
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IV Discussion
The knowledge of the molecular basis of apoptosis-signalling pathways plays a key
role in the development of novel therapeutics that can improve treatment of many human
diseases such as cancer or neurodegenerative disorders. The members of the Bcl-2 family
are evolutionarily conserved core components of the apoptotic machinery that control the
balance between cell death and proliferation in multicellular organisms. Alterations of
those genes caused by mutations or modifications at the transcriptional/translational level
can result in tumor formation or in excessive neuronal cell death as observed in Parkinson
or Alzheimer (Reed, 2001; Thompson, 1995). The present study aimed to reveal the
mechanisms, by which Bcl-2-like proteins are controlled leading to their activation or
deactivation. Three distinct types of mechanisms, implicated in apoptosis control, have
been elucidated in this thesis including transcriptional upregulation, protein-protein
interaction and subcellular translocation that will be discussed in the following.
RDA screening for genes, upregulated upon IL-2 deprivation, yielded a novel
regulator of cell death, ITM2BS, that induces apoptosis in T lymphocytes. Integral
membrane protein 2B (ITM2B) was described as a type II transmembrane protein that is
associated to chondrogenic differentiation (Deleersnijder et al., 1996; Pittois et al., 1998).
ITM2B belongs to a multiple gene family containing at least two further members, ITM2A
and ITM2C. The three isoforms share 50% identity at the amino acid level being the C-
terminal the most conserved part. ITM2B has no significant homology with any known
protein domain in the current databases. However, intensive sequence analysis revealed a
stretch of 9-16 amino acids corresponding to a BH3 homology region (Chittenden et al.,
1995). Although the two isoforms ITM2BS and ITM2BL contain the BH3 motif, expression
of ITM2BL was not able to induce apoptosis. Moreover, the mRNA level of ITM2BL was
not upregulated after IL-2 withdrawal. Probably, the N-terminal domain, specific to
ITM2BL, may have a negative regulatory role. It is interesting to notice that ITM2BL
comprises a binding motif for IAPs (inhibitors of apoptosis) (Salvesen and Duckett, 2002).
It is tempting to speculate that IAPs are associated to the N-terminal region of ITM2BL,
avoiding its pro-apoptotic function. The small BH3 domain is the only region of ITM2BS
exhibiting homology with other members of the Bcl-2 family lacking conserved BH1, BH2
and BH4 domains. It has been described that deletion of the BH3 domain blocks apoptotic
function of Bad, Bim, Hrk and Noxa (Inohara et al., 1997; Kelekar et al., 1997; O'Connor
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et al., 1998; Oda et al., 2000). Mutation of the critical amino acids leucine (L) and aspartic
acid (D) within ITM2BS BH3 domain inhibits its pro-apoptotic activity likewise. As the
BH3 domain was essential for most of its cytotoxic action, ITM2BS can be considered
together with Bik, Bid, Bim, Bmf, Harakiri, Noxa and Puma as a group of pro-apoptotic
BH3-only proteins. To explain this redundancy, it has been proposed that BH3-only
members function as death sensors, activated by distinct upstream apoptotic stimuli
(Bouillet and Strasser, 2002). Both Noxa and Puma have been involved in DNA damage-
induced apoptosis (Nakano and Vousden, 2001; Oda et al., 2000; Yu et al., 2001). A
different stress stimulus, nerve growth factor withdrawal, is mediated through Harakiri
(Imaizumi et al., 1997), whereas Bmf is activated by loss of cellular attachment (anoikis)
(Puthalakath et al., 2001). Bim is the best studied BH3-only protein and has been
implicated in mediating apoptosis in autoreactive thymocytes during negative selection
(Bouillet and Strasser, 2002), in activated T cell death in response to antigens (Hildeman et
al., 2002) and in peripheral deletion of autoreactive CD8 T cells by cross presentation of
self antigen (Davey et al., 2002). Here, ITM2BS was shown to be activated by another
death stimulus, IL-2 deprivation. Interestingly, ITM2BS is not able to trigger apoptosis in
IL-4-stimulated T cells, indicating that the observed apoptotic effect of ITM2BS is
physiologically relevant (Fleischer et al., 2002a). Moreover, these data confirm that the
mechanisms that control programmed cell death via IL-2R and IL-4R are different, as it
has previously been demonstrated (Cerezo et al., 1998; Rebollo et al., 2000). As distinct
BH3-only proteins sense different stress conditions, generation of mutant mice lacking
individual BH3-only proteins or combinations of these pro-apoptotic members would
provide fundamental insights into developmental and apoptotic processes of multicellular
organisms.
Transcriptional upregulation of BH3-only proteins appears to play a critical role in
apoptosis control. EGL-1, required for the initiation of all developmentally deaths of
somatic cells in C . elegans (Conradt and Horvitz, 1998) lies under the control of
transcription factors or repressors (Conradt and Horvitz, 1999). Noxa and Puma have been
identified as p53-inducible genes (Nakano and Vousden, 2001; Oda et al., 2000; Yu et al.,
2001). Cytokine withdrawal has been reported to augment Bim expression by the Forkhead
transcription factor FKHR-L1 (Dijkers et al., 2000). Similarly, ITM2BS was upregulated at
mRNA and protein level in response to IL-2 deprivation. The 5’ untranslated region of
ITM2BS harbours putative binding sites for the transcription factor E2F that can probably
activate ITM2BS expression (unpublished observations). Recently, E2F-1 has been shown
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to target the promoter region of caspase-7, thus leading to apoptosis triggered by mitogenic
oncogenes (Nahle et al., 2002). The question, whether E2F-1 is able to transactivate BH3-
only proteins such as ITM2BS, has yet to be addressed.
ITM2BS is located on human chromosome 13q14.3 and on mouse chromosome 14
(32.5 cM). Several pro-apoptotic molecules residues in the same locus; BNIP3L (Bcl-
2/E1B 19 kDa-interacting protein 3-like protein), which contains a BH3 domain and
induces apoptosis (Imazu et al., 1999); CIDE-B (cell death inducing effector) that triggers
apoptosis upon DNA damage (Inohara et al., 1998) or VDAC2 (voltage dependent anion
channel) that is involved in germ cell apoptosis (Hinsch et al., 2001). It is interesting to
notice that chromosome 13q14 deletions (about 50% of the patients) are the most frequent
chromosomal alterations in B-cell chronic lymphocytic leukemia (B-CLL) and they have
also been reported in many other human tumors (Migliazza et al., 2001). Given that the
gene product of ITM2BS has pro-apoptotic properties, it is possible that ITM2BS represents
a tumor suppressor gene. However, further studies are required to prove, whether loss of
ITM2BS occurs in tumors by means of somatic mutations, deletion of ITM2BS alleles, gene
methylation or aberrant transcriptional or post-transcriptional regulation.
BH3-only regulators are often expressed constitutively in cells and acquire usually
their pro-apoptotic function by other events. ITM2BS synthesis is regulated by alternative
splicing after IL-2 withdrawal. Alternative splicing affecting the properties of apoptotic
proteins is well documented in the case of Bcl-x protein. Bcl-xL and Bcl-xS are encoded by
two different spliced mRNAs, the long isoform has anti-apoptotic and the short form pro-
apoptotic effects (Boise et al., 1993). Recently, several groups have identified various
novel Bim isoforms indicating that alternative splicing may play a pivotal role in Bim
regulation. Upon g-irradiation, the short form BimS was the strongest inducer of cell death,
while BimEL and BimL were less potent (O'Connor et al., 1998). Bimg inhibits clonal
growth and promotes apoptosis in prostate cancer cells (Liu et al., 2002). BimAD and BimS
have been shown to interact with the multidomain member Bax triggering its
conformational change that is required for its insertion into the outer mitochondrial
membrane (Marani et al., 2002).
As demonstrated for the multidomain member Bak, the BH3 region of pro-apoptotic
Bcl-2 member may form an amphipathic helix that interacts with the hydrophobic cleft
created by the BH1, BH2 and BH3 regions of pro-survival molecules such as Bcl-2 or Bcl-
xL (Sattler et al., 1997). Thus, Bim was shown to bind to various anti-apoptotic Bcl-2-like
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proteins including Bcl-2, Bcl-xL, Bcl-w, A1 and Mcl-1 (O'Connor et al., 1998). In contrast,
Harakiri and Noxa seem to bind only to Bcl-2 and Bcl-xL (Inohara et al., 1997; Yu et al.,
2001). In the present study, ITM2BS interacted with Bcl-2, but not with Bad. Low level of
Bcl-2/ITM2BS association was observed in IL-2-deprived T-cells because Bcl-2 was the
limiting molecule in the formation of this complex. Total expression analysis from IL-2-
stimulated and deprived cells confirmed downregulation of Bcl-2. Downregulation of Bcl-
2 transcription has also been observed in apoptotic CD4(+) and CD8(+) T lymphocytes
from HIV-infected individuals, which can be partially prevented by exogenous IL-2
addition (Regamey et al., 1999). Recently, it has been demonstrated that activated T cells,
undergoing apoptosis, contained lower levels of Bcl-2, which could be in part due to
limiting amounts of the IL-2 family of cytokines thereby increasing the ratio between Bim
and Bcl-2 within the cell (Akbar et al., 1996; Hildeman et al., 2002; Mitchell et al., 1999;
Vella  et al., 1998). Collectively, these data emphasize a critical role for Bcl-2
downregulation in dying T-cells and strongly support that the results obtained from the T-
cell line TS1ab are indeed physiological significant. Susceptibility of cells to death stimuli
seems to be regulated partially by relative levels and competing dimerization of death-
suppressing and death-promoting Bcl-2-like proteins (Oltvai and Korsmeyer, 1994; Sato et
al., 1994). Letai and colleagues have proposed a modified “rheostat” model, in which
BH3-only proteins can be divided into two groups depending on their apoptotic function:
Bid-like proteins promote apoptosis by directly interacting and activating Bax/Bak
proteins, whereas Bad-like BH3-only proteins enable apoptosis through binding to pro-
survival Bcl-2 members and thus abolishing the sequestration of Bid-like activator proteins
(Letai et al., 2002). In both cases, formation of Bax/Bak oligomers into the outer
mitochondrial membrane lead to release of apoptogenic factors such as cytochrome c, AIF
or Smac into the cytosol (Wei et al., 2000). ITM2BS could act as a protein with intrinsic
apoptotic activity promoting Bax/Bak oligomerization, while pro-survival Bcl-2-like
molecules may serve as dominant inhibitors. In favour of this model, overexpression of
Bcl-2 prevented the cell death-inducing effect of ITM2BS. However, whether ITM2BS can
activate pro-apoptotic multidomain Bax/Bak proteins, remains to be determined.
Alternatively, ITM2BS could promote cell death by inhibiting the protective activity of
Bcl-2 and perhaps other functional homologues thereby facilitating the activation of
Bax/Bak proteins through Bid-like BH3-only proteins. Since IL-2-deprived cells
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downregulate Bcl-2 and upregulate ITM2BS expression, the balance is strongly shifted
towards ITM2BS, which allows rapid capturing of the majority of anti-apoptotic molecules.
To delineate the role of ITM2BS in apoptosis signalling, the biochemical pathway
implicated in ITM2BS cell death was studied in detail. Mitochondria are the bioenergetic
and metabolic centers of eukaryotic cells. One of the decisive steps of the mitochondria-
mediated apoptosis is the permeabilization of the outer mitochondrial membrane. In the
course of the apoptotic process, mitochondria suffer specific damage that results in loss of
their function due to release of cytochrome c and other critical intermembrane space
proteins. It has been demonstrated that cytochrome c release from mitochondria can occur
with or without loss of membrane potential. Some groups have found that loss of
mitochondrial membrane potential precedes apoptosis (Shimizu et al., 1996; Zamzami et
al., 1996), others have suggested that apoptosis is not accompanied by loss of membrane
potential (Kluck et al., 1997; Yang et al., 1997a). Probably, this phenomenon can be
explained through the activation of different members of the Bcl-2 family. Bid and Bik
seems to induce cytochrome c release, but not loss of membrane potential. On the other
side, Bax and Bak trigger cytochrome c and membrane potential loss and Bcl-2 as well as
Bcl-xL prevent these changes (Shimizu and Tsujimoto, 2000). In the present study,
overexpression of ITM2BS was shown to perturb the barrier function of mitochondrial
membrane in IL-2-stimulated TS1ab cells, which induces loss of mitochondrial membrane
potential (Fleischer et al., 2002b). ITM2BS localizes to mitochondria and promotes
cytochrome c release during apoptosis progression suggesting that this protein operates by
activating a death pathway transduced through the mitochondria. It has been reported that
cleavage of Bcl-2 by caspases might further activate downstream caspases and contribute
to amplification of the caspase cascade (Cheng et al., 1997). This was not the case in the
TS1ab cell system, since expression of ITM2BS does not induce Bcl-2 cleavage.
Irrespective of the exact mechanism of mitochondrial membrane permeabilization, it
appears that pro-survival members of the Bcl-2 family stabilize the mitochondrial
membrane barrier function (Kluck et al., 1997), while pro-apoptotic Bcl-2-like proteins
permeabilize the mitochondrial membrane (Desagher et al., 1999; Jurgensmeier et al.,
1998). In agreement, endogenous Bcl-2 was not capable to rescue ITM2BS-transfected
cells maintained in IL-2 and Bcl-2 overexpression was the sole way to block ITM2BS-
induced apoptosis (Fleischer et al., 2002a).
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The permeability transition pore complex (PTP) contains as core components the
voltage-dependent anion channel (VDAC) in the outer as well as adenine nucleotide
translocator (ANT) in the inner mitochondrial membrane and it is thought to regulate
mitochondrial respiration and ATP efflux (Crompton et al., 1999). PTP plays an essential
role in the increase of mitochondrial membrane permeability and is regulated by the Bcl-2
family of proteins via direct interaction. Anti-apoptotic Bcl-2 family members close the
VDAC, whereas several pro-apoptotic members such as Bax bind to VDAC, in order to
form a protein-conducting channel, through which cytochrome c and other apoptogenic
cofactors can pass (Marzo et al., 1998a; Marzo et al., 1998b; Narita et al., 1998; Shimizu
et al., 1999). Even BH3-only proteins appear to interact with the PTP complex as
illustrated by Bim-VDAC and Bid-ANT interactions (Sugiyama et al., 2002; Zamzami et
al., 2000). Since ITM2BS is a mitochondrial BH3-only protein, it would be possible that
ITM2BS might act at the PTP level interacting with VDAC or some of its components.
Alternatively, ITM2BS containing a transmembrane region could generate channels itself
into the outer mitochondrial membrane as proposed for the BH3-only molecule Bid
(Grinberg et al., 2002; Schendel et al., 1999) or for the multidomain Bax protein
(Antonsson et al., 1997). Very recently, it has been suggested that permeabilization only
requires the interaction of Bcl-2 family proteins such as Bax and Bid with the outer
mitochondrial membrane. In response to death stimuli, Bax, which is activated by Bid, can
form supramolecular openings in mitochondrial outer membranes allowing the passage of
large intermembrane space proteins (two megadalton) into the cytosol. The mitochondrial
lipid cardiolipin seems to be required for Bax function, whereas proteins of the PTP
complex were not necessary for protein efflux (Kuwana et al., 2002). Thus, ITM2BS could
rather function as a Bax-stimulating factor than directly forming pores into the outer
mitochondrial membrane. Regardless of the functional behaviour of ITM2BS, the final
result of ITM2BS action is loss of mitochondrial membrane potential and release of
cytochrome c.
Upon apoptotic stimuli, mitochondria release apoptogenic factors specific for both
caspase-dependent (through cytochrome c and Smac) and caspase-independent apoptotic
pathways (through AIF and Endo G) (Bidere and Senik, 2001). As cytochrome c release
was observed in ITM2BS-induced apoptosis, further studies have been focused on the role
of caspases. Caspases are organized in a cascade with upstream initiator caspases
responsible for activating the downstream effector caspases. Once activated within the
apoptosome, caspase-9 propagates the death signal by activating downstream caspases.
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Both types of caspases are activated by proteolytic cleavage resulting in the generation of a
catalytic active heterotetramer (Thornberry and Lazebnik, 1998). Using cytoplasmic
extracts, the present study demonstrated that caspase-9 was activated in IL-2-deprived as
well as in ITM2BS-transfected T-cells thereby transducing apoptotic mitochondrial signals
(Fleischer et al., 2002b). The fact that loss of caspase-9 abrogates cleavage of all other
caspases, attributes a central role to the apical caspase-9 in cytochrome c-initiated cell
death program (Slee et al., 1999). In addition, CASP-9 null embryonic stem cells and
embryonic fibroblasts were found to be resistant to a variety of pro-apoptotic stimuli that
signal through the mitochondrial, but not death receptor pathway (Hakem et al., 1998). In
vivo experiments confirmed that ITM2BS-triggered pathway culminates finally in the
activation of the downstream caspases-3 and -7 in T-lymphocytes. Once activated, the
effector caspases are thought to carry out the execution phase cleaving a wide variety of
cellular substrates leading ultimately to cell death (Shi, 2002). Taken together, the data
strongly suggest that ITM2BS mediates apoptotic signals through promoting the
mitochondrial apoptotic pathway resulting in cytochrome c release and activation of a
caspase cascade although cooperation of additional mediators cannot be excluded.
While transcriptional regulation of apoptosis-associated genes accounts for the
decision of a cell to undergo apoptosis, functional interactions between proteins play as
well a pivotal role in transducing signals through apoptotic pathways (Hengartner, 2000).
In the present study, a specific interaction between Aiolos and Bcl-xL was observed in IL-
4-deprived TS1ab cells as well as in thymocytes and provide an explanation for the
inability of Bcl-xL to exert its pro-survival role (Rebollo et al., 2001). The Bcl-x protein
shows significant homology to the anti-apoptotic Bcl-2 and can be alternatively spliced to
produce two isoforms, the death-suppressing Bcl-xL and the death-promoting Bcl-xS (Boise
et al., 1993; Gonzalez-Garcia et al., 1994). Stimulation of TS1ab lymphocytes by IL-4
triggered Bcl-xL expression that was not altered during IL-4 starvation. On the contrary, the
short isoform could not be detected in both conditions. Although Bcl-xL is present after IL-
4 addition, it appears to be insufficient to promote cell survival because Bcl-xL is also
expressed in IL-4-deprived cells. These results suggest that IL-4-deprived cells mediates
apoptotic signals via pathways that do not implicate changes in Bcl-xL expression
confirming former reports, where apoptosis induction correlates with downregulation of
Bcl-2, but not Bcl-x expression (Gomez et al., 1998; Regamey et al., 1999; Zhang et al.,
1999). Albeit Bcl-x was found to be upregulated in T cells and Bcl-xL overexpression can
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enhance T cell survival (Boise et al., 1995; Fang et al., 1994; Mueller et al., 1996),
physiological expression of Bcl-xL cannot contribute to resistance of apoptosis after TCR
ligation, since it is constantly expressed in apoptotic and non-apoptotic T cell blasts
suggesting association with other partners (Yang et al., 1997b). In fact, there is increasing
evidence that function of Bcl-xL is modulated by several interacting proteins including
Bax, Bad, Bag-1 and Siva-1 (Oltvai et al., 1993; Takayama et al., 1995; Xue et al., 2002;
Yang et al., 1995). In the present study, Aiolos was identified as a Bcl-xL-binding partner
by means of two-hybrid screen. It is interesting to mention that Bcl-xL also associated with
Aiolos in freshly isolated thymocytes confirming the results obtained in the T cell line. The
Aiolos transcription factor has been initially identified as a homologue of the Ikaros
transcription factor, whose expression is restricted to the lymphoid lineage. Aiolos
homodimers are potent transcriptional activators, whereas the transcriptional activity of
Aiolos/Ikaros heterodimers range from low to undetectable. Lack of Aiolos causes
deregulation in B cell maturation, proliferation and differentiation as well as development
of B cell lymphoma (Morgan et al., 1997; Wang et al., 1998a). Recently, our group has
demonstrated that IL-2 deprivation induces Ras/Aiolos association resulting in apoptotic
cell death (Romero et al., 1999). One of the functional consequences of this interaction is
the blockade of Aiolos translocation to the nucleus, so that Aiolos cannot transactivate the
Bcl-2 promoter. However, despite of Aiolos expression in nucleus, IL-4 stimulation does
not trigger Bcl-2 expression (Gomez et al., 1998) suggesting repression of Bcl-2
transcription by some induced factors. Alternatively, the nuclear level of Aiolos could be
too low to induce Bcl-2 expression. In the presence of IL-2, phosphorylation of Aiolos
occurs at tyrosine sites correlating with its dissociation of Ras. In a similar way, IL-4
induces tyrosine phosphorylation of Aiolos and dissociation of Bcl-xL. It is possible that
IL-4-triggered tyrosine phosphorylation of Aiolos diminishes the affinity of Aiolos for Bcl-
xL, impeding this association. However, the possibilities that phosphorylated Aiolos
increases its affinity for other partners or that Aiolos/Bcl-xL interaction may involve further
proteins, cannot be excluded. A pathway distinct from Bcl-xL may be initiated by IL-4 to
prevent apoptosis. Indeed, IL-4 deprivation was shown to inhibit Bcl-3 transcription during
programmed cell death, which can be blocked by Bcl-3 overexpression (Rebollo et al.,
2000). This result suggests that Bcl-3 can substitute the function of Bcl-xL acting as
survival factor in IL-4-deprived TS1ab cells. Probably, downregulation of Bcl-3 leads to
changes in gene regulation silencing genes, which are normally essential for proliferation
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and survival. Bcl-3 expression might be controlled by IL-4-regulated transcription factors
recognizing AP1-specific binding sites in the Bcl-3 promoter (Rebollo et al., 2000).
Moreover, a correlation between Bcl-3 expression and proliferation has been observed in B
lymphocytes (Bhatia et al., 1991). Thus, transcriptional (Bcl-3 expression) and non-
transcriptional (Bcl-xL/Aiolos interaction) pathways seem to be implicated in the control of
apoptosis in IL-4-stimulated cells. In summary, a novel role has been proposed for the
lymphoid-specific transcription factor Aiolos as a blocker of the anti-apoptotic function of
Bcl-xL in IL-4-deprived T cells through its sequestering by unphosphorylated Aiolos.
In the last few years, new findings have provided a deeper insight into the regulation
of phosphatases (Zolnierowicz and Bollen, 2000). Phosphatases are often targeted to their
physiological substrates by association with specific regulatory subunits, since simple
diffusion is not sufficient for their translocation within the cell (Jia, 1997). Our group has
recently demonstrated that the phosphatase PP1a is targeted to the pro-apoptotic molecule
Bad by Bcl-2 (Ayllon et al., 2001). In the present study, the anti-apoptotic proteins Bcl-xL
and Bcl-w were identified as targeting subunits of PP1a in IL-4-stimulated T-lymphocytes
as well as in freshly isolated thymocytes, replacing Bcl-2 as regulatory subunit of PP1a in
IL-2-stimulated cells (Ayllon et al., 2002a). Using co-immunoprecipitation assays, Bcl-xL
or Bcl-w were shown to interact with PP1a  and Bad thus forming two types of
trimolecular complexes, BclxL/PP1a/Bad and Bcl-w/PP1a/Bad. Depletion of Bcl-xL and
Bcl-w resulted in loss of the interaction of PP1a and its substrate Bad preventing
dephosphorylation of Bad. It is interesting to notice that the level of trimolecular
complexes was reduced in IL-4-deprived cells as compared to IL-2-stimulated cells,
although total expression of these proteins did not change during the starvation period. As
the targeting subunits Bcl-xL and Bcl-w are not the limiting factors in the formation of the
trimolecular complexes, post-translational mechanisms could modify any of these
molecules leading to lower complex aggregation. Indeed, serine phosphorylation of Bcl-xL
and Bcl-w was observed in IL-4-stimulated diminishing upon IL-4 deprivation, which
correlates with a decrease in formation of trimolecular complexes. Similarly, it has been
shown that Bcl-2 is modified by phosphorylation on serine 70 induced by IL-3, whereas
withdrawal of IL-3 leads to dephosphorylated and non-functional Bcl-2 (Deng et al., 1998;
Ito et al., 1997). According to the solution structure of Bcl-xL (Sattler et al., 1997), the
corresponding serine 70 would be located within a flexible loop domain and its
phosphorylation could change the affinity for interaction partners supporting the possible
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influence of phosphorylation on Bcl-xL/Aiolos interaction. It has been reported that IL-3
induces serine phosphorylation of Bad and its binding to 14-3-3 protein thus avoiding its
dimerization with Bcl-xL (Datta et al., 1997). In TS1ab cells, Bad is phosphorylated at
serine 112 and 136 or serine 112 in IL-2- or IL-4-stimulated cells, respectively.
Interestingly, neither phosphorylated nor dephosphorylated Bad were associated to 14-3-3
protein. Therefore, Bad is able to bind to Bcl-xL and Bcl-w upon IL-4 stimulation and
deprivation. Additional findings confirmed that interaction of Bad with 14-3-3 protein
requires Bad phosphorylation at serine 155 (Datta et al., 2000; Lizcano et al., 2000; Virdee
et al., 2000; Zhou et al., 2000) that does not occur in TS1ab cells.
The majority of targeting subunits harbour a PP1-binding motif. Bcl-2 as well as Bcl-
xL and Bcl-w also possess this well-conserved R/K-X-V/I-X-F motif, in addition to F-X-X-
R-X-R motif, which has recently been identified (Ayllon et al., 2002a). Binding of one of
the anti-apoptotic proteins to PP1a excludes binding of the other, explaining the presence
of two types of trimolecular complexes. Probably, these motifs are implicated in binding
and stabilization of the association Bcl-xL/PP1a/Bad or Bcl-w/PP1a/Bad. In agreement,
competition of binding using only one of the peptide containing the R/K-X-V/I-X-F or F-
X-X-R-X-R motif partially prevented the interaction, whereas competition with both R-
and F-peptides completely abolished the formation of trimolecular complexes and resulted
in loss of phosphatase activity. Mutation of valine or phenylalanine to alanine within the
R/K-X-V/I-X-F strongly inhibits binding to PP1a. Other groups have also reported that
substitution of these critical residues prevents association of targeting subunits to PP1
(Egloff et al., 1997). In a similar way, mutation of the conserved arginine residue to
glycine within the F-X-X-R-X-R motif blocks binding to PP1a, while mutations to serine
hardly show effects. These results suggest that, at least, these two motifs seem to be critical
for interaction with PP1a. However, further amino acids may be involved in mediating the
association Bcl-xL or Bcl-w with PP1a. Indeed, recent results demonstrated that some
regulatory proteins possess multiple sites of interaction with PP1 (Egloff et al., 1997). The
PP1a-inhibitor ocadaic acid was able to block Bad dephosphorylation and subsequently
programmed cell death in IL-4-deprived lymphocytes underlining the importance of Bad
phosphorylation in cell survival. Taken together, Bcl-xL is phosphorylated at serine
residues in IL-4-stimulated TS1ab cells, while Aiolos is phosphorylated at tyrosine
residues abolishing its interaction with Bcl-xL thus allowing Bcl-xL to act as a targeting
subunit of PP1a. Upon IL-4 starvation, Bcl-xL and Aiolos are dephosphorylated, which
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correlates with association of both proteins, thereby blocking Bcl-xL function and
decreasing the number of trimolecular complexes Bcl-xL/PP1a/Bad.
Given that phosphorylated Bad is not associated to 14-3-3 in TS1ab cells stimulated
with IL-4 suggests the existence of other mechanisms that control Bad function (Ayllon et
al., 2002a). To address this question, the subcellular localization of Bad has been analyzed
in IL-4-stimulated or -deprived cells, since localization of proteins to distinct subcellular
compartments including membranes plays an important role in many cellular signalling
pathways such as apoptosis and cell survival. Using two distinct biochemical approaches,
sucrose ultracentrifugation gradient and Triton-X flotation gradient, Bad was mainly found
in the lipid raft fraction of IL-4-stimulated TS1a b  cells. This pool of Bad is
dephosphorylated, but it is unable to exert its cell death-inducing function due to its
sequestration in these plasma membrane structures. Association of Bad to lipid rafts were
also demonstrated in vivo by confocal microscopy using cholera toxin B subunit labelled
with fluorochrome. Lipid rafts are plasma membrane microdomains enriched in
glycosphingolipids, cholesterol and other lipids. This special composition makes lipid rafts
insoluble in non-ionic detergents and they can be isolated by density gradient
ultracentrifugation. Lipid rafts can be considered as platforms in a liquid ordered phase that
randomly move in the plane of the plasma membrane (Brown and London, 1998). A broad
range of proteins are able to associate with lipid rafts like SRC kinases family, trimeric G
proteins or adaptor proteins suggesting a pivotal step in signalling pathways. Furthermore,
it has been demonstrated that lipid rafts have a key role in TCR signalling, and disruption
of these microdomains with agents that sequester cholesterol inhibits signalling through the
receptor (Janes et al., 2000). Rafts have also been implicated in signalling via IL-2 receptor
(Marmor and Julius, 2001). The sequestration of IL-2Ra within lipid rafts controls IL-2R
signalling through impeding its interaction with the b- and g-chain of IL-2R. Interestingly,
the present study provides evidence that withdrawal of IL-4 triggers disorganization of
lipid rafts resulting in segregation of dephosphorylated Bad from the plasma membrane
and translocation to mitochondria correlating with T-lymphocyte death. Taken these results
into account, a model can be proposed, in which IL-4 deprivation induces a two-step
apoptotic process: disorganization of lipid rafts and release of Bad from rafts, which
translocates to mitochondria and promotes apoptosis. Following observations support this
hypothesis. Depletion of cellular cholesterol by chemical agents like methyl-b-cyclodextrin
causes a severe disruption of rafts structures and Bad association with rafts, similar to that
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observed in IL-4 deprived cells. Addition of FCS to IL-4-supplemented medium restored
the lipid components of the plasma membrane preventing the progression of apoptosis.
Indeed, lipid rafts appear to be important in apoptosis signalling. In mature B cells,
signalling through the B cell antigen receptor is initiated from rafts and leads to its
activation, while immature B cells are destined to undergo by apoptosis, since the B cell
antigen receptor is excluded from rafts (Aman et al., 2001; Cheng et al., 1999). In addition,
Fas clustering in lipid rafts is an essential feature for signalling and cell death (Grassme et
al., 2001; Grassme et al., 2002). CD24 induces apoptosis in human B cells via a raft-
mediated signalling pathway (Suzuki et al., 2001a). The BH3-only protein Bim was also
found to be regulated by its subcellular localization to distinct cellular structures. In
healthy cells, Bim is sequestered to the microtubule-associated dynein motor complex.
Upon an apoptotic stimulus, Bim is released and translocates to mitochondria, where it
binds to the anti-apoptotic molecule Bcl-2 (Puthalakath et al., 1999). These results
underline the importance of subcellular localization in apoptosis signalling pathways. Most
of the proteins associated to rafts suffer a post-translational modification consisting in the
addition of saturated lipids such as glycosylphosphatidylinositol, myristic or palmitic acid
groups. Interestingly, Bad has a glycine residue at its N-terminal exhibiting high
probability to be myristoylated. N-myristoylation has already been observed in other
proteins that associate with rafts like the SRC-kinase, Lck (Yasuda et al., 2000). Another
possibility to associate with lipid rafts would be the interaction with proteins localized in
rafts, but this kind of association is more labile, being largely disrupted by detergents
(Janes et al., 2000). As raft localization of Bad has also been demonstrated using Triton-X
flotation gradient, it would be more conceivable that Bad could interact with rafts via a
lipid anchor. Further studies are in progress, in order to determine, whether Bad can be
really myristoylated at this glycine residue, probably responsible for its localisation to lipid
rafts or mitochondria.
In conclusion, the data provided in this thesis contribute to elucidate the complex
signalling network implicated in the apoptotic process. Several apoptosis-regulating
mechanisms have been described such as transcriptional upregulation, protein interactions
and subcellular translocation. Most of the components necessary to initiate apoptosis are
locally concentrated in or around the outer mitochondrial membrane emphasizing the
central role for mitochondria in programmed cell death. In contrast to the execution phase
of the mitochondrial apoptotic pathway, little is known about how damage signals are
transduced to and integrated in the mitochondria. Certainly, the regulation, crosstalks and
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precise roles of these pathways will be the focus of much future research. A deeper
understanding of the apoptotic machinery might help in identifying apoptosis-relevant
targets for developing novel therapeutics that can modify cell death pathways in human
diseases such as diabetes, neurodegenerative disorders and cancer.
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V Summary
Apoptosis or programmed cell death is a conserved cellular suicide program that
selectively eliminates excess or potentially dangerous cells. To elucidate the signalling
pathways implicated in the regulation of apoptosis and proliferation, cytokine withdrawal
was used as a physiological stimulus to trigger programmed cell death.
By means of representational difference analysis, the short isoform of the integral
membrane protein (ITM2BS) was identified in the present study as a novel regulator of cell
death that was upregulated upon IL-2 deprivation. ITM2BS was shown to belong to the
BH3-only members of the Bcl-2 family and promoted apoptosis by antagonizing the pro-
survival function of Bcl-2 protein. Biochemical and confocal studies demonstrated that
association of ITM2BS to mitochondria correlated with loss of mitochondrial membrane
potential, release of cytochrome c into the cytosol as well as activation of up- and
downstream caspases suggesting signalling via mitochondrial-mediated pathways.
Functional interactions between proteins play a pivotal role in signal transduction. In
this work, a novel function has been uncovered for the lymphoid-specific transcription
factor Aiolos that was found to be associated with the pro-survival Bcl-xL protein in IL-4-
deprived, but not IL-4-stimulated T-lymphocytes. The phosphorylation status appeared to
be important in the regulation of this interaction since dephosphorylation of Aiolos and
Bcl-xL increased their binding affinity following IL-4 withdrawal. These data propose a
model, in which the anti-apoptotic effects of Bcl-xL are blocked through its sequestration
by unphosphorylated Aiolos. Moreover, the anti-apoptotic proteins Bcl-xL and Bcl-w were
identified as targeting subunits of the serine/threonine phosphatase PP1a  in IL-4-
stimulated T-lymphocytes as well as in freshly isolated thymocytes, replacing Bcl-2 as
regulatory subunit of PP1a in IL-2-stimulated cells. Using co-immunoprecipitation assays,
Bcl-xL or Bcl-w were shown to interact with PP1a  and Bad forming two types of
trimolecular complexes, Bcl-xL/PP1a/Bad and Bcl-w/PP1a/Bad. Depletion of Bcl-xL and
Bcl-w resulted in loss of the interaction of PP1a and its substrate Bad, thus preventing
dephosphorylation of Bad. Two distinct PP1-binding motifs, R/K-X-V/I-X-F and F-X-X-
R-X-R, may be involved in mediating the association of Bcl-xL or Bcl-w with PP1a. The
PP1a-inhibitor ocadaic acid was able to block Bad dephosphorylation and subsequently
programmed cell death in IL-4-deprived lymphocytes underlining the importance of Bad
phosphorylation in cell survival.
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In addition to phosphorylation, the function of the pro-apoptotic Bad is also regulated
by subcellular localization. It was demonstrated that a major fraction of Bad was localized
in rafts upon IL-4 stimulation. This pool of Bad was dephosphorylated, but it was unable to
exert its cell death-inducing function due to its sequestration in these plasma membrane
microdomains. Confocal microscopy studies provided evidence that IL-4 deprivation
triggered disorganization of lipids rafts, resulting in the segregation of dephosphorylated
Bad from the plasma membrane and subsequent translocation to mitochondria, correlating
with T-lymphocyte death. In conclusion, several apoptosis controlling mechanisms have
been described in the present thesis including transcriptional upregulation, sequestration by
protein interactions and subcellular localization as well as phosphatase targeting to its
substrate by regulatory subunits. However, further biochemical, structural and genetic
analyses are required to reveal the complex picture of cellular life and death switches.
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VII Appendix
VII.1 Abbreviations
°C degree Celsius
m micro (10-6)
aa amino acid(s)
Ab antibody
ATP adenosine triphosphate
BH Bcl-2 homology
b base(s)
CARD caspase recruitment domain
cDNA complementary DNA
cM centi-Morgan
CTL cytotoxic T lymphocyte
CTx cholera toxin
cyt c cytochrome c
Da dalton
DD death domain
DEAE diethylaminoethyl
DED death effector domain
DISC death inducing signalling complex
DMSO dimethylsulfoxide
DNA deoxyribonucleic acid
dNTP deoxynucleoside triphosphate
ECL enhanced chemiluminescence
E. coli Escherichia coli
EDTA ethylene diamine tetraacetic acid
ER endoplasmic reticulum
FADD Fas-associated protein with death domain
FasL Fas ligand
FasR Fas receptor
FCS fetal calf serum
Fig. figure
g gravitational constant (9.81 m s--1)
h hour(s)
HEPES N-(2-hydroxyethyl)piperazine-N’-(2-ethanesulfonic acid)
HPLC high performance liquid chromatography
Ig immunoglobulins
IP immunoprecipitation
IL interleukin
k kilo (¥ 103)
KO knockout
l liter
LB Luria-Bertani medium
M molar
m milli (¥ 10-3)
M-b-CD methyl-b-cyclodextrin
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min minute(s)
mRNA messenger RNA
MEF mouse embryonic fibroblast
MOPS 3-(N-morpholine)propanesulfonic acid
nt nucleotide(s)
OA okadaic acid
OD optical density
O.N. overnight
PAGE polyacrylamide gel electrophoresis
PBS phosphate-buffered saline
PCR polymerase chain reaction
pH potentio hydrogenii
PI propidium iodide
PO peroxidase
RNA ribonucleic acid
R.T. room temperature
s second(s)
SD standard deviation
SDS sodium dodecylsulfate
TNF tumor necrosis factor
Tris Tris(hydroxymethyl)aminomethane
UV ultraviolet
WB western blot
VII.2 Amino acid code
A Ala alanine
C Cys cysteine
D Asp aspartic acid
E Glu glutamic acid
F Phe phenylalanine
G Gly glycine
H His histidine
I Ile isoleucine
K Lys lysine
L Leu leucine
M Met methionine
N Asn asparagine
P Pro proline
Q Gln glutamine
R Arg arginine
S Ser serine
T Thr threonine
V Val valine
W Trp tryptophan
Y Tyr tyrosine
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VII.3 Figure index
Figure I-1: Schematic representation of the morphological changes occurring during
apoptosis.
Figure I-2: Implication of apoptosis-related proteins in human diseases.
Figure I-3: Two major apoptosis signalling pathways in mammalian cells: the
mitochondrial and death receptor mediated pathway.
Figure I-4: Structural organisation of mammalian caspases.
Figure I-5: Schematic diagram of the Bcl-2 family of proteins.
Figure I-6: The serine/threonine phosphatase PP1 is a holoenzyme and consists of a
catalytic (PP1c) as well as a regulatory subunit.
Figure I-7: Two distinct models for the release of mitochondrial apoptogenic
proteins.
Figure III-1: Effect of interleukin withdrawal on apoptosis.
Figure III-2: Transcriptional induction of ITM2BS mRNA upon IL-2 deprivation.
Figure III-3: ITM2BS is a novel BH3-containing protein.
Figure III-4: Upregulation of ITM2BS expression at the protein level.
Figure III-5: Expression of ITM2BS induces apoptosis, which is abolished by the
pro-survival Bcl-2.
Figure III-6: The BH3 domain of ITM2BS is essential for induction of apoptosis.
Figure III-7: ITM2BS interacts with Bcl-2 in vivo.
Figure III-8: ITM2BS localizes to mitochondria, increasing upon IL-2 deprivation.
Figure III-9: ITM2BS expression induces release of cytochrome c.
Figure III-10: ITM2BS expression triggers loss of mitochondrial membrane
potential.
Figure III-11: Effect of ITM2BS expression on caspase activation.
Figure III-12: Association of Bcl-xL and Bcl-w to PP1a and Bad.
Figure III-13: Effect of IL-4 deprivation on serine phosphorylation of Bcl-xL and
Bcl-w and on association to 14-3-3 protein.
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Figure III-14: Measurement of serine/threonine phosphatase activity in control
or OA-treated Bcl-xL, Bad and Bcl-w immunoprecipitates.
Figure III-15: Determination of serine/threonine phosphatase activity after Bcl-xL
and Bcl-w depletion.
Figure III-16: PP1a binding assay on cellulose-bound Bcl-xL or Bcl-w peptides.
Figure III-17: Competition of the interaction Bcl-xL/PP1a/Bad and Bcl-w/PP1a/Bad
with R, R*, F and R+F peptides.
Figure III-18: Effect of OA on serine 136 phosphorylation of Bad and effect of
antisense oligonucleotides on apoptosis.
Figure III-19: Bcl-xL expression in the presence and absence of IL-4.
Figure III-20: Interaction of Aiolos and Bcl-xL in the two-hybrid system.
Figure III-21: Analysis of Aiolos expression upon IL-4 deprivation.
Figure III-22: Reciprocal co-immunoprecipitation experiments of Aiolos and Bcl-xL.
Figure III-23: Tyrosine phosphorylation of Aiolos.
Figure III-24: Cell cycle analysis and western blot of TS1ab cells transfected with
Bcl-xL or Bcl-xL and Aiolos.
Figure III-25: Interaction of Bcl-xL and Aiolos in Bcl-xL or Bcl-xL/Aiolos transfected
cells.
Figure III-26: Antisense Aiolos causes apoptosis inhibition.
Figure III-27: Lack of association of Bad with 14-3-3 protein in TS1ab cells.
Figure III-28: Subcellular localization of Bad in IL-4-stimulated or -deprived cells.
Figure III-29: Association of Bad with mitochondria and Bcl-xL.
Figure III-30: Rafts localization of Bad in IL-4-stimulated cells.
Figure III-31: Mitochondrial localization of Bad.
Figure III-32: Methyl-b-cyclodextrin (M-b-CD) treatment prevents association of
Bad to rafts.
Figure III-33: M-b-CD is able to induce apoptosis in the presence of IL-4.
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